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Abstract 
Mutations in the gene encoding parkin, an E3-ubiquitin ligase, result in 50% of 
Autosomal Recessive Juvenile Parkinsonism cases. Parkin has been identified as a key 
mediator of mitochondrial regeneration following oxidative stress, and pathogenic 
mutations have been shown to impair its ubiquitin ligase activity. Neurodegeneration of 
dopamine-producing neurons appears to be a downstream consequence of parkin loss-of-
function, resulting in early-onset forms of Parkinson’s disease. Although ubiquitination 
activity is essential for its neuroprotective function, parkin is autoinhibited in its native 
state by various mechanisms, including its N-terminal ubiquitin-like (UBL) domain. 
Therefore, the overarching objective of this thesis was to structurally characterize the 
autoinhibited state of parkin and determine how this inactive structure is modified to a 
catalytically-competent form. 
 
It was determined that autoinhibited parkin maintains a compact tertiary structure 
mediated by a tight intramolecular association between the UBL and C-terminal region. A 
high-resolution NMR strategy was developed and used to identify the binding site of the 
UBL domain that further revealed allosteric structural changes associated with UBL 
binding and displacement.  
 
Recently, multiple reports emerged identifying serine 65 phosphorylation of both 
ubiquitin and parkin’s UBL domain as key inducers of parkin activity. To examine the 
roles of these phosphorylation signals, several methods were used to generate 
homogenous S65-phosphorylated ubiquitin and UBL including: chemical modification, 
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orthogonal translation, and phosphorylation by a catalytically-active kinase. 
Thermodynamic parameters of ubiquitin and UBL binding to parkin were measured and it 
was demonstrated how these are significantly altered upon S65 phosphorylation to 
promote a loss of autoinhibition. 
 
To understand the structural consequences of S65 phosphorylation, the three-dimensional 
structure of the phosphorylated parkin UBL was solved. Phosphorylation impacts the 
structure, stability and autoinhibitory association of the UBL domain in parkin. Further, 
cooperative roles of phospho-ubiquitin and phospho-UBL were established in 
reorganizing the parkin to an extended structure, allowing its engagement in the 
ubiquitination cascade. 
 
Finally, to investigate a chemical mechanism of catalysis in activated parkin, a detailed 
characterization of active site atoms in parkin was performed. Chemical biology 
approaches were used to generate an activated parkin~ubiquitin intermediate that will 
provide further mechanistic insight into ubiquitin transfer onto mitochondrial substrates. 
 
 
 
 
 
Keywords:  Parkinson’s disease, ubiquitin, parkin, Ub, UBL, RBR, ubiquitin ligase, E3, 
autoinhibition, PINK1, phosphorylation, nuclear magnetic resonance, neurodegeneration, 
protein structure, protein dynamics 
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Chapter 1 
Introduction and Background 
 
1.1  Parkinson’s Disease and Hereditary Causes 
The symptoms of Parkinson’s disease (PD) were first documented in Western medicine 
by James Parkinson, a British physician, in his seminal 1817 essay (1). Parkinson termed 
the disease “Shaking Palsy” and famously defined the malady as follows: 
 
“Involuntary tremulous motion, with lessened muscular power, in parts 
not in action and even when supported; with a propensity to bend the trunk 
forwards, and to pass from a walking to a running pace: the senses and 
intellects being uninjured.” 
 - James Parkinson, 1817 
 
In his essay, Parkinson chronicled six aging patients with what he believed to be a 
common medical condition, distinct from other trembling disorders. Parkinson 
illustratively documented the lives of these patients, their physical and mental conditions, 
in a remarkably emotional style that would be foreign to medical journals today. His work 
recognized resting tremors, muscle weakness and abnormal posture as common hallmark 
symptoms in his patients. Importantly, Parkinson recognized the severely progressive 
nature of this disease that later became synonymous with his name. He stressed the 
importance of early detection and treatment, and these aspects remain critical to patient 
prognosis today. 
 
The first biochemical link to PD came nearly 150 years after Parkinson’s essay, largely 
through the research of Austrian chemist, Oleh Hornykiewicz, who discovered depleted 
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levels of the neurotransmitter dopamine in post-mortem brains of PD patients (2). This 
was the first evidence of a link between dopamine and neurodegeneration, which had 
been suspected for several years. Remarkably, only one year after this finding, 
Hornykiewicz, along with his colleague Walther Birkmayer in 1961, showed remission of 
symptoms in 20 PD patients by a single intravenous injection of levodopa, a dopamine 
analog (3). The magnitude of this discovery was termed “the dopamine miracle” in 
popular culture and to this date levodopa remains the primary measure for relief of PD 
symptoms. In the years that followed, impairment of dopaminergic neurons in the 
substantia nigra section of the midbrain was shown to be responsible for depleted 
dopamine levels that are causative of PD (4,5). Unfortunately, since these groundbreaking 
discoveries, remarkably little progress has been made in further unraveling the 
biochemical origins of PD. 
 
Major advances in PD etiology came near the completion of the human genome project in 
the late 1990s, when mutations in several genes were linked to PD, often with an early-
age onset form of the disease (ie: before 50 years old). The first gene was identified in 
1997, termed PARK1, and encodes the protein α-synuclein (6). It was discovered that PD 
in a family of Italian descent was inherited over generations in an autosomal dominant 
manner by mutations at the PARK1 locus. The link between α-synuclein and PD 
represented a breakthrough but raised many questions about the basis of 
neurodegeneration. This arose from observations that α-synuclein itself is contained 
within protein aggregates in brains of PD patients, called “Lewy bodies” (7), as well as 
so-called “amyloid plaques” in the brains of Alzheimer’s patients (8). 
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Subsequently, Kitada and coworkers discovered a second PD-causing gene locus, 
PARK2, encoding a protein proposed to be involved in the ubiquitin-proteasome system 
from analysis of its primary sequence (9). They named this protein product “parkin”. In 
contrast to PARK1, disease-causing mutations in PARK2 are inherited in a recessive 
manner, causing a disease termed Autosomal Recessive Juvenile Parkinson’s disease 
(ARJP), which had been described previously (10). The hallmark of ARJP is the 
extremely early onset of the disease, with dystonia and tremors often beginning before 
age 30. Although there are exceptions, most studies have found that ARJP patients 
typically do not have Lewy Bodies characteristic of idiopathic PD, pathologically 
distinguishing this form of inherited Parkinsonism (11-13). 
 
Beyond PARK1 and PARK2, several other PARK genes have been subsequently 
associated with inherited forms of PD. The best characterized of these genes and their 
respective protein products are summarized in Table 1.1. Most PD-causing gene products 
have known enzymatic functions today, with the notable exception of α-synuclein, which 
plays an unspecified role in neuronal synapse transmission. The focus of this thesis will 
be on the structure and function of the PARK2 gene product: the ubiquitin ligase, parkin.  
 
Table 1.1. PARK-designated PD loci in the human genome.  
Gene Protein product Inheritance Proposed function Ref 
PARK1 α-synuclein Dominant Unknown (6) 
PARK2 Parkin Recessive Ubiquitin ligase (9) 
PARK5 UCH-L1 Dominant Ubiquitin hydrolase (14) 
PARK6 PINK1 Recessive Kinase (15) 
PARK7 DJ-1 Recessive Deglycase / chaperone (16) 
PARK8 LRRK2 Dominant Kinase (17,18) 
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1.2 Mitochondrial Impairment and Mitophagy in PD 
Mitochondrial impairment has long been suspected as causative of Parkinson’s disease. 
This link first arose in 1976 when Barry Kidston, an American graduate student, 
developed permanent symptoms of Parkinsonism after intravenously injecting himself 
with a contaminated batch of 4-propionyloxy-4-phenyl-N-methylpiperidine (MPPP), a 
synthetic opioid that he (erroneously) synthesized himself. Unbeknownst to Kidston, he 
in fact had synthesized 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a 
hydrolyzed byproduct of MPPP. Kidston developed muscle rigidity, weakness and 
uncontrollable tremors within days of using the drug (19). He was initially admitted to a 
psychiatric facility and unsuccessfully treated with antipsychotics and electro-convulsion 
therapy. Only after a doctor tried administering levodopa did Kidston’s condition recover 
and doctors subsequently diagnosed Parkinson’s disease in this 23 year old male (19).  
 
 
Figure 1.1.  Chemical structures of MPPP, a synthetic opioid; MPTP, a hydrolysis 
byproduct of MPPP synthesis; MPP+, the metabolized form of MPTP that inhibits 
complex I of the electron transport chain. 
MPPP MPTP 
 N 
CH3 
MPP+ 
 N 
CH3 
+ 
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Today, we know that MPTP is metabolized in the brain to MPP+, a potent neurotoxin that 
acts by inhibiting complex I of the mitochondrial electron transport chain. Studies in 
primates showed MPTP-treatment selectively destroys dopaminergic neurons, leading to 
a disorder with classic symptoms of idiopathic PD (20,21). Brains of these primates also 
contain inclusion bodies that bear resemblance to Lewy Bodies often observed in post-
mortem PD patients, containing aggregates of α-synuclein and ubiquitin (22). Other 
inhibitors of complex 1 include the commonly used pesticide, rotenone, which also 
induces permanent Parkinsonian symptoms in mammals, including humans (23). For 
unknown reasons, dopaminergic neurons appear particularly susceptible to these 
mitochondrial toxins. Thus, dysfunction of oxidative phosphorylation can recapitulate 
Parkinsonism and certain pathological hallmarks of idiopathic PD. These mitochondrial 
toxins are widely used to this day to reproduce Parkinsonism in animal models for various 
scientific studies.  
 
Mitochondria are dynamic structures, undergoing large-scale transformations in shape 
and bioenergetic functions over their lifetimes. Although commonly depicted as bean-
shaped structures in illustrations, mitochondria continuously change their morphology by 
dividing and fusing together in processes termed fission and fusion, respectively (24). 
Repair of mitochondria following oxidative damage is separately governed by a unique 
autophagy-like process, termed mitophagy. This pathway selectively recruits autophagy 
receptors to damaged mitochondria, which results in their engulfment, lysosomal 
degradation and subsequent regeneration (25,26). This recycling process is stimulated in 
response to oxidative stress, therefore it is hypothesized that mitophagy is a major 
mechanism by which mitochondria protect themselves from damage caused by reactive 
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oxygen species (ROS), which impair oxidative phosphorylation, amongst other cellular 
processes. 
 
Induction of mitophagy has been attributed to a complex signaling pathway governed by 
the protein products of two PD-linked genes, PARK2 and PARK6, encoding the ubiquitin 
ligase parkin and the Ser/Thr kinase PINK1, respectively. Studies in Drosophila 
melanogaster discovered knock-out flies for either PARK2 or PARK6 showed remarkably 
similar phenotypes, with difficulties flying and extensive damage to dopaminergic 
neurons (27-29). These studies also showed the two genes function in a common 
biological pathway, with PINK1 acting upstream of parkin, since overexpression of 
parkin could rescue PINK1 deficient flies, but not vice-versa (27-29). PINK1 contains a 
mitochondrial targeting sequence, trafficking the protein to the outer mitochondrial 
membrane (OMM). Under normal cellular conditions, this targeting sequence is cleaved 
by the protease PARL (presenilin-associated rhomboid-like protein) and the cleaved 
PINK1 is degraded by the canonical ubiquitin proteasome system through the N-end rule 
mechanism (30-33) (see Figure 1.2 A). This results in very low levels of PINK1 in 
healthy mitochondria, despite its constitutive expression. Remarkably, during oxidative 
stress, inhibition of oxidative phosphorylation or depolarization of the mitochondrial 
proton gradient, cleavage of PINK1 is inhibited and PINK1 is subsequently stabilized on 
the OMM of these dysfunctional mitochondria (34,35). This regulatory mechanism makes 
PINK1 a de facto “sensor” of mitochondrial damage, accumulating selectively on 
damaged mitochondria. PINK1 subsequently recruits Parkin to the mitochondria and 
stimulates its activity, allowing parkin to ubiquitinate a multitude of protein substrates, 
predominantly OMM proteins (36,37) (see Figure 1.2 B). Rather than signaling for 
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Figure 1.2. PINK1 recognizes damaged mitochondria to induce mitophagy. 
(A) In healthy mitochondria, PINK1 is constitutively expressed and degraded. PINK1 is 
localized to the outer mitochondrial membrane (OMM) by its N-terminal targeting 
sequence. Insertion of the N-terminus through the membrane results in its cleavage by 
the PARL protease. After cleavage, an N-terminal phenylalanine on PINK1 recruits the 
ubiquitin-proteasome machinery to degrade PINK1 by the N-end rule. (B) In mitochondria 
that are stressed, damaged or depolarized, PARL cleavage is inhibited. This stabilizes 
PINK1 on the OMM and recruits Parkin. Parkin subsequently ubiquitinates a multitude of 
OMM proteins, including TOMs (translocases of the outer membrane), MFNs (mitofusins) 
and VDACs (voltage-dependent anion channels). Ubiquitination of these mitochondrial 
proteins induce mitophagy. This figure is adapted from Pickerell and Youle, (2015). 
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proteolytic degradation, parkin-mediated ubiquitination of these substrates appears to 
induce mitophagy in these damaged mitochondria, leading to their turnover (36,38). 
These parkin substrates include TOMM70a; mitofusin 1 and 2; VDAC 1, 2 and 3; and 
hexokinase 1 (37). Notably, the mitofusins are critical regulators of mitochondrial 
morphology and govern fusion, fission and mitophagy processes, the significance of 
which is exemplified by the fact that certain mutations in mitofusin 2 are causative of the 
incurable neurological disorder Charcot–Marie–Tooth disease (24,39). Activation of 
parkin’s ubiquitin ligase activity is therefore a critical step in initiating mitophagy and 
maintaining mitochondrial fidelity. Consequently, several PD-linked mutations in parkin 
that directly or indirectly hinder its ubiquitin ligase activity have been found to impair 
mitophagy (40-42). 
 
 
 
1.3 Ubiquitination and Protein Degradation 
A delicate balance between protein synthesis and degradation keeps all living organisms 
in a constant state of flux. This dynamic nature of cellular metabolism was established in 
work by Rudolph Schoenheimer, who challenged the historical view that proteins and 
body tissues were largely static entities. Schoenheimer was one of the first scientists to 
use chemical isotopes to address biological problems. In the late 1930s, he fed rodents a 
variety of fatty acids and proteins containing deuterium (2H) and heavy nitrogen (15N), to 
test whether these isotopes were metabolized for energy, or withheld in cells (43,44). His 
finding that the vast majority of 2H and 15N were incorporated into existing tissues was a 
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shock to many, who predominantly believed that ingested fats and proteins were used as 
immediate energy sources. Schoenheimer’s experiments suggested that new proteins were 
being continuously synthesized in the body. However, since the weights of the animals 
were unchanged after the experiment, an equivalent amount of protein degradation must 
have occurred to compensate. It was subsequently established that protein degradation, 
termed “proteolysis”, actually consumes energy despite the seemingly contradictory fact 
that peptide bond hydrolysis is exothermic (45).  
 
In the 1980’s the biochemical mechanism of protein degradation began to surface, largely 
through discoveries by Aaron Ciechanover and Avram Hershko. They found a small 
protein, only ~8 kDa, was required for ATP-dependent protein degradation (46). The 
landmark study showed this small heat-stable protein, which they originally named ATP-
dependent Proteolysis Factor 1 (APF-1), became covalently linked to protein substrates 
during the proteolytic cycle. Amazingly, Ciechanover and colleagues already recognized 
the importance of cysteine residues in the protein’s function at this early stage, as 
proteolysis was significantly inhibited by N-ethyl-maleimide, a thiol-blocking reagent 
(46). Experiments performed shortly after showed APF-1 was in fact, the same protein 
that was previously found attached covalently to histones through an isopeptide bond with 
its C-terminus (47,48). The protein was renamed ubiquitin (Ub) owing to its ubiquitous 
expression and high degree of sequence conservation across eukaryotes (48). It was 
recognized that Ub-bound proteins were ultimately degraded by proteolytic machinery, 
although the precise details of this mechanism took several years to establish.  
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1.4 E1, E2, E3 and DUB enzymes 
We now know that Ub transfer is a coordinated cascade between multiple different 
enzymes, each with a role to specifically deliver the Ub molecule onto a particular 
substrate protein. Classically, these ubiquitinated substrate proteins are destined for 
degradation by the proteolytic machinery, although it is now recognized that 
ubiquitination also governs many other signaling pathways in the cell. The canonical 
ubiquitination pathway is shown graphically in Figure 1.3 A and can be described as 
follows. Firstly, Ub is “activated” by a ubiquitin-activating enzyme (E1), in an ATP-
dependent step (49). Hydrolysis of ATP by the E1 is coupled to adenylation of the Ub C-
terminus, resulting in subsequent transfer of Ub onto the catalytic cysteine of the E1 (50). 
The linkage between the catalytic cysteine of the E1 and carboxy C-terminus of Ub is a 
thiolester bond, containing sufficient free energy to drive subsequent enzymatic steps. 
Secondly, the E1~Ub conjugate associates with a ubiquitin-conjugating enzyme (E2), 
which accepts Ub from the E1 enzyme by means of thiolester transfer reaction onto its 
own catalytic cysteine (49,51,52). Thirdly, the E2~Ub conjugate associates with a 
ubiquitin ligase enzyme (E3), which catalyzes the final ligation step of Ub onto an amino 
group of a substrate protein, resulting in an isopeptide bond between the substrate and 
carboxy C-terminus of Ub (47,49). This process can repeat several times, adding 
consecutive Ub molecules by means of a polyubiquitin chain. The Ub-substrate linkage is 
maintained until the protein is degraded by the proteolytic machinery, or Ub is removed 
by a deubiquitinating (DUB) enzyme that catalyzes the removal of Ub, the reverse 
reaction of ubiquitin ligases (49). 
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Figure 1.3. Proposed mechanisms of ubiquitination by E3 ubiquitin ligases. 
(A) The canonical ubiquitination pathway is shown, as described in the text. The final 
step in the pathway, catalyzed by E3 ubiquitin ligases, can be achieved by multiple 
mechanisms. These are shown below for (B) RING-type, (C) HECT-type and (D) RBR-
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This simplistic representation of the ubiquitination pathway overlooks many of the 
complexities that enable ubiquitin to act as a signal for so many fundamental cellular 
processes. The completion of the human genome in particular demonstrated the critical 
hierarchical structure of the pathway. While there are only two E1 enzymes in humans, 
there are dozens of E2 enzymes and thousands of E3 enzymes (53). In this manner, the 
ubiquitin-conjugating machinery gains specificity as the pathway proceeds. E1 and E2 
enzymes have relatively conserved protein folds and active site structures, while E3 
enzymes are more unique and employ various functional mechanisms. E3 enzymes 
frequently contain accessory domains or are themselves part of larger multi-domain 
proteins. This hierarchical structure enables remarkable substrate specificity, with E3 
ligases ultimately determining the fate of Ub.  
 
E3 ubiquitin ligases are diverse in structure and functionality, but can generally be 
grouped into a few major families. The first family, the Really-Interesting-New-Gene 
(RING) E3s comprise the vast majority of E3 enzymes in the genome. These ubiquitin 
ligases contain a zinc-binding RING domain, which coordinate two Zn2+ ions in a cross-
brace fashion (54). These enzymes harbor conserved structural features that allow them to 
act as scaffolds for E2~Ub conjugates. RING E3s also generally have affinity for specific 
substrates, bringing them in close proximity to the E2~Ub conjugate. This allows for 
direct transfer of Ub from E2 onto substrate (Figure 1.3 B). In contrast, a second family, 
the Homologous with E6-associated protein C-Terminus (HECT) E3s catalyze 
ubiquitination through a HECT~Ub covalent intermediate. This occurs by transfer of Ub 
onto a catalytic cysteine in the HECT domain, resulting in a thiolester bond (55) (Figure 
1.3 C). Subsequently, Ub is transferred from the HECT domain onto a substrate lysine. 
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While RINGs and HECTs comprise the vast majority of ubiquitin ligases, other smaller 
families of E3s exist, including the “U-box” and “RBR” ubiquitin ligases, which will be 
described in detail below (56,57).  
 
The functional consequence of protein ubiquitination is dictated by several factors, 
including: (i) The substrate tagged with the ubiquitin moiety; (ii) The specific lysine 
residue modified on the substrate; and (iii) The nature of the ubiquitin modification, 
whether a single Ub or a polyubiquitin chain is formed. Multiple ubiquitin molecules can 
be conjugated together in a polymeric chain through of one of seven lysine residues in Ub 
(K6, K11, K27, K29, K33, K48, K63) or the N-terminal amino group (Figure 1.4 A). The 
innumerable potential structures of these polyubiquitin chains bestow the specificity of 
the ubiquitin signal. For example, K48-linked polyubiquitin adopts a relatively compact 
structure, while K63-linked polyubiquitin is significantly more extended (Figure 1.4 B–
C) (58,59). Further, due to a lack of intramolecular contacts in K63-linked polyubiquitin, 
these ubiquitin linkages can adopt a wide range of relative conformations, adding an 
additional level of diversity to the polyubiquitin signal. In general, K48-linked 
polyubiquitinated substrates are destined for proteolytic degradation by the proteasome, 
the classic interpretation of ubiquitination. Conversely, K63-linked chains govern other 
cellular processes including DNA-damage repair in the nucleus and organelle trafficking 
in the cytosol. K6, K11, K27, K29 and K33 polyubiquitin linkages are less well-studied, 
but have also generally been associated with non-proteolytic roles (53). Therefore, the 
signaling possibilities of the ubiquitin system extend far beyond the original proteolysis 
functions originally described by Hershko, Ciechanover and colleagues.  
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Figure 1.4. Different polyubiquitin linkages bestow unique structural features. 
(A) Structure of human ubiquitin, highlighting the N-terminal amino group and seven 
lysine residues (coloured red) that are able to form polyubiquitin linkages with the C-
terminus of another ubiquitin moiety. (B) Lysine 48-linked di-ubiquitin crystal structure, 
PDB: 1AAR. The proximal Ub contributes the amino group in the linkage, while the distal 
Ub is linked by its C-terminus. The proximal Ub is oriented as in (A). (C) Lysine 63-linked 
di-ubiquitin crystal structure, PDB: 2JF5. The proximal Ub is oriented as in (A). 
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Once the ubiquitin signal has served its purpose, the ubiquitin moiety is removed from 
substrates and recycled by deubiquitinating (DUB) enzymes. These are a family of 
approximately 100 hydrolase enzymes that specifically cleave the peptide bond at the 
junction between the C-terminus of ubiquitin and the substrate. Thus, DUB enzymes 
frequently counteract the degradative signal conveyed by E3 ubiquitin ligases and have a 
stabilizing effect, often increasing levels of substrate proteins. Most DUBs catalyze 
deubiquitination using a cysteine protease mechanism, employing a catalytic triad of a 
cysteine, histidine and a third charged or polar residue (60). The histidine residue is 
aligned and polarized by the charged residue, raising its pKa such that it can deprotonate 
the catalytic cysteine’s thiol group. The resulting thiolate anion then performs a 
nucleophilic attack on the peptide bond, resulting in its hydrolysis.  
 
Catalytic mechanisms of DUB enzymes have been well-studied using irreversible 
ubiquitin probes that bind to the active site cysteine in a non-reversible manner, trapping 
the covalent intermediate (61-63). An interesting observation from these studies is that 
active site histidine residues of DUB enzymes are often mis-aligned in the absence of 
substrates (64-66). That is, the orientation of the histidine residue is such that it cannot 
form a Cys-His thiolate-imidazolium ion pair to initiate catalysis. Substrate binding is 
often necessary for DUB enzymes to rearrange the active site residues into a catalytically-
competent conformation. It has been speculated that this regulatory mechanism prevents 
undesirable oxidation of the active site cysteine or engagement of other cysteine-reactive 
molecules in the cell (67,68). DUBs recognize the C-terminal tail of ubiquitin, which is 
linked to a substrate or another ubiquitin molecule in a polyubiquitin linkage (69,70). 
Therefore, different DUB enzymes show remarkable specificity for hydrolyzing specific 
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polyubiquitin linkages, allowing them to relay targeted biological signals. These features 
have made DUB enzymes attractive therapeutic targets in pharmaceutical research (71).  
 
 
 
1.5 RBRs: A Novel Class of Autoinhibited Ubiquitin Ligases 
A small family of E3 ligases exists known as “RBR” ubiquitin ligases, comprising only 
about a dozen of 1000+ E3 ligases contained in the human genome (Figure 1.5). The best 
characterized members of the RBR E3 ligase family are parkin, which is mutated in 
hereditary forms of Parkinson’s disease; HHARI (human homologue of Ariadne), which 
is most closely related to parkin by primary amino acid sequence; and HOIP (HOIL-1-
interacting protein) and HOIL-1 (haem-oxidized IRP2 ubiquitin ligase 1), both of which 
are members of the linear ubiquitination chain assembly complex (LUBAC) that 
specifically catalyzes linear polyubiquitin chains, linked through the N-terminal amino 
group of Ub.  
 
RBR was historically an abbreviation for RING-inBetween-RING, recognizing their 
shared composition of three consecutive protein domains, originally thought to be 
multiple RING domains that cooperated to catalyze ubiquitin ligation (57). This 
assumption was based on the observed ubiquitin ligase activity of these cysteine-rich 
enzymes that presumably coordinated Zn2+ ions like traditional RING domains. However, 
recent advances in our knowledge of these enzymes, including through this work, render 
this nomenclature invalid. Today, we know RBR proteins contain only one RING 
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domain, while the other domains adopt a zinc-coordinating fold that is completely distinct 
from a RING (72-74). Mechanistic studies also revealed that RBR ubiquitin ligases do not 
catalyze Ub transfer directly from E2 to substrate, like traditional RINGs. Instead, RBRs 
employ a catalytic thiolester intermediate with Ub analogous to the HECT mechanism of 
ubiquitin transfer (75-77). Because of the mixed characteristics of both RING and HECT 
ubiquitin ligases, this has led to RBRs being described as “RING/HECT hybrids” (75).  
 
To reduce ambiguity in communication and scientific reports, a new nomenclature has 
been proposed for the RBR domain triad, maintaining the familiar RBR abbreviation 
(Figure 1.5) (78). First, the most C-terminal domain harbors the catalytic site, will be 
named Rcat, and is absolutely Required for catalysis. Secondly, the domain directly 
upstream adopts a similar structure to Rcat but lacks a catalytic site, and is therefore a 
Benign Rcat (BRcat). Finally, the most N-terminal domain is the only true RING domain 
and retains its historic name RING1. It is interesting that, despite their covalent 
mechanism of ubiquitin transfer, the active sites of RBR proteins do not resemble those of 
HECT E3s. Similarly, the RING1 domain in RBRs actually lacks several hallmarks of 
other RING proteins that enable them to recruit E2 enzymes (78). These observations 
suggest that RBRs employ a novel mechanism of ubiquitin transfer. Consistent with this 
idea, there are no examples of isolated Rcat or BRcat domains in other proteins, 
suggesting the triad of RING1–BRcat–Rcat always cooperate together in nature. 
 
In addition to the “RBR” domain triad, most RBR ubiquitin ligases contain an assortment 
of different accessory domains upstream or downstream in sequence from the RBR 
catalytic module (Figure 1.5). Parkin and HOIL-1 both contain N-terminal ubiquitin-like 
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Figure 1.5. Domain architecture of RBR ubiquitin ligases. 
Domain architecture of ten selected members of the RBR family of E3 ubiquitin ligases. 
The common RBR domains; RING1, BRcat and Rcat; are aligned and shown in 
magenta, grey and dark green, respectively. Other notable accessory domains found in 
these proteins are also shown and include Ubiquitin-like domain (UBL), Ubiquitin-
associating domain (UBA), Ubiquitin-interacting motif (UIM), Linear-determining domain 
(LDD), and Glu/Asp rich stretches (Acidic). This figure is adapted from Spratt et al., 2014 
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domains (UBLs), which bear high sequence and structural similarity to ubiquitin and 
subsequently recruit other ubiquitin-associating machinery (79-81). HHARI and its close 
relative, ARI2, both contain an extended C-terminal region named the Ariadne domain. 
Dorfin likewise harbours a C-terminal region of similar size eponymously termed the 
Dorfin domain. HOIP contains a ubiquitin associating (UBA) domain in its N-terminus 
that recruits its associating E3 partner, HOIL-1 during linear polyubiquitin chain 
formation (81). HOIP also contains multiple other zinc-finger domains that confer its 
linear ubiquitin chain specificity (82). Parkin contains an additional zinc-binding domain 
outside the RBR module, originally termed RING0 due to its sequential arrangement 
directly upstream of RING1 (83).  
 
One hallmark of RBR ubiquitin ligases that has recently become apparent is the 
autoinhibited nature of their ubiquitin ligase activity, first demonstrated for parkin in 
2011 (84). Subsequent studies have shown this autoinhibited characteristic also exists in 
other RBRs, although occurring through completely distinct mechanisms. For example, 
the Ariadne domain associates with the Rcat domain to suppress ligase activity in HHARI 
and ARI2 (85), while HOIPs UBA domain maintains an autoinhibited state in the absence 
of HOIL-1 (76,77). This suggests that RBR proteins must be activated by some 
extraneous signal to carry out their full ubiquitination potential. The structural mechanism 
for autoinhibition and release of this state, specifically as it relates to parkin, will be the 
major focus of this dissertation.  
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1.6  Parkin 
Parkin is the most studied member of the RBR family of ubiquitin ligases, due to its 
direct causative link with inherited forms of PD (9). Mutations in the PARK2 gene, which 
encodes parkin, are causative of ARJP, an early-onset form of PD. The nature of these 
mutations are extremely diverse, including exon rearrangements, deletions, and dozens of 
unique missense and nonsense mutations (86) (Figure 1.6 A). The translated product of 
the PARK2 gene is 52 kDa (465 residues), with the RBR module found at the C-terminal 
end of parkin. Directly upstream of RING1, parkin contains a fourth zinc-coordinating 
domain, originally termed RING0, discovered by limited proteolysis experiments (83). 
This name is a misnomer, as we now know this domain is not a RING, and more closely 
resembles an NZF-like zinc finger fold (87). Due to historical connotations—and 
because, BEATLES—this domain name will be amended to RINGO. Parkin also harbors 
a ubiquitin-like (UBL) domain at its N-terminus, followed by a ~75 residue linker with 
little predicted structure. The UBL shares 30% sequence identity and ~60% sequence 
similarity with ubiquitin  (Figure 1.6 D–E). Available structures of the isolated parkin 
UBL and ubiquitin show the overall folds of both proteins are indistinguishable, however 
differences in the primary sequence of the UBL in parkin render it significantly less 
thermodynamically stable than ubiquitin, and more prone to unfolding (88,89). The only 
other region of parkin with a known three dimensional structure is the Benign Rcat 
(BRcat), solved in solution as the isolated domain with an unstructured N-terminal linker 
preceding the structure (72). The BRcat coordinates two Zn2+ ions through a linear zinc-
finger-like fashion and are indispensable to the structure of the domain. At the beginning 
of this dissertation, no other structures of parkin were available and it was unclear how 
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Figure 1.6. Parkin domain map and existing three-dimensional structures. 
(A) Domain map for parkin. Residue numberings and domain boundaries are shown 
beneath. Selected disease-causing mutants are shown above. (B) 1.7 Å resolution 
crystal structure of the UBL domain from mouse parkin. Secondary structure elements 
are labelled. (C) Solution NMR structure of the BRcat domain from human parkin.       
(D) 1.8 Å resolution crystal structure of human ubiquitin, oriented the same way as (C). 
(E) Sequence alignment of ubiquitin and parkin’s UBL, highlighting regions of similarity. 
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the UBL and BRcat domains contributed to the overall structure or function of full-length 
parkin. 
 
Pathogenic mutations in parkin are found throughout each of the 5 structural domains of 
the protein but tend to cluster to the N and C-termini (90) (Figure 1.6 A). Despite 
extensive research, there appears to be no unifying mechanism for how pathogenic parkin 
mutations induce neurodegeneration. Many pathogenic substitutions in parkin are found 
at cysteine residues. Native mass spectrometry experiments have shown Parkin 
coordinates a total of 8 structural Zn2+ ions using its many cysteine residues (35 cysteines 
in total, 7.5% of sequence composition) as zinc-coordinating ligands, suggesting protein 
misfolding as a rationale for loss-of-function in these mutations (83). Additionally, 
certain substitutions in the UBL and BRcat domains (R42P, T351P) have also been 
shown to cause protein unfolding, leading to subsequent proteasomal degradation 
(72,89,91). In contrast, many other substitutions (including, but not limited to: K48A, 
G328E, R334C, T415N, G430D) retain their native fold, but are apparently functionally 
perturbed (72,73,83,88). Unfortunately, the vast majority of these parkin mutations lack a 
biochemical explanation for their deleterious effects. 
 
The best-described role of parkin is at the mitochondria where its ubiquitin ligase activity 
stimulates autophagic recycling of damaged mitochondria through a specialized process 
termed mitophagy (36). Proteomic studies showed that parkin acts to ubiquitinate a range 
of substrates on the outer mitochondrial membrane (37), presumably recruiting 
mitophagy machinery. Proteomic analyses of parkin-dependent polyubiquitin chains in 
mitochondria showed parkin preferentially synthesizes K48 and K63-linked polyubiquitin 
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chains on OMM proteins to stimulate mitophagy (92). Screening of E2 enzymes in vitro 
and in vivo showed specific E2 enzymes appear to be used by parkin, specifically to 
induce mitophagy. These included UbcH5a/b, UbcH7 and the Ubc13/MMS2 
heterodimeric E2 enzyme (93,94). Beyond its role in mitophagy, parkin has also been 
shown to play a role in endoplasmic reticulum-associated protein degradation (ERAD). 
Parkin ubiquitinates misfolded forms of proteins at the endoplasmic reticulum, including 
the parkin-associated endothelin receptor-like receptor (Pael-R), that results in its 
degradation (95). Importantly, Pael-R is a component of Lewy bodies and its degradation 
by parkin is inhibited by certain PD-causing mutations in parkin (95-97). Parkin may also 
play a role in cellular immunity by mediating resistance to intracellular pathogens, 
including Mycobacterium tuberculosis and Salmonella enterica through an autophagy-
like pathway (98). 
 
Biochemical studies using native parkin were sparse in the literature prior to 2011, owing 
to practical difficulties studying untagged, purified forms of parkin. Expression and 
purification of recombinant parkin is challenged by the absolute necessity of protein 
folding around 8 structural Zn2+ ions, dispersed throughout its 4 C-terminal domains. To 
circumvent these challenges, N-terminal solubility tags were regularly employed to aid in 
protein folding and improving solubility both in vitro and in vivo. Commonly used N-
terminal tags included maltose-binding protein (MBP), glutathione S transferase (GST), 
green fluorescent protein (GFP), HA and FLAG tags. These studies identified numerous 
putative parkin interacting proteins and ubiquitination substrates (for an exhaustive list, 
see ref (78)). Unfortunately, it has been demonstrated that these N-terminal tags have 
significant implications on the structure, stability and enzymatic activity of parkin, calling 
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in to question the biological relevance of most of these observations (84,99). N-terminal 
tags decrease the thermal stability of parkin and artificially stimulate its ubiquitin ligase 
activity, increasing the likelihood of false-positive results from experimental assays 
(Figure 1.7 A) (99). It was proposed that this occurs by remodeling parkin from its native 
conformation to a more active form. Therefore, it is essential to study parkin in a native 
state in vitro and in vivo without N-terminal tags.  
 
Indeed, many studies using endogenous or untagged forms of parkin were unable to 
observe robust ubiquitin ligase activity, in contrast to experiments using tagged parkin 
(100-103). A landmark study in 2011 by Chaugule and colleagues used purified human 
parkin and showed the protein actually lacks detectable ubiquitin ligase activity in its 
native state, even when excesses of all other ubiquitination machinery (E1, E2, Ub and 
ATP) were present (Figure 1.7 B) (84). Astonishingly, it was shown that parkin’s 
ubiquitin ligase activity is robustly stimulated simply by deleting the N-terminal UBL 
domain, suggesting the UBL suppresses enzymatic activity in native parkin (84). It was 
rationalized that this occurs through an association of the UBL with the catalytic RBR 
module of parkin, suppressing its activity. Consistent with this idea, addition of excess 
UBL domain to in-vitro ubiquitination assays showed a dose-dependent inhibition of 
parkin’s ubiquitin ligase activity (Figure 1.7 C). The experiments suggested that native 
parkin is autoinhibited, mediated by an intramolecular association of the UBL domain 
(Figure 1.7 D). The structural basis of this autoinhibition and how parkin becomes 
modulated to an activated state remained unknown. 
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Figure 1.7. Ubiquitination assays with untagged parkin showed the UBL domain 
suppresses ubiquitin ligase activity. 
All data in this figure are reproduced, with permission from Chaugule et al. (2011). 
Parkin ubiquitination assays are shown, containing E1 (Uba1), E2 (UbcH7), E3 (various 
parkin species), His-tagged ubiquitin and ATP. Reactions were incubated at 37°C for 1 h 
and then quenched with SDS gel-loading buffer and boiled. Samples were run by SDS-
PAGE and visualized by Western Blot or Coomassie staining as labelled. (A) N-terminal 
tags increase parkin’s ubiquitin ligase activity. (B) Deletion of the UBL (∆UBL) increases 
parkin ubiquitin ligase activity. (C) Dose-dependent inhibition of parkin’s ubiquitin ligase 
activity by an excess of UBL domain. (D) Domain layout of parkin, proposing an 
intramolecular association of UBL with the C-terminal RBR region of parkin.  
Anti-Parkin Anti-HisUb 
Ub’n Ub’n 
C 
Coomassie  
UBL 
+ UBL  
gradient 
+ UBL  
gradient 
+ UBL  
gradient 
D 
	   


? ? ? 
Anti-HisUb 
Ub’n 
Ub’n 
25
1.7 Scope of Thesis 
Although ubiquitin ligase activity is essential for its neuroprotective function, parkin is 
autoinhibited in its native state, most notably by its N-terminal UBL domain. At the start 
of this thesis, the only available structures of parkin were of the N-terminal UBL and the 
BRcat, both solved as the isolated domains (72,104). No information existed about the 
orientation of these structures with respect to the other domains of parkin. Further, it was 
unclear how the three RBR domains, which had not been structurally characterized, 
cooperate together to confer ubiquitin ligase activity.  
 
The objectives of this thesis were: 
1) Identify the mechanism by which the UBL domain maintains an autoinhibited 
structure to suppress parkin’s ubiquitin ligase activity. 
2) Determine how the autoinhibited structure of parkin is modulated to a catalytically-
competent state. 
3) Assess how pathogenic mutations in parkin affect its activation and catalysis. 
4) Rationalize a chemical mechanism of Rcat-mediated ubiquitination for parkin 
 
To address these goals, a comprehensive biophysical characterization of autoinhibited 
parkin was undertaken. A high-resolution NMR strategy was developed to study 
isotopically-labelled human parkin in solution for the first time. These data were used to 
identify the intramolecular binding site of the UBL domain and further revealed allosteric 
structural changes that accompany UBL association and dissociation. Thermodynamic 
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parameters of both UBL and Ub binding were determined to rationalize how parkin’s 
inhibitory domain (UBL) and substrate (Ub) cooperate to regulate autoinhibition. 
 
While this study was underway, multiple reports emerged identifying serine 65 
phosphorylation of both Ub and parkin’s UBL as key inducers of parkin activity. To 
examine the roles of these phosphorylation signals, several methods were used to 
generate S65-phosphorylated Ub and UBL including: chemical modification, orthogonal 
translation in E. coli, and phosphorylation by catalytically active forms of PINK1. To 
understand the structural consequences of phosphorylation, the three-dimensional 
structure of S65-phosphorylated parkin UBL was determined. Further, the roles of 
phospho-ubiquitin and phospho-UBL were examined in reorganizing the structure of 
parkin to an activated state. 
 
Finally, to investigate a chemical mechanism of catalysis in activated parkin, a detailed 
characterization of active site atoms in parkin was performed, using primarily NMR 
spectroscopy. Chemical biology approaches were used to generate an activated 
parkin~ubiquitin intermediate that will provide further mechanistic knowledge into 
ubiquitin transfer from parkin onto target mitochondrial substrates. Since all RBR 
ubiquitin ligases harbour conserved catalytic machinery, these studies likely extend our 
knowledge across the family of RBR ubiquitin ligase. Specifically with respects to parkin, 
this work provides valuable insight into the induction of the mitophagy pathway, which 
has key implications for cellular fidelity and neurodegenerative diseases, including PD.  
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Chapter 2 
  
Disruption of the Autoinhibited State Primes Parkin for 
Activation and Catalysis† (1,2) 
 
2.1  Introduction  
Parkin belongs to the family of E3 ubiquitin ligases, known as RING1–BRcat–Rcat 
(RBR) ubiquitin ligases (3,4). This family of E3 ligases catalyze ubiquitination using a 
RING-HECT hybrid mechanism, employing both an E2-recruiting RING domain and a 
covalent catalytic intermediate with ubiquitin (5). Members of the RBR family are 
autoinhibited by unique accessory domains (see Figure 1.5) (6-8). Specifically, parkin 
contains an N-terminal Ubiquitin-like (UBL) domain that resembles parkin’s substrate, 
ubiquitin, in sequence and structure (see Figure 1.6). Native parkin is largely inactive but 
studies have shown deletion of the UBL domain dramatically increases parkin’s ubiquitin 
ligase activity (see Figure 1.7) (6,9). It was hypothesized this occurs through an 
intramolecular association of the UBL with parkin’s C-terminal region to suppress 
catalytic activity. At the beginning of this study, the structural basis of UBL-mediated 
autoinhibition was unknown. Only structures of the isolated UBL and BRcat were 
available (10,11), providing little insight into how the UBL regulates catalytic activity or 
how parkin recruits ubiquitin or E2 enzymes. To understand how the inhibitory and 
 †  Data presented in this chapter has been published. It is reproduced here, with permission from:  
1. Spratt, D. E., Julio Martinez-Torres, R., Noh, Y. J., Mercier, P., Manczyk, N., Barber, K. R., Aguirre, J.
D., Burchell, L., Purkiss, A., Walden, H., and Shaw, G. S. (2013) A molecular explanation for the
recessive nature of parkin-linked Parkinson's disease. Nat Commun 4, 1983. 
2. Kumar, A., Aguirre, J. D., Condos, T. E., Martinez-Torres, R. J., Chaugule, V. K., Toth, R.,
Sundaramoorthy, R., Mercier, P., Knebel, A., Spratt, D. E., Barber, K. R., Shaw, G. S., and Walden, H.
(2015) Disruption of the autoinhibited state primes the E3 ligase parkin for activation and catalysis.
EMBO J 34, 2506-2521. 
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catalytic domains function in parkin, an extensive biophysical and biochemical 
characterization of parkin was carried out in solution. It was shown that the tertiary 
structure of native parkin is dependent on the interaction of the UBL domain with the C-
terminus to maintain a compact, globular structure. Using a new isotopic labelling 
strategy, amide resonance assignments were determined for the RORBR domain of parkin 
and these were used to characterize the autoinhibitory association of the UBL by NMR 
spectroscopy, complemented by high-resolution X-ray crystal structures. It was 
discovered that extensive intramolecular contacts in parkin convey allosteric changes 
throughout the structure that are influenced by the UBL domain. Further, the effects of 
serine 65 phosphorylation of ubiquitin and parkin’s UBL was studied, a proposed 
activating signal for parkin (12-16), and it was found the role of the UBL is to maintain 
autoinhibition in the absence of this phosphorylation signal. Phospho-ubiquitin binding 
induces an allosteric displacement of the UBL domain, revealing a ubiquitin recognition 
site used to assist recruitment of the E2~ubiquitin conjugate. Together, the data establish 
a framework for understanding the cycle of parkin inhibition and activation. 
 
 
 
2.2  Materials and Methods 
2.2.1 Cloning, Protein Expression and Purification 
The DNA fragment encoding the human park2 gene was inserted into a pET SUMO 
expression system vector (Invitrogen). UBL, ∆UBL, RORBR, RINGO–RING1 and 
BRcat–Rcat constructs were then generated using a modified site directed mutagenesis 
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protocol (17). PCR reactions were then subjected to extensive Dpn1 digestion overnight 
at 37 °C. The following day, plasmid DNA was purified using a PCR clean-up kit (Bio 
Basic Inc) and 10 µL of plasmid product was transformed into competent MM294 cells 
and incubated on antibiotic-treated LB-agar plates overnight at 37 °C. Multiple colonies 
(four to six) were selected, cultured and their plasmid DNA sequenced to verify the 
desired mutagenesis.  
 
All human parkin constructs (full-length parkin, UBL, ∆UBL, RORBR, BRcat–Rcat) 
were expressed as His-SUMO fusion proteins in E. coli BL21(DE3) cells (see Figure 
2.1). Cells were grown at 37 °C in either LB or minimal media (described in detail below) 
supplemented with 500-700 µM ZnCl2. Cells were induced at an OD600 of 0.8 with 0.5 
mM of isopropyl β-D-1-thiogalactopyranoside (IPTG) (or 25 µM IPTG for full-length 
parkin) and incubated overnight at 16 °C. Cells were harvested in lysis buffer (50 mM 
Tris, 500 mM NaCl, 0.5 mM TCEP, 25 mM imidazole, pH 8.0), lysed by an EmulsiFlex-
C5 homogenizer (Avestin), ultracentrifuged at 41,000 rpm (124,000 x g) and proteins 
purified by Ni2+ affinity using a HisTrap FF column on an AKTA FPLC (GE Healthcare). 
The column was extensively washed with wash buffer (50 mM Tris, 200 mM NaCl, 0.5 
mM TCEP, pH 8.0) and proteins eluted with elution buffer (50 mM Tris, 200 mM NaCl, 
0.5 mM TCEP, 500 mM imidazole, pH 8.0). Fractions containing the protein of interest 
were pooled, Ulp1 protease was added to cleave the SUMO tag (~1:50 ratio Ulp1:parkin) 
and dialyzed overnight at 4 °C against wash buffer. After cleavage was complete, proteins 
were passed over the HisTrap FF column again in wash buffer and the flow through was 
collected, containing proteins of interest. Proteins were concentrated and subjected to size 
exclusion chromatography on a HiLoad Superdex 75 for a final purification step.  
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Drosophila Melanogaster parkin constructs (RORBR, BRcat, Rcat) were expressed as 
GST-fusion proteins in E.coli BL21 codon+RIL cells. Cells were grown in either LB or 
minimal media supplemented with 500-700 µM ZnCl2. Cells were induced at an OD600 of 
0.8 with 0.5 mM of isopropyl b-D-1-thiogalactopyranoside (IPTG) (or 25 µM IPTG for 
full-length parkin) and incubated overnight at 16 °C. Cells were harvested in lysis buffer 
(25 mM Tris, 150 mM NaCl, 3 mM DTT, pH 7.5) and lysed by an EmulsiFlex-C5 
homogenizer (Avestin), ultracentrifuged at 41,000 rpm (124,000 x g) and proteins 
purified by GST affinity on a GSTrap FF column on an AKTA FPLC (GE Healthcare). 
Proteins were eluted from the GST column using a high pH gradient elution buffer (25 
mM Tris, 150 mM NaCl, 3 mM DTT, pH 10), followed by addition of 10% (v/v) 
neutralizer buffer (1 M Tris, pH 7.0). Fractions containing the protein of interest were 
pooled, TEV protease was added to cleave the GST tag (~1:50 ratio TEV:parkin) and 
proteins were dialyzed overnight against lysis buffer at 4 °C. After cleavage was 
complete, proteins were passed over the GSTrap FF column again in lysis buffer and the 
flow through was collected, containing proteins of interest. Proteins were concentrated 
and subjected to size exclusion chromatography on a HiLoad Superdex 75 for a final 
purification step. 
 
2.2.2 MOPS Minimal Media 
MOPS minimal media was prepared as either a 10X stock solution (for H2O growths) or a 
1X solution (for D2O growths).  
 
To prepare 1 L of 10X MOPS stock solution in H2O: 83.7 g MOPS and 7.2 g tricine were 
added to a sterile flask and 500 mL autoclaved H2O was added. The solution was basified 
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to pH 7.4 with ~20 mL of 10 M KOH. Next, 10 mL of 10 mM FeSO4*7H2O (freshly 
made) was added, causing the media to turn a yellow colour. 0.48 g of K2SO4, 5 µL of 1 
M CaCl2, 1.06 g MgCl2*6H2O and 29.22 g NaCl were then added. Finally, 10 mL of a 
1000X micronutrient stock (standard trace elements used with M9 media) was added and 
the final volume was brought to one liter with autoclaved H2O. The solution was filter 
sterilized (0.2 µm filter), removing much of the yellow colour, and aliquoted and stored at 
-20 °C until use. To prepare 1X media from 10X stock, 100 mL of 10X MOPS was added 
to 900 mL autoclaved H2O along with 3 mL of 0.132 M K2HPO4. Glucose and 
ammonium chloride (either isotopically enriched or natural abundance) were added along 
with the appropriate antibiotic for the expression plasmid. For expression of parkin 
proteins containing zinc, 1.2 mL of a 0.5 M ZnCl2 solution was always added to the 
media before induction. 
 
To prepare 900 mL (1 kg) of 1X MOPS media in 100% D2O: 7.54 g MOPS and 0.65 g 
tricine were added to a sterile flask and 500 mL D2O was added. The solution was pH’d 
to 7.4 with KOD (potassium deuteroxide). Next, 0.9 mL of 10 mM FeSO4*7H2O (freshly 
made in D2O) was added. 0.04 g of K2SO4, 0.5 µL of 1 M CaCl2 (in D2O), 0.09 g 
MgCl2*6H2O, 2.63 g NaCl and 0.07 g of K2HPO4 were then added. 0.9 mL of a 1000X 
micronutrient stock (standard trace elements used for M9 media but in D2O) was added 
and the final volume was brought to one liter with D2O. The solution was filter sterilized 
(0.2 µm filter) and used immediately. 13C/2H-glucose (2 g) and 15N-ammonium chloride 
(1 g) were added as powder along with the appropriate antibiotic for the expression 
plasmid (antibiotics were separately prepared in D2O for deuterated growths). For 
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expression of parkin proteins containing zinc, 1.2 mL of a 0.5 M ZnCl2 solution (also 
prepared in D2O) was always added to the media before induction. 
 
To prepare 150 mL of 70% D2O MOPS media: 15 mL of 10X MOPS stock solution, 1.5 
mL of 0.132 M K2HPO4, 1.5 mL of 40% glucose, 1.5 mL of 10% NH4Cl and the 
appropriate antibiotic (all in H2O) were added to 82 mL 70% D2O and 48 mL 100% D2O. 
 
For deuterated growths, cells were transitioned into 100% D2O as follows. E. coli 
BL21(DE3) cells were freshly transformed and plated on LB-agar plates with the 
appropriate antibiotic. Once colonies were visible on the plates, 4 mL starter cultures 
were prepared in LB media and allowed to reach saturation at 37 °C. Saturated cultures 
were used to inoculate 150 mL 70% D2O MOPS media to an OD600 of 0.05 (150 mL of 
70% D2O MOPS media was sufficient for 2 L growths). 70% D2O cultures were grown at 
37 °C with shaking until an OD600 of 0.8-0.9 was reached (avoiding senescence). Cultures 
were then centrifuged at 4000 x g (without cooling) and resuspended in 1-2 mL of pre-
warmed 100% D2O MOPS media. Resuspended cells were then added to the final 100% 
D2O media until an OD600 of ~0.04 was reached and allowed to grow at 37 °C until 
induction with IPTG at an OD600 of ~0.8. Induction was at 16 °C for 20-24 hours.  
 
2.2.3 Analytical Ultracentrifugation 
Sedimentation velocity experiments were performed using a Beckman Coulter XL-A 
analytical ultracentrifuge equipped with an An-60 Ti rotor. Samples at 2-20 µM protein 
concentration were extensively dialyzed into 25 mM Tris HCl, 50 mM NaCl and 0.5 mM 
TCEP pH 8.0 before experiments. Samples (380 µl) and matching buffer blank (400 µL) 
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were prepared in a double sector cell (1.2 cm) with quartz windows. All experiments were 
conducted at 45,000 rpm at 20 °C with 30+ minutes for temperature equilibration. 
Velocity cells were scanned at equal intervals (60 scans total) and the absorbance at 280 
nm measured with three replicates averaged per scan. Data were processed by c(s) 
distribution and analyzed using the program SEDFIT v12.1 (18). Non-linear regression 
was used to determine the frictional ratio (f/f0) for each species as well as the 
sedimentation coefficient corrected to 20 °C. All data were fit to an rmsd equal or less 
than 0.008 in SEDFIT. 
 
2.2.4 Isothermal Titration Calorimetry 
All isothermal titration calorimetry experiments were performed using a NanoITC (TA 
Instruments) at 25°C. Experiments were completed 2–3 times using freshly prepared  
proteins in 50 mM HEPES, 50 mM NaCl and 250 µM TCEP at pH 7.5. Proteins in the 
cell and syringe were extensively dialyzed in the same buffer before experiments. In all 
cases, concentrated RORBR was injected into UBL variants in the cell. The optimal 
concentrations of protein in the experiments were determined to be: 300 µM RORBR 
parkin titrated into 30 µM UBL, 650 µM RORBR titrated into 60 µM UBLS65E, 500 µM 
RORBR titrated into 35 µM pUBL. Concentrations of RORBR and UBL were verified by 
absorbance at 280 nm when unfolded in guanidine HCl. The extinction coefficients used 
were 11,000 M-1cm-1 for unfolded UBL and 47,900 M-1cm-1 for unfolded RORBR. All 
data were processed and analyzed in NanoAnalyze v3.1.2 (TA instruments) to determine 
best fit values for KA, ∆H and N. ∆S was calculated according to eq (1).  
 ∆G = –RTlnKA = ∆H – T∆S 
 ∆S = RlnKA  + (∆H/T)                                              eq (1) 
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2.2.5 NMR Spectroscopy 
All NMR experiments were collected at 25˚C on a Varian Inova 600 MHz NMR 
spectrometer equipped with a triple resonance cryogenic probe and z-field gradients. All 
NMR data were collected in 25 mM HEPES pH 7.0, 100 mM NaCl, 0.5 mM TCEP, 10% 
D2O, 200 µM DSS as an internal reference and 200 µM imidazole as an internal pH 
indicator. All data were processed using NMRPipe (19) and analyzed using NMRViewJ 
(20). 
 
NMR experiments for RORBR were all collected using a sensitivity-enhanced 1H-15N 
TROSY pulse sequence without 15N decoupling (21,22). The 1H spectral window was 
8000 Hz centered on 4.780 ppm and the 15N spectral window was 1700 Hz centered on 
118.100 ppm. An acquisition time of 64 ms and a 1.7 s recycling delay were used in all 
cases. Triple resonance experiments (HNCA (23), HN(CO)CA (24), HN(CA)CB (25), 
HN(COCA)CB (24), HNCO (23), HN(CA)CO (24)) for assignment of the RORBR 
backbone were conducted using 1H-15N TROSY-based pulse sequences with deuterium 
decoupling for fully deuterated proteins (26). 
 
Heteronuclear NOE experiments (27) were performed using 500 µM 2H/13C/15N-labelled 
RORBR. Proton saturation was achieved through a 5-s irradiation following an 11-s 
relaxation delay. The equivalent non-saturated experiment contained a 16-s relaxation 
delay. Long recycling delays were essential due to the long T1 relaxation times of amides 
in deuterated RORBR, which must be completely recovered for accurate NOE 
measurement (28,29). Both saturated and non-saturated experiments were conducted in 
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duplicate, collected in an interleaving manner. NOEs were measured in NMRViewJ (20) 
and plotted as the average NOE ± standard error. 
 
Interaction experiments were conducted using 2H/12C/15N-labelled RORBR and 13C-
labelled Ub or UBL (or phosphorylated/phosphomimetic variants). 1H-15N TROSY-
HSQC spectra were collected to monitor chemical shifts of backbone amide in RORBR 
as described above. 1H-13C HMQC spectra (30) were collected to monitor chemical shifts 
of side chain methyl groups in Ub or UBL. Amide chemical shift perturbations were 
quantified according to eq (2). 
 
CSP= 0.2∆δN2+∆δH2        eq (2) 
Where ∆δN represents the change in nitrogen chemical shift (in ppm) and ∆δH represents 
the change in proton chemical shift (in ppm).  
 
 
Paramagnetic relaxation enhancement (PRE) experiments were used to confirm the 
orientation of the pUb molecule with respect to the RORBR protein. Briefly, 2H/12C/14N-
labelled cysteine-substituted Ub (L8C or K48C) was expressed in minimal media, 
purified and phosphorylated using Pediculus humanus GST-PINK1 as described in 
Chapter 3. Proteins were spin-labelled with 3-(2-iodoacetamido)-PROXYL (Sigma 
Aldrich) by incubating each protein with 10 molar equivalents of spin label for 2 h at 
room temperature and then dialyzed exhaustively at 4°C. ESI-MS confirmed quantitative 
(> 95%) phosphorylation and successful incorporation of spin label (~90 and ~60% spin 
label incorporation for L8C and K48C, respectively). 1H-15N TROSY-HSQC spectra were 
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collected monitoring 400 µM 2H/13C/15N-labelled RORBR before and after the addition 
of 1.2 molar equivalents of each nitroxide-labelled pUb variant. Identical spectra were 
collected following the addition of 10 molar equivalents of fresh ascorbic acid to quench 
the nitroxide spin tag. PRE factors (I/I0) for RORBR were determined in NMRViewJ (20) 
by measuring peak intensities with the active and quenched nitroxide spin tag.  
 
 
 
2.3 Results 
2.3.1 Expression and purification of parkin constructs  
At the time this study was conceived, few biochemical experiments had been performed 
with untagged, human parkin owing to the protein’s poor solubility without an 
appropriate affinity tag. His or GST-fusions of full-length parkin produced relatively 
small quantities of soluble recombinant protein with protease degradation evident even 
under expression at 16 °C (31). It was determined that recombinant expression of human 
parkin in E. coli was markedly improved using an N-terminal His-SUMO(small 
ubiquitin-like modifying protein)-fusion tag. Interestingly this tag folds into a stable 
protein with similar structure to parkin’s substrate, ubiquitin, and parkin’s own UBL 
domain. Using site directed mutagenesis, over 6 parkin constructs were generated 
employing an N-terminal His-SUMO tag (Figure 2.1 A): Full length parkin (1-465), UBL 
(1-76), ∆UBL (77-465), RORBR (141-465), BRcat–Rcat (321-465), and Rcat (410-465). 
While UBL, Rcat and BRcat could all be expressed as isolated domains, RINGO and 
RING1 domains were only soluble as part of longer fragments (Figure 2.1 B). This 
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Figure 2.1. Overview of parkin constructs used and their recombinant purification. 
(A) Domain map of parkin constructs used in this study. Residue numberings denote 
construct boundaries. (B) SDS-PAGE gels showing representative affinity purification of 
each construct. An asterisk (*) represents the final product used for experiments.          
Note: RINGO-RING1 construct was not soluble and could not be purified. 
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suggested RINGO and RING1 may have an indispensable position in the overall structure 
in parkin, central to the protein folding. All constructs were soluble in LB and minimal 
media (as described in section 2.3.3) supplemented with 0.5-0.7 mM ZnCl2 and protein 
induction only after cells had been cooled to 16 ˚C. The SUMO-fusion protein is easily 
removed from parkin after purification by the SUMO-specific protease, Ulp1, to generate 
native, untagged protein. The use of untagged parkin in all experiments was essential 
given the known influence of affinity tags on parkin’s E3 ligase activity (9). All the above 
constructs were purified to homogeneity using gel filtration chromatography as a final 
purification step prior to all experiments. 
 
2.3.2 Parkin maintains a compact structure mediated by the UBL domain 
To understand the parkin structure in the context of the full-length protein, analytical 
ultracentrifugation was used to study its overall shape in solution. Under the conditions 
used, full-length parkin sediments as a monomer with a sedimentation coefficient of 4.1 S 
(Figure 2.2 A). Interestingly the frictional coefficient, f/f0, which reports the offset in 
shape of a molecule relative to a perfect sphere, increased from 1.38 to 1.53 in ∆UBL–
parkin, where the UBL domain is removed. This suggests parkin adopts a globular 
structure dependent on the presence of the UBL domain. This observation was also 
observed by small-angle X-ray scattering (SAXS) data collected by our colleagues at the 
University of Dundee. The results show removal of the UBL domain leads to an extended 
conformation of parkin, with a larger radius of gyration (32.0 Å; Dmax 110 Å) than the 8-
kDa larger full-length protein (29.0 Å; Dmax 95 Å) (Figure 2.2 B, C). These results 
indicate the molecular envelope of ∆UBL–parkin has a more extended shape, and that in 
the presence of the UBL domain parkin adopts a more compact conformation. The most 
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Figure 2.2. Parkin maintains a compact tertiary structure mediated by the UBL. 
(A) Sedimentation velocity experiments of parkin, ∆UBL, and BRcat–Rcat. All data were 
analyzed using the Lamm equation and fit to a c(s) distribution. Sedimentation 
coefficients, corrected to 20 °C and in H2O, were determined to be 4.1 S for full-length 
parkin, 3.5 S for ∆UBL and 2.2 S for BRcat–Rcat. Fitted frictional coefficients (f/f0) were 
calculated to be 1.38 for full-length parkin, 1.53 for ∆UBL and 1.31 for BRcat–Rcat.     
(B) Superposition of scattering data (left) and distance distribution (right) plots from 
purified human parkin samples, wild-type (red) and ∆UBL-parkin (blue). The plots show 
the quality of the data and the radius of gyration. (C) Representative and averaged ab 
initio models of wild-type parkin (red, left) and ∆UBL (blue, right). Two views for each 
protein are shown rotated 90° about the x axis.  (D) 1H-15N HSQC spectra of UBL 
domain alone (left spectrum) and after addition of 3 molar equivalents unlabelled ∆UBL 
(right spectrum). The significant broadening of UBL resonances reports an interaction 
with ∆UBL, forming a higher molecular weight species.  
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logical rationale for these findings is that the UBL interacts with the C-terminal region of 
parkin through an unstructured linker from residues 77-140, as was suggested by 
Chaugule and colleagues (6). To confirm this, 1H-15N HSQC spectra of 15N-labelled UBL 
were acquired by NMR spectroscopy. Given the small molecular weight of the UBL 
domain (~8.5 kDa), a spectrum is obtained where all backbone amide correlations are 
readily observed (Figure 2.2 D, left). Conversely, the equivalent sample of 15N-labelled 
UBL with an excess of unlabelled ∆UBL produced a severely broadened spectrum, with 
few resonances visible at equivalent contour levels (Figure 2.2 D, right). The result is 
indicative of an interaction of UBL with ∆UBL, forming a higher molecular weight 
species with attenuated T2 relaxation time, resulting in the broadened spectrum.  
 
Since the NMR data suggested an intramolecular interaction between UBL and ∆UBL, 
we also wondered if other intramolecular interactions might exist within the RINGO–
RING1–BRcat–Rcat domains. At the time of the study, human parkin could not be 
expressed in minimal media due to poor protein solubility, presumably due to mis-
incorporation of the eight Zn2+ ion cofactors required for protein folding (31). As a 
substitute, the Rcat, BRcat–Rcat and RORBR domains were expressed from Drosophila 
melanogaster (fly) parkin in minimal media to acquire NMR spectra. The analogous 
domains in fly parkin were significantly more soluble in E. coli and sufficient protein was 
purified to conduct NMR experiments. Comparison of HSQC spectra for Rcat and 
BRcat–Rcat show the resonances in Rcat overlap nearly perfectly in the tandem domain, 
suggesting the two domains do not interact in parkin (Figure 2.3 A). This was further 
supported by NOE data showing the 26-residue linker between the two proteins is 
unstructured (PDB: 2M48, BMRB: 18990). Conversely, the spectrum of RORBR showed 
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Figure 2.3. BRcat and Rcat are remote in parkin but interact with RINGO and RING1 
(A) Superposition of 1H-15N HSQC spectra for fly parkin BRcat–Rcat(black contours) with 
spectra for the individual BRcat (pink) and Rcat (blue) domains. The alignment of 
resonances in the tandem protein indicates these domains do not interact together.      
(B) Superposition of 1H-15N HSQC spectra for RORBR (red contours) and BRcat–Rcat 
(teal contours). The large number of chemical shift changes indicates that RINGO–RING1 
interact with BRcat–Rcat. Residue assignments in BRcat and Rcat that undergo the 
largest changes in chemical shift are indicated. 
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B 
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many chemical-shift changes were observed in both BRcat (including D367, V380, V381 
and N384) and Rcat (including G447, A457, W465 and C475) domains in the context of 
RORBR (Figure 2.3 B). This indicates that the environments of these residues in BRcat 
and Rcat are changed by the presence of the RINGO and RING1 domains. The 
interpretation of the data is that the RINGO and/or RING1 domains are interacting with 
the BRcat–Rcat structure forming a more compact arrangement in native parkin. 
 
2.3.3  Development of a high-resolution NMR strategy for human parkin 
While the results in Figure 2.3 represented the first report of NMR spectra of parkin’s C-
terminus encompassing all four zinc binding domains, the quality of the data precluded a 
high-resolution analysis of protein interactions in parkin. The NMR spectra suffer from a 
lack of resonance intensity, broad linewidths, and significant overlap in both 1H and 15N 
dimensions. This arises from several factors including limited sample concentration and 
the relatively large molecular weight of RORBR (~37 kDa). In NMR spectroscopy, 
molecules larger than about 20 kDa experience significantly slower molecular tumbling 
and decreased transverse (T2) relaxation times, the major source of signal attenuation in 
protein samples (32). This manifests as increased (broad) linewidths and often-
undetectable resonance signals. To overcome these challenges, we sought to design a 
minimal media that could produce a significantly increased fraction of soluble human 
parkin, and that could be broadly applied to different isotopic labeling schemes for NMR.  
 
As previously mentioned, human parkin constructs comprising the C-terminal zinc 
binding domains were largely insoluble in M9 minimal media, by far the most widely 
used minimal media used for isotopic labeling (Figure 2.4). Compared to LB media, 
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Figure 2.4. Solubility of human parkin RORBR in different expression media. 
SDS-PAGE showing solubility of overexpressed His-SUMO-RORBR (indicated by black 
arrow) from E. coli BL21(DE3) cells grown in LB media, M9 minimal media, and MOPS 
minimal media. Gel samples were taken directly before induction with IPTG 
(uninduced), 16 hours after induction with IPTG (induced), and following cell lysis and 
ultracentrifugation to separate soluble and insoluble fractions.  
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parkin RORBR expressed in M9 minimal media was almost completely insoluble, despite 
similar overall protein expression levels. Therefore, other minimal media compositions 
were explored. While M9 minimal media is buffered by high concentrations of phosphate, 
alternate culture media can be designed using other buffering agents, for example, with 3-
(N-morpholino)propanesulfonic acid (MOPS) to maintain the media buffering capacity. A 
medium using MOPS buffer was developed by Neidhardt and colleagues in 1974 and was 
initially targeted towards 32S-labelling of proteins and DNA (33). Initial trials using this 
recipe were promising in attaining soluble parkin RORBR from minimal media. It was 
suspected the enhanced solubility was from improved protein folding and zinc 
incorporation in RORBR domains due to significantly less phosphate available to deplete 
zinc in the insoluble form of zinc(II) phosphate. Therefore, the Neidhardt recipe was 
modified to further reduce the phosphate concentration to minimal levels necessary for 
E.coli growth and an excess of zinc chloride was added (Table 2.1). In the modified 
recipe, hereafter referred to as “MOPS minimal media”, human RORBR-parkin solubility 
was dramatically improved (Figure 2.4). Further, 13C-glucose and 15N-ammonium 
chloride could be used as the sole carbon and nitrogen sources to obtain isotopically 
labelled protein for NMR studies.  
 
While employing the MOPS minimal media significantly increased protein concentration 
in our NMR samples (≥500 µM), this does not address the unfavourable T2 relaxation 
properties of such a large molecule. The problem of rapid T2 relaxation in large proteins 
is often overcome by deuteration (2H incorporation) of all non-exchangeable protons in 
the protein backbone and sidechains (34,35). This seeks primarily to reduce proton-proton 
dipolar coupling in the sample by replacing most protons in the molecule with deuterium. 
55
Chemical MOPS M9 
 K2HPO4 0.4 mM 
 KH2PO4 22 mM 
 Na2HPO4 42 mM 
 MOPS 40 mM 
 Tricine 4.0 mM 
 ZnCl2  0.5 mM‡  0.5 mM‡ 
 NaCl 50 mM 8.6 mM 
 K2SO4 276 µM 
 MgSO4 2 mM 
 MgCl2 523 µM 
 CaCl2 0.5 µM 100 µM 
 FeSO4 10 µM 1 µM 
Table 2.1. Composition of MOPS minimal media.  
Final chemical composition of MOPS minimal media 
compared to standard M9 minimal media. An 
identical amount of carbon/nitrogen sources (as 
glucose/NH4Cl) and trace micronutrients (including B, 
Mo, Co, Cu, Mn) were supplemented to both media. 
‡ Supplemental zinc is added specifically for parkin expression 
and is not required for cell growth.  
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Therefore it was attempted to express RORBR–parkin in MOPS minimal media 
generated in 100% D2O and using 15N-ammonium chloride and 2H/13C-glucose as the sole 
nitrogen and carbon sources. It was determined that E. coli can successfully culture in the 
MOPS minimal media in 100% D2O with a growth time from inoculation to an OD600 of 
0.8 at 37 °C on the order of 10 hours (Figure 2.5 A). Further, overexpressed RORBR was 
properly folded and could be purified to homogeneity by standard affinity purification 
procedures and gel filtration chromatography (Figure 2.5 B). NMR spectra of 
perdeuterated RORBR clearly show the increase in spectral quality when compared to the 
protonated spectrum (Figure 2.5 C, D). Dozens of amide resonances that were 
undetectable in the protonated spectrum are readily observed in the deuterated spectrum. 
The well-dispersed nature of the deuterated spectrum also confirms the protein remains 
well-folded and adopts significant secondary structure in solution. In large, deuterated 
proteins, spectral resolution can be enhanced by employing a Transverse Relaxation 
Optimized Spectroscopy (TROSY) pulse sequence (21). TROSY experiments select for 
only the slowest relaxing (most narrow) component of an NMR multiplet signal, 
discarding the faster relaxing components that only serve to broaden the final signal. 
While the TROSY effect is theoretically most pronounced at magnetic field strengths of 
900 MHz–1 GHz, significant benefits were observed when spectra of perdeuterated 
RORBR were collected with a TROSY-HSQC pulse sequence at 600 MHz (Figure 2.5 
E). The spectra show increased resolution in the 15N dimension and more equalized peak 
intensities across the spectrum. 
 
Next, triple resonance experiments were collected with the goal of assigning the protein 
backbone of RORBR. 1H-15N-13C-correlated HNCA, HN(CO)CA, HN(CA)CB, 
57
Figure 2.5. MOPS minimal media can be employed to produce perdeuterated 
parkin for TROSY-NMR experiments. 
(A) Growth curve of E. coli in MOPS minimal media in 100% D2O, supplemented with 
2H/13C-glucose and 15N-ammonium chloride. Cell density was measured by absorbance 
at 600 nm. The marked arrow represents the time of induction with 0.7 mM IPTG and 
temperature reduction to 16 °C. (B) SDS-PAGE of purification of 2H/13C/15N-labelled  
RORBR parkin. The final lane represents the purified protein used for NMR 
experiments. (C-E) 1H-15N correlated NMR spectra of parkin RORBR showing 
significant improvement of spectral intensity upon perdeuteration (D panel) and spectral 
linewidth upon application of a TROSY pulse sequence (E panel). 
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HN(COCA)CB, HNCO and HN(CA)CO experiments were all obtained using a TROSY-
HSQC pulse sequence and deuterium decoupling optimized for large, perdeuterated 
proteins (Figure 2.6 A-F) (26). Using sequential backbone assignment techniques, over 
95% of non-proline amide resonances in RORBR–parkin could be assigned. This 
provided atomic probes evenly distributed throughout the entire structure of parkin that 
can be used to define protein interaction sites, dynamics and conformational changes in 
the protein backbone.  
 
The amide assignments were used to measure 1H-15N heteronuclear NOEs, which provide 
valuable information on flexibility and dynamics of the protein backbone (27). In these 
experiments, two 1H-15N-correlated spectra are collected where one experiment contains a 
5 second proton saturation period prior to the pulse sequence and the other spectrum 
contains a delay of equivalent length. Amides that undergo rapid motions (on the ps to ns 
timescale) show decreased intensity in the proton-saturated spectrum. Analysis of 
heteronuclear NOE values across the RORBR backbone showed significant rigidity 
within all 4 zinc-binding domains, with NOE values near 0.7 (Figure 2.7). Notably, the 
entire BRcat domain exhibited decreased NOE intensity, indicative of overall greater 
flexibility in this domain. However, the smallest NOEs were observed throughout the 
“tether” linking BRcat and Rcat domains, suggesting this is the most flexible region of 
the protein. Interestingly, the tether domain appears to be separated into two regions, 
separated by a significantly less flexible section from residues E395-E404. The data show 
RORBR–parkin adopts significant tertiary structure, with increases in backbone 
flexibility observed in BRcat and tether regions. 
 
59
Figure 2.6. TROSY triple resonance experiments for RORBR backbone assignment.  
1H-13C projections of three-dimensional NMR experiments used for RORBR backbone 
assignment. The nitrogen spectral window for all experiments was 103.5-131.5 ppm. All 
experiments were collected using a TROSY pulse sequence and deuterium decoupling. 
The experiments shown are as follows: (A) HNCA, (B) HN(CO)CA, (C) HN(CA)CB,               
(D) HN(COCA)CB, (E) HNCO, (F) HN(CA)CO.  
A B 
C 
E 
D 
F 
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Figure 2.7. Backbone dynamics in parkin RORBR. 
Heteronuclear NOE analysis for parkin RORBR. (A) The values plotted are the average 
NOE of two independent experiments (indicated by error bars) at 600 MHz. Only 
resolved resonances in the 1H-15N HSQC spectrum were selected for analysis. The 
average NOE for data within 1 SD of the mean was 0.71, indicated by a dashed line. 
Decreased NOE values in the BRcat and tether domains are indicative of increased 
mobility in the protein backbone. (B) Representative 1D proton slice, exemplifying the 
differences in amide resonance intensity for 4 residues in the non-saturated (black) and 
saturated (red) experiment pair. 
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It will be addressed here that during the first year of this study, three independent research 
groups published crystal structures of the RORBR domain from human and rat parkin, all 
released in May 2013 (36-38). The three crystal structures were all in remarkable 
agreement, with no major differences between structures. Therefore, for all further 
discussions of the free RORBR structure, the higher resolution, 1.6 Å human RORBR 
structure by Riley and coworkers is referenced (PDB: 4I1H, Figure 2.8) (37). As the 
earlier experiments had predicted, the RORBR domain adopts a relatively compacted 
shape, with extensive intramolecular contacts between the four zinc-binding domains. 
The Rcat and BRcat domains are positioned opposite each other, separated by the long 
“tether” spanning residues V380-T415. In all crystals, the tether contains significantly 
less electron density, reflected in high temperature(B)-factors, which preclude the 
observation of structure in most of this region. However, the tether adopts a 2-turn helix 
in all structures from residues E395-R402, which makes extensive contacts with the 
RING1 domain and is well defined, reflected by lower B-factors in these atoms. This is in 
remarkable agreement with the heteronuclear NOE data for RORBR that showed 
flexibility in the tether, with a significant gain of structure from residues E395-E404  
(Figure 2.7). Also in agreement with this data is the increased flexibility of the BRcat 
domain, which is the least defined zinc-binding domain across all structures. Multiple 
loops in this domain are unobserved in the different crystal structures, suggesting a lack 
of rigidity. While an atomic structure of RORBR was unlikely to be solved ab initio by 
NMR owing to the inability to collect NOE experiments on a deuterated protein, the 
crystal structures provided a remarkable opportunity to use the NMR assignments to 
uncover dynamics, interaction surfaces and conformational changes that cannot be 
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Figure 2.8. Structure of human parkin RORBR. 
Rendering of the 1.6 Å crystal structure of human parkin RORBR (Riley et al., 2013, 
PDB: 4I1H). Two views are shown, rotated 180° around the x-axis. The crystallized 
fragment (residue 141 to C-terminus) lacks the UBL domain. Domains are labelled and 
coloured according to the scheme in Figure 2.1. Linkers where electron density was not 
observed are shown as dashed lines. The eight zinc atoms in the structure are 
represented as grey spheres.  
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revealed by crystallography. In this manner, NMR spectroscopy is highly complementary 
to X-ray crystallography when examining these high-molecular weight systems.  
 
2.3.4  Autoinhibitory association of the UBL domain with RORBR 
The RORBR backbone resonance assignments with the complementary RORBR crystal 
structure allowed for detailed identification of protein interaction sites using chemical 
shift perturbations from NMR experiments. Atoms near an interaction site will experience 
a change in their chemical environment upon ligand binding, which will be reported by a 
chemical shift change. Given the strong inhibitory role of the UBL on parkin activity (6), 
we sought to determine the UBL-binding interface that maintains autoinhibition in parkin. 
NMR interaction experiments were conducted by adding 13C-labelled UBL domain to 
2H/12C/15N-labelled RORBR and 1H-15N TROSY-HSQC spectra were collected as well as 
1H-13C HMQC spectra. The selected isotopic-labelling scheme allows parallel data 
experiments from both the RORBR (observing amide chemical shifts) and UBL 
(observing methyl chemical shifts) perspectives while preserving spectral quality by 
deuterating the RORBR component. The HSQC spectrum of RORBR undergoes 
significant chemical shift changes upon addition of 1 and 3 molar equivalents UBL 
domain, consistent with a tight interaction. Slow and intermediate chemical shift 
exchange was observed in RING1, BRcat and tether domains upon UBL binding (Figure 
2.9). Significant chemical shift changes, often beyond detection in the bound state, were 
observed in the region connecting RING1 and BRcat (helix “H3”, residues I298-G329). 
Notably, UBL binding does not seem to influence chemical shifts in the Rcat or RINGO 
domains, suggesting these domains do not contribute to the autoinhibitory UBL 
interaction.  
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Figure 2.9. RORBR interaction with the UBL observed in trans. 
(A) Selected regions from 600 MHz 1H-15N TROSY HSQC spectra showing 200 µM    
2H/13C/15N-labelled RORBR (black contours) and following the addition of 300 µM of the 
UBL domain (red contours). Residues shown that undergo chemical shift changes are 
F277 (RING1), Y312 and Y318 (helix “H3”) and G385 (tether following BRcat domain 
and not visible in the crystal structure). (B) Chemical shift perturbation plot for RORBR 
domain following addition of UBL. CSP was calculated as CSP = [ ∆δHN2 + 0.2∆δN2 ]0.5 . 
Grey bars indicate resonances that broadened or shift beyond assignment in the bound 
species. A dashed line (0.62) represents the mean CSP + 1.5 standard deviation.  
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 To determine the complementary interaction interface on the UBL domain, changes in the 
1H-13C HMQC spectrum of UBL were monitored upon binding of RORBR. It has been 
demonstrated that methyl resonances in an HMQC-type experiment are optimized for the 
TROSY effect exploited in the 1H-15N experiments described previously (30). Therefore, 
methyl resonances were used as probes to monitor the association of UBL and RORBR, 
which form a 46 kDa protein complex. The HMQC spectrum of UBL shows numerous 
slow exchange chemical shift changes as the protein is saturated with RORBR (Figure 
2.10). Methyl groups from residues I2, L41, I44, A46, L50, L61, I66 and V70 show large 
chemical shift changes, reporting their involvement in formation of the UBL–RORBR 
complex. Many of these residues localize to the β-sheet face of the UBL domain, 
including the hydrophobic patch (I44, A46, V70). 
 
Mapping the chemical shift perturbations observed in UBL and RORBR upon their 
association provided an interaction surface on each of the two molecules, which have 
known crystal structures (10,37). As stated above, the UBL interaction surface involves 
its hydrophobic patch, as supported by numerous methyl chemical shift perturbations in 
this region (Figure 2.11 A). Complementary interacting residues mapped on to the 
RORBR structure were localized to one half of the structure, with extensive chemical 
shifts observed in RING1, BRcat and tether domains and no significant chemical shifts in 
RINGO or Rcat domains (Figure 2.11 B). However, the RORBR interaction surface was 
less conclusive, as there appeared to a larger interface area than could be explained by 
UBL binding alone. This suggested there might be a conformational change that 
accompanies UBL binding that manifests as additional chemical shift changes.  
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Figure 2.10. UBL interaction with RORBR observed in trans. 
Selected methyl regions for 600 MHz 1H-13C HMQC spectra of 150 µM 13C-labelled Ubl 
domain alone (black contours) and in the presence of 1.5 molar equivalents 2H/12C/15N-
labelled RORBR (red contours). Based on the crystal structure, chemical shift 
perturbations for A46, L61 and I66 face the tether region following the BRcat domain 
where A383-A390 were not observed indicating these residues in the UBL domain 
transiently interact with this region. 
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Figure 2.11. The autoinhibitory interface is observed in solution and in crystallo. 
(A) RORBR surface representation with UBL interaction surface highlighted as observed 
by solution NMR experiments. Yellow represents amide chemical shift perturbations ≥ 
1.5 standard deviations above the mean (See also Figure 2.8). Red represents amide 
chemical shifts that are shifted or broadened beyond reassignment in the bound species. 
(B) UBL surface representation with RORBR interaction surface highlighted as observed 
by solution NMR experiments. Yellow represents methyl chemical shifts that are 
significantly perturbed (≥ 1.5 standard deviations above mean) upon RORBR binding. 
(C) 1.8 Å crystal structure of autoinhibited human parkin (PDB: 5C1Z). Residues 84-144 
in the flexible “linker” were deleted to assist with crystallization. Each domain is labelled 
as in Fig 2.1. The eight zinc atoms in the structure are represented as grey spheres. 
RING1 
RING1 
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To investigate the UBL–RORBR interaction surface further, our colleagues at the 
University of Dundee crystallized a construct of parkin where the flexible linker 
connecting UBL and RORBR domains (residues 84-144) was deleted to assist with 
crystallization (construct termed UBLRORBR). An X-ray crystal structure of 
UBLRORBR was solved and refined to 1.8 Å resolution (PDB: 5C1Z, Figure 2.11 C). 
Residues 354 and 357–360 in the BRcat domain were missing in the density, as are 
residues 383–390 and 406–413 in the tether, similar to what was observed in isolated 
RORBR crystal structures described previously. The position of the UBL domain, located 
between the RING1 and BRcat domains, is in excellent agreement with the solution NMR 
data (Figure 2.11 A, B). The interface formed between the UBL domain and RORBR 
buries ~2,150 Å2 accessible surface area. The primary contact is between the UBL and 
RING1 domains, where the core interface is stabilized by hydrophobic interactions 
mediated by I44 and V70 of the UBL domain and L266, V269 and T270 of RING1. 
Interestingly, the UBL lies adjacent to the tether region that is unresolved in the crystal 
structure. The NMR data showed chemical shift changes occur in this region including 
A383, S384 and G385, indicating these residues interact with the UBL at least transiently.  
 
Because the NMR data also suggested there may be a conformational change as a 
consequence of UBL binding, the UBLRORBR structure was compared with the 
truncated RORBR structures. The global RORBR structure in the autoinhibited (UBL-
bound) form is surprisingly consistent with structures of the free RORBR, with RMSDs 
between 1.4 Å (compared to rat RORBR, PDB: 4K7D) and 1.8 Å (compared to human 
RORBR, PDB: 4I1F). Interestingly, when the structures are superimposed using the 
RINGO/Rcat domains as the reference point (which exhibited negligible chemical shift 
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changes upon UBL binding), the flexibility of the other domains is more pronounced 
(Figure 2.12 A). In particular, the RINGO/RING1 interface widens in the absence of the 
UBL domain as the BRcat domain swings ~12 Å away from its position when the UBL 
domain is attached. This movement propagates from the RINGO/RING1 interface 
through a long, bent helix comprising residues K299-G329 (termed “helix H3”), which is 
the site of numerous large chemical shift perturbations that were observed in the NMR 
interaction experiments. Close examination of this interface in UBLRORBR with that in 
RORBR reveals a number of changes (Figure 2.12 B). A salt bridge formed by R234 and 
E404 pinning the domains together is absent in the RORBR structure, but present when 
the UBL domain is bound. A hydrogen bond between H227 and E300 is observed in the 
presence of the UBL domain, but not in the RORBR structures. In the UBL-bound 
structure, the side chains of H302 and E300 are facing into the interface, while in the 
RORBR structures, these residues are flipped out ~180° away from the interface (Figure 
2.12 C). This latter conformation is observed in all RORBR structures, suggesting this is 
a consequence of the absence of the UBL domain, rather than an artifact of crystal 
packing. These subtle, but significant conformational changes upon UBL binding provide 
an explanation for the chemical shift perturbations that could not be reconciled by the 
UBL binding site alone. The UBLRORBR crystal structure and complimentary NMR 
data therefore suggest a conformational hinge in parkin centered near the RING0/RING1 
interface that is regulated by the UBL. 
 
2.3.5       S65 phosphorylation modifies UBL and Ub interactions with parkin 
Numerous studies published in 2012-2014 discovered that parkin’s ubiquitin ligase 
activity is dramatically stimulated by the kinase PINK1. The first site of phosphorylation 
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Figure 2.12. The RINGO/RING1 interface is a hinge. 
(A) Overlay of autoinhibited UBLRORBR parkin (PDB: 5C1Z, 1.8 Å crystal structure) 
and RORBR (PDB: 4I1H, 1.6 Å crystal structure lacking the UBL domain). Removal of 
the UBL causes a hinge opening at the RINGO/RING1 interface that results in a swing 
of the BRcat domain. (B) Overlay of the RINGO/RING1 interface from UBLRORBR 
(coloured) and RORBR (grey). Green dashes show distances in Å between residues in 
UBLRORBR, and red dashes show distances between residues in RORBR.                
(C) Comparison of the hinge in UBLRORBR and RORBR. 
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was found to be serine 65 in parkin’s UBL domain (12,13). However, subsequent studies 
showed that parkin’s substrate, ubiquitin, is also phosphorylated by PINK1 at the 
equivalent serine 65 position and this also dramatically increases parkin’s ubiquitination 
activity (14-16). It was hypothesized that phosphorylation of the UBL weakens the 
autoinhibitory association with RORBR, as serine 65 faces the tether in the UBLRORBR 
structure. However, a rationale of how the analogous phosphorylation of ubiquitin would 
also induce parkin activity was unclear. To examine the effects of serine 65 
phosphorylation on the association of UBL with RORBR, isothermal titration calorimetry 
was used to measure thermodynamic properties of the interaction in trans. 
Phosphorylation of serine 65 in the UBL (referred to as “pUBL”) weakens the affinity of 
the RORBR interaction by an order of magnitude (KD of 3.8 vs 31 µM for UBL and 
pUBL, respectively) (Figure 2.13). This was observed as significantly less binding 
enthalpy in the ITC isotherms when the UBL was phosphorylated (∆H of -44 vs -15 
kJ/mol for UBL and pUBL, respectively). As expected from the crystal structures, pUBL 
interacts exothermically with RORBR with negative enthalpy (-15 kJ/mol) and small 
entropy (+33 J/mol*K) changes consistent with new ionic and hydrophobic interactions 
formed and minimal overall structural change (Table 2.2). The data also show that UBL 
binding to RORBR is enthalpically driven regardless of whether the phosphomimetic 
(UBLS65E) or pUBL is used, indicating the phosphomimetic UBL and pUBL proteins 
likely have similar binding modes to RORBR. This suggests that S65 phosphorylation of 
parkin increases ubiquitin ligase activity by weakening the autoinhibitory association of 
the UBL.  
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Figure 2.13. Phosphorylation of the UBL weakens the autoinhibitory interaction. 
Representative isothermal Titration Calorimetry (ITC) experiments showing binding of 
RORBR to (A) UBL, (B) UBLS65E and (C) UBL phosphorylated at Ser65 (pUBL). Best-fit 
dissociations constants and binding stoichiometry are indicated.  
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Protein Activator KD (µM) N ∆H (kJ/mol) ∆S (J/mol*K) 
A. RORBR parkin with UBL and Ub 
R0RBR UBL 3.8 ± 1.3 0.98 − 44 − 44 
UBL (S65E) 5.3 ± 1.2 0.98 − 46 − 54 
pUBL 31 ± 17 1.04 − 15 + 37 
Ub 67 ± 1.0 1.05 + 31 + 184 
Ub (S65E) 6.6 ± 0.1 1.10 + 48 + 261 
pUb 0.016 ± 0.002 0.93 + 32 + 261 
B. Full-length parkin with UBL and Ub 
Parkin UBL N.O. ‡ 
Ub 45 ± 9.0 0.9 + 10  + 115 
pUb 0.16 ± 0.02 1.09 + 50  + 293 
pParkin pUb 0.021 ± 0.006 
Table 2.2. Thermodynamic properties for parkin activation 
All values derived from Isothermal Titration Calorimetry experiments at 25 °C 
‡ N.O., binding not observed 
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To observe whether a similar effect is observed when ubiquitin is phosphorylated, 
thermodynamic properties were measured for Ub, UbS65E  and phosphorylated Ub (pUB) 
in a similar manner. Remarkably, the affinity of Ub for RORBR was enhanced by over 
4000-fold upon phosphorylation of S65 (Table 2.2). In contrast to UBL binding, the 
binding of pUb to RORBR is an endothermic binding event marked by large positive 
enthalpy (+32 kJ/mol) and entropy (+261 J/mol*K) changes. The large positive entropy 
change signifies that the pUb–RORBR interaction is driven by an increase in disorder in 
the system, likely a result of a loss of structure in parkin that accompanies pUb binding. 
Interestingly, a previous three-dimensional structure of the BRcat domain (PDB: 2JMO, 
comprising residues 308-384) shows little structure in the region that contains helix H3, 
the site of several chemical shift changes upon RORBR interaction with pUb (11). This is 
in contrast to the RORBR crystal structure (Figure 2.8) that shows a well-defined, albeit 
bent helix that interacts with the first Zn2+-binding site of the BRcat domain and the 
RING1 domain. Together, these data show that pUb binding to the RINGO/RING1 hinge 
interface results in a concomitant loss of structure near helix H3 and the BRcat domain. 
 
The significant thermodynamic differences between pUBL and pUb interactions with 
RORBR suggest the two molecules use different binding mechanisms. Therefore, to 
understand how pUb binds to RORBR chemical shift perturbation experiments were 
performed using TROSY NMR experiments as described previously for UBL. Addition 
of pUb to RORBR results in a cluster of residues with significant chemical shift changes 
including Y149, C150, K151 and G152 (in RINGO); R275, F277, V278, D280, Q282, 
G284, Y285 and S286 (in RING1); and I306, G308, E309, Y312 and N313 (helix H3). 
These residues surround the hinge at the RINGO/RING1 interface that was modified by 
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UBL binding and suggested the hinge region is a pUb-binding site. To determine the 
orientation of pUb with respect to parkin, paramagnetic relaxation enhancement (PRE) 
experiments were collected with a nitroxide spin label engineered at positions L8 or K48 
in pUb. This was accomplished by mutagenesis of L8 or K48 to cysteine, followed by 
cysteine modification with an alkyl halide-linked spin label. Spin-labelled pUb species 
were then added to RORBR and TROSY-HSQC experiments were collected. Resonances 
were heavily suppressed for atoms within ~20 Å of the unpaired electron radical, owing 
to the distance dependence (r–6) of the PRE effect (39). In this manner, the PRE factor 
(ratio of peak intensity with or without an unpaired electron radical) can be used to define 
molecule orientation and obtain long-range distance restraints beyond the ability of 
NOEs. When an unpaired electron spin label was present at the L8 position in pUb, many 
resonances localized to the BRcat domain were attenuated, suggesting the probe lies close 
to these residues when pUb is bound (Figure 2.14 A). A similar experiment with a spin 
label at the K48 position in pUb produced a different result, with PRE effects broadly 
observed across RINGO, RING1 and helix H3 (Figure 2.14 B). These restraints, along 
with the chemical shift perturbations allowed us to generate a model of pUb bound to 
RORBR using HADDOCK (40). In the model, pUb sits across a V-shaped cavity formed 
at the RINGO/RING1 hinge (Figure 2.14 C). A basic triad, consisting of K151-H302-
R305, surrounds pSer65 of pUb. The pUb orientation is governed by the β1– β2 loop in 
pUb that interacts with residues on helix H3 and residues in the adjacent BRcat domain. 
The C-terminal tail of pUb including residues V70 and L71 runs parallel to helix H3. In 
addition, residues in the β3–β4 region of pUb (I44, A46) intercalate between strands β16–
β17 and helix H3. Of note, the pUb-binding site is remote from the UBL site on the 
opposite side of RING1, suggesting that pUb may activate parkin in an allosteric manner, 
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Figure 2.14. PRE experiments define the pUb binding site in RORBR. 
A nitroxide spin tag was incorporated into unlabelled pUb at positions Leu8 (A) or Lys48 
(B). Each pUb species was then added to 2H/15N-labelled RORBR and TROSY HSQC 
spectra were recorded. For each position, two identical spectra were collected with an 
active or ascorbate quenched spin tag. Relative peak intensities in the quenched/active 
spin tags were plotted as a function of residue. A representative spectrum and 1H trace 
showing the paramagnetic effect in pUb-L8* is shown. (C) NMR restraints were used to 
drive pUb molecular docking to RORBR using HADDOCK. The 20 lowest energy 
structures for phosphorylated ubiquitin bound to parkin are shown. PDB coordinates for 
pUB (4WZP) and RORBR parkin (4I1F) were used as starting structures. 
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rather than by acting as canonical ubiquitin substrate. This idea was further supported by 
ITC data that showed full-length parkin with its UBL domain phosphorylated (pParkin) 
binds pUb approximately 8x more strongly than unphosphorylated parkin (Table 2.2).  
 
An allosteric mechanism could suggest pUBL and pUb cannot be bound to parkin 
simultaneously. In order to test this hypothesis, a competition experiment was performed 
and monitored by NMR spectroscopy. Unlabelled RORBR parkin was titrated into 13C-
labelled UBLS65E and monitored in 1H-13C HMQC spectra such that signals from both the 
unbound and bound forms of UBLS65E were visible. For example, changes in the positions 
of A46 and L61 of the UBL domain show a clear chemical shift upon binding with 
RORBR (Figure 2.15 B). Upon addition of UbS65E, the signals for the bound form of 
UBL revert back to those of the unbound UBL state (Figure 2.15 C). The experiment 
shows that phosphomimetic Ub binding displaces the bound UBLS65E domain from 
parkin. A reciprocal experiment from the perspective of 13C-labelled UbS65E produced the 
same effect, showing UBLS65E is unable to bind an activated RORBR–UbS65E complex, 
despite similar dissociation constants for UBLS65E and UbS65E binding to the RORBR 
module (Table 2.2). Together, these experiments suggest that simultaneous binding of 
phosphorylated UBL and phosphorylated ubiquitin to RORBR is not possible. Further, 
the data suggest the binding of phosphorylated Ub releases the UBL from parkin, 
consistent with the proposed allosteric loss of structure to the near helix H3 and BRcat 
domains that would disrupt the UBL-binding site. This would also indicate that activation 
of parkin through pUb binding would prevent re-engagement with the UBL domain until 
the pUb is released.  
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Figure 2.15. Allosteric release of phosphomimetic UBL by phosphomimetic Ub. 
(A) 1H traces of 13C-labelled UBLS65E spectra as shown beneath in panels B and C.    
(B) Selected regions of 1H-13C HMQC spectra for 150 µM 13C-labelled UBLS65E (black 
contours) following the addition of one molar equivalent of unlabelled RORBR parkin. 
Approximately 83% of UBLS65E is bound to RORBR parkin (orange contours) based on a 
Kd of 6 µM. The arrows show the position of the bound 13C-labelled UBLS65E signal upon 
RORBR binding. (C) The same sample and regions following the addition of one molar 
equivalent unlabelled UbS65E shows the disappearance of most bound UBLS65E–RORBR 
species and re-appearance of unbound UBLS65E (red contours), indicating UbS65E is able 
to displace UBLS65E. 
  
 

	





	
 	 




 


 


 





 





 




13C UBLS65E  ( + RORBR )  
13C UBLS65E  ( + RORBR, + UbiquitinS65E )  
A 
B 



	









 

	
 	 


 





 





 




C 
79
2.4 Discussion 
Historically, parkin was thought to be constitutively active due to its apparent ubiquitin 
ligase activity in cells (3,4). The discovery of UBL-mediated autoinhibition (6) propelled 
efforts to uncover the structural role of the UBL and activators of parkin activity. Here, 
NMR and X-ray crystallography were used to determine the UBL-binding site on 
RORBR, resulting in the first high-resolution structure of this important autoinhibitory 
interface in human parkin (Figure 2.11). An important observation from the structure of 
autoinhibited parkin is that the catalytic cysteine (C431) in the Rcat domain remains in a 
similar environment as in truncated parkin structures lacking the UBL domain (36-38). 
The NMR chemical shift perturbation experiments showed minimal changes for C431 or 
to residues at the RINGO/RING2 interface near the catalytic site, confirming this region 
of parkin does not undergo any large structural change that might expose C431 (Figure 
2.9). However, close inspection of the NMR data and crystal structures revealed a hinge 
at the RINGO/RING1 interface that is allosterically regulated by the UBL association 
(Figure 2.12). Binding of the UBL to RORBR propagates a structural signal through 
helix H3 to the phosphoubiquitin-binding site at the RINGO/RING1 hinge. Thus, the 
increased E3 ligase activity observed upon phosphoubiquitin binding likely results from 
enhanced recruitment of the E2~Ub conjugate following release of the UBL domain, 
rather than a change in structure at the catalytic site. This would explain why UBL uses 
its I44-patch surface to interact with parkin, as this interaction interface on RORBR could 
presumably accommodate a substrate ubiquitin in the context of an E2~ubiquitin 
conjugate. 
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The development of the NMR strategy described here to study human parkin represents a 
breakthrough in our ability to observe interactions and conformational changes in the 
context of the entire RORBR module rather than the isolated domains contained therein. 
The RORBR backbone assignments obtained from TROSY triple resonance experiments 
provide atomic probes covering the whole protein that can serve to identify binding sites 
for E2 enzymes, mitochondrial substrates and other regulators of parkin activity. 
Importantly, the data showed the RORBR molecule observed in crystal structures is 
representative of the structure in solution, as supported by the heteronuclear NOE 
experiments (Figure 2.7). The NMR assignments were also used to determine the binding 
sites of the UBL and pUb on the RORBR surface of parkin. It is remarkable that pUb and 
UBL occupy completely distinct binding sites on parkin, despite the high structure and 
sequence conservation between these two molecules (62% sequence similarity). 
Interestingly, both pUb and UBL heavily invoke their β1-β2 loops for binding to RORBR 
and this section is the most dissimilar between the two proteins, suggesting a role of 
structural specificity in this region.  
 
At present, the most compelling activator of parkin is the Ser/Thr kinase, PINK1, 
functioning upstream of parkin in cellular function (41-43). Isothermal titration 
calorimetry experiments discovered opposing thermodynamic effects of UBL and Ub 
phosphorylation at Ser65, which cooperate to relieve UBL-mediated autoinhibition 
(Table 2.2). Importantly, UBL (and pUBL) binding is enthalpically driven, while pUb 
binding is favoured entropically. Phosphorylation of the UBL weakens its affinity (~10-
fold) for RORBR, while phosphorylation of ubiquitin dramatically enhances its affinity 
(~4,000-fold) for a pUb-binding site that is centered around a basic triad that 
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accommodates the phosphoserine group (Figure 2.14). Using a competition experiment, 
it was showed that binding of phosphorylated ubiquitin releases the UBL domain from 
RORBR (Figure 2.15). This occurs through translation of an allosteric signal through 
helix H3 to the UBL binding site. The release of the UBL domain from RORBR would 
presumably enhance the accessibility of serine 65 in UBL to be phosphorylated by PINK1 
to promote the maintenance of this released state. This is consistent with observations 
that, while parkin can be phosphorylated by PINK1 in the absence of phosphoubiquitin, 
the addition of pUb enhances parkin phosphorylation, suggesting that parkin bound to 
pUb is a better substrate for PINK1 than parkin alone (44). The release of the UBL 
domain therefore primes parkin for catalysis by revealing a binding site for an 
E2~ubiquitin conjugate to engage the E3 ligase, and subsequently transfer ubiquitin to a 
mitochondrial substrate. The structures determined here of autoinhibited (UBL-bound) 
and primed (pUb-bound) parkin provide important insights into parkin regulation and 
activation and will be key to designing potential therapeutics to perturb these 
conformational states. 
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Chapter 3 
 
Generation of Ser65-Phosphorylated Ubiquitin-Like Proteins† 
 
 
3.1  Introduction(1) 
It has recently been shown that phosphorylation of serine 65 in the ubiquitin-like (UBL) 
domain of parkin stimulates its ubiquitin ligase activity (2,3). Subsequently, 
phosphorylation of ubiquitin (Ub) at the analogous serine 65 position was also discovered 
to stimulate parkin ubiquitination (4-6), which was shown to function through an 
allosteric mechanism in Chapter 2. The kinase responsible for these phosphorylation 
events is the PARK6 gene product, PTEN-induced kinase 1 (PINK1) (2-6). To further 
identify the structural basis of this phosphorylation signal, we sought to produce 
preparative amounts of ubiquitin and parkin UBL proteins stoichiometrically 
phosphorylated at serine 65. Such biophysical studies had remained elusive since 
recombinant forms of human PINK1 display little intrinsic kinase activity, and PINK1 
itself undergoes extensive post-translational processing in mammals that regulates its 
activity (2,7-12). Generation of homogenously-phosphorylated proteins by their 
respective kinases is often challenging due to promiscuity of catalyzed phosphorylation 
sites, and the fact that in-vivo scenarios rarely merit total phosphorylation of biological 
targets. Consequently, several chemical biology techniques to generate custom 
phosphorylated proteins have been described to circumvent these challenges.  
 †  Data presented in this chapter has been published. It is reproduced here, with permission from:  
1. George, S., Aguirre, J.D., Spratt, D.E., Bi, Y., Jeffery, M., Shaw, G.S., and O'Donoghue, P.D. (2016)
Generation of phosphoubiquitin variants by orthogonal translation reveals codon skipping. FEBS. Lett.
590, 1530–1542. 
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Chemical conversion of cysteine residues to phosphocysteine has been largely pioneered 
by Benjamin Davis’ research group. This method proceeds by conversion of a target 
cysteine residue to an electrophilic dehydroalanine (DHA) intermediate, which can be 
subsequently modified by a variety of nucleophiles to mimic post-translational 
modifications (13-15). This method has been successfully applied to generate structural 
mimics of glycosylation (14), acetylation (15), and phosphorylation (16,17) modifications 
in proteins, providing unique biological insights to these post-translational modifications 
in their respective systems. The major drawbacks to this technique include the relatively 
harsh conditions required during the chemical conversion and the dependency on a 
solvent-accessible cysteine residue in the protein for modification. 
 
A second method to generate custom post-translational modifications is by genetic code 
expansion in E. coli by selective re-assignment of the TAG stop codon, first explored by 
Peter Schultz’s lab. The use of an orthogonal translation system with a desired 
tRNA/tRNA synthetase pair recognizing the UAG codon in mRNA can introduce non-
canonical amino acids, including phosphoserine, at any desired position in a protein 
(18,19). The use of this system in E. coli with release factor 1 (RF1) deletion, eliminating 
cellular recognition of UAG as a stop signal, was highly toxic to the cells by disrupting 
termination of endogenously expressed mRNA with UAG codons (20). Subsequently, 
bacterial strains have been created in which all genomic UAG codons have been recoded 
to UAA, significantly improved cell fitness and protein expression (20-22). Expressed 
phosphoproteins, however, are frequently contaminated by incorporation of natural amino 
acids as a result of near-cognate decoding at the UAG locus, limiting the use of this 
method when pure phosphoproteins are required (21).  
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 Finally, for serine 65-phosphorylation specifically, the recent discovery that certain insect 
orthologues of PINK1 are constitutively active kinases provided an avenue for 
overcoming the latent activity of human PINK1 (23). The primary sequence of PINK1 in 
Drosophila melanogaster (fruit fly), Tribolium castaneum (red flour beetle) and 
Pediculus humanus (body louse) contain variable-length insertions throughout the kinase 
domain which apparently increase the intrinsic kinase activity in these insect PINK1 
orthologues relative to the human protein (23). However, this discovery was largely made 
in the context of PINK1 self(auto)-phosphorylation and of peptide substrates and 
therefore the utility of these insect kinases with regards to phosphorylating ubiquitin or 
parkin directly had not been robustly demonstrated.  
 
In this work, the aforementioned methods were applied to generate serine 65 
phosphorylated ubiquitin (pUb) and UBL (pUBL) from parkin. Serine 65 phosphorylated 
proteins were successfully obtained by orthogonal translation and using a recombinant 
form of Pediculus humanus PINK1. When generating pUBL by the orthogonal translation 
strategy, a previously undocumented “codon-skipping” phenomenon was serendipitously 
discovered, where the ribosome underwent apparent +3 frameshifting. Ultimately, the 
method yielding the most phosphorylated protein was found to be through use of a 
catalytically active insect PINK1, which is easily amenable to isotopic labelling 
strategies, enabling its use in structural studies. The advantages and disadvantages of each 
technique are discussed with regards to generating phosphorylated proteins. 
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3.2  Materials and Methods 
3.2.1 Chemical modification of cysteine to phosphocysteine 
A cysteine residue was substituted for the position of serine 65 in Ub and parkin UBL 
using a modified site-directed mutagenesis protocol (24). Additionally, in parkin UBL, 
the C59S and C59L substitutions were introduced in a similar manner. Proteins were 
overexpressed in E. coli BL21(DE3) cells grown in LB media. Cells were grown at 37 °C 
until an OD600 of 0.6 was reached at which point cells were cooled to 16 °C and induced 
with 0.5 mM IPTG for 16 hours. Cells were harvested and resuspended in lysis buffer (50 
mM Tris, 500 mM NaCl, 0.5 mM TCEP, 25 mM imidazole, pH 8.0). Cells were lysed 
using an EmulsiFlex-C5 homogenizer (Avestin), ultracentrifuged at 41,000 rpm (124,000 
x g) and proteins purified by Ni2+ affinity using a HisTrap FF column on an AKTA FPLC 
(GE Healthcare). Affinity captured proteins were eluted from the column with elution 
buffer (50 mM Tris, 200 mM NaCl, 0.5 mM TCEP, 500 mM imidazole, pH 8.0). 
Fractions containing the protein of interest were pooled, protease (TEV for Ub; Ulp1 for 
UBL) was added to cleave the His tag (~1:50 ratio protease:protein) and dialyzed 
overnight at 4 °C against lysis buffer. After cleavage was complete, proteins were passed 
over the HisTrap FF column again in lysis buffer and the flow through was collected, 
containing proteins of interest. Proteins were concentrated and subjected to size exclusion 
chromatography on a HiLoad Superdex 75 equilibrated with 50 mM HEPES, 50 mM 
NaCl, pH 8.0 for a final purification step and to remove TCEP.  
 
For cysteine modification to dehydroalanine, α,α′-dibromo-adipyl(bis)amide (DBAA) 
was synthesized as described in (16) and obtained as a solid. DBAA (500 µmol, 151 mg, 
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250 equiv.) was added as a solid to purified Ub or UBL proteins (2 µmol, 20 mg, 1.0 
equiv.). The cloudy suspension was incubated at 37 °C with shaking for 3 hours. The 
mixture was then centrifuged at 40,000 rpm (or syringe filtered with a 0.2 µm filter) to 
remove precipitated proteins and insoluble DBAA and proteins dialysed overnight against 
50 mM HEPES, 100 mM NaCl, pH 8.0 to remove soluble DBAA. The following day, 
sodium thiophosphate tribasic hydrate (33 mmol, 6.0 g, 16,500 equiv.) was added 
gradually as a solid (in about 5 intervals over 25 mins). The final pH of the reaction after 
sodium thiophosphate addition was between 10.5 and 11. The reaction mixture was then 
incubated at 37 °C with shaking for 4 hours. Following incubation, the cloudy reaction 
mixture was spun down and put into dialysis against 50 mM HEPES, 100 mM NaCl, pH 
8.0 to remove excess sodium thiophosphate. Proteins were then subjected to LC-MS 
analysis to assess the reaction products.  
 
Mass spectrometry was performed on a Quattro Micro mass spectrometer (Waters) 
equipped with a Z-spray source and run in positive ion mode with an Agilent 1100 HPLC 
used for LC gradient delivery. Reverse phase chromatography was performed using a 
C18 1 x 150 mm column. Briefly, proteins were injected into the column in 95 % buffer 
A (H2O + 0.1% formic acid), 5% buffer B (acetonitrile + 0.1 % formic acid) at 0.1 
mL/min. Over 30 mins, a gradient buffer change to 5% buffer A, 95 % buffer B was 
performed and eluent injected in-line into the mass spectrometer. The mass survey range 
was set to 600-1600 m/z. Cone voltage for electrospray ionization was 30V and source 
temperature was 80 °C. Calibration was performed with a myoglobin standard, with mass 
error of 0.5 Da.  
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3.2.2 Dissolving and refolding of synthetic pUBL peptide 
A synthesized pUBL peptide was obtained from ChemPeptide (Shanghai, China) as a 
lyophilized solid (10 mg peptide). For rapid dilution refolding, 1.8 mg peptide was 
dissolved in 2 mL of 2 M guanidine hydrochloride in refolding buffer (50 mM KH2PO4 , 
100 mM KCl, 100 mM arginine, 100 mM glutamine, 1 mM EDTA, 1 mM DTT, pH 7.5). 
This 100 µM peptide solution was slowly added (0.5 mL/hour) dropwise from a fine-
needle syringe, into a stirring 50 mL solution of cold refolding buffer on ice. After 
addition, the 4 µM peptide solution contained approximately 75 mM guanidine 
hydrochloride. To remove residual guanidine hydrochloride, the solution was dialyzed 
overnight against 2 L of refolding buffer. The following day, the dialysis buffer was 
changed to 25 mM KH2PO4 , 25 mM KCl, 1 mM EDTA, 1 mM DTT, pH 7.5 to remove 
arginine and glutamine.  
 
3.2.3 Expression of pUb and pUBL in release-factor deficient E. coli 
Recombinant proteins were expressed in E. coli ∆RF1 (C321.∆A.exp, Addgene 49018) 
(22). The 1st generation pSer system was on the plasmid pKD-pSer1 (Addgene 52054) 
that expresses SepRS, EFSep and 5 copies of the tRNASep expression cassette. The Ub 
and UBL expression plasmid was constructed using a T7 promoter, T7 terminator, and a 
cloning site (NdeI/BamHI) in an ampicillin-resistant backbone derived from pUC18. A 
modified quick-change mutagenesis protocol (24) was used to insert in-frame TAG 
codons and DNA sequencing confirmed the correct sequence of the plasmids. pKD-pSer1 
and Ub/UBL expression plasmids were freshly co-transformed into E. coli ∆RF1 cells 
and plated on LB-agar plates with 25 µg/mL kanamycin and 100 µg/mL ampicillin. 
Single colonies were picked to inoculate 10 mL starter cultures in LB (with 100 µg/mL 
92
ampicillin and 25 µg/mL kanamycin), which were grown, shaking overnight at 37 °C. 
Once saturated, the starter culture was used to inoculate 1 L of LB media supplemented 
with ampicillin (100 µg/mL), kanamycin (25 µg/mL), and O-phospho-L-serine (2.5 mM, 
Sigma-Aldrich). Cultures were grown at 37 °C until OD600 was 0.6. An additional 2.5 mM 
O-phospho-L-serine was added to cultures at this point (5 mM total O-phospho-L-serine) 
and the incubation temperature was reduced to 16 °C. Protein expression was induced at 
OD600 of 0.8 by addition of 1 mM IPTG and continued for 18 hours at 16 °C. Cells were 
harvested and proteins purified by Ni2+ affinity exactly as described in section 3.2.1 
except that 50 mM NaF and 2 mM NaVO3 were included in the lysis buffer as 
phosphatase inhibitors. For some Ub variants, the His tag was retained to differentiate Ub 
chains by molecular weight. It has been established that the presence or absence of an N-
terminal His tag has no effect on the interaction of the Ub substrate with E1, E2 or E3 
enzymes involved in the parkin ubiquitination pathway (25). 
 
Purified Ub or UBL proteins were separated on a 1 mL HiTrap SP-XL column using an 
AKTA FPLC system (GE Healthcare). Prior to purification, samples were dialysed 
overnight in buffer A (20 mM MES, pH 6.0). Cation exchange chromatography was 
carried out at a flow rate of 0.3 mL/min with a 1 hour gradient of 0-100% buffer B (20 
mM MES, 200 mM NaCl, pH 6.0). Phosphorylated protein species were collected in the 
unbound (flow-through) fractions while the salt gradient eluted the non-phosphorylated 
species.  
 
Mass spectrometry was performed both before and after ion exchange chromatography. 
Samples were prepared for MS by overnight dialysis in 15 mM ammonium acetate to 
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remove salt adducts. Whole protein ESI-MS was performed on a Q-Tof Micro mass 
spectrometer (Waters) equipped with a Z-spray source and run in positive ion mode (+ 
0.1% formic acid). Samples were prepared for Tandem ESI-MS/MS by digestion with 
trypsin or Glu-C protease as follows. Briefly, 25 µg of protein in 100 µL was reduced 
with DTT (5 mM final concentration) at 70 °C for 15 minutes. Samples were then 
alkylated with iodoacetamide (30 mM final concentration) at room temperature for 45 
minutes in the dark. Alkylation was quenched with DTT (30 mM final concentration) for 
30 minutes at room temperature. Protease digestion was performed using a 1:40 ratio of 
protease to sample at 37 °C overnight. Samples were evaporated by centrifugal speedvac 
and stored at -20 °C until mass spectrometry was performed.  
 
Ubiquitination assays were adapted from a previous study (26) and contained 0.1 µM E1 
(Uba1), 1 µM E2 (UbcH7), 1 µM E3 (Parkin), 5 mM ATP, 5 mM MgCl2, 50 mM HEPES 
pH 7.4, and a 20 µM final concentration of Ub and/or pUb in a 20 µL final reaction. 
Reactions were initiated by addition of ATP and incubated at 30 °C for 1 h. Reactions 
were quenched with SDS-loading buffer (containing 50 mM EDTA) and subjected to 
standard SDS-PAGE and western blotting procedures using anti-parkin primary antibody 
(kind gift from Dr. Michael Schlossmacher, University of Ottawa) and fluorescent-
labeled secondary antibody (Mandel Scientific). Blots were visualized using the Odyssey 
imaging system (Li-Cor biosciences). 
 
The E2-loading assay was adapted from a previous study (27) with modifications as 
follows. The reaction contained 0.5 µM E1 (Uba1), 20 µM E2 (UbcH7), 20 µM Ub or 
pUb variants, and 10 mM ATP in reaction buffer containing 50 mM HEPES and 100 mM 
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NaCl at pH 7.0. Reactions were initiated by addition of ATP and incubated at 37 °C for 
10 minutes. Samples were quenched with SDS non-reducing loading buffer (containing 
50 mM EDTA). The reaction products were separated by SDS-PAGE and visualized by 
Coomassie staining. 
 
3.2.4 Phosphorylation of Ub and UBL by Pediculus humanus PINK1  
GST-tagged Pediculus humanus PINK1 (128-C) was expressed in E. coli BL21(DE3) 
cells in LB media. Cells were grown at 37 °C until an OD600 of 0.8 was reached, at which 
point overexpression was induced with 0.5 mM IPTG and the incubation temperature 
lowered to 16 °C for 18 hours. Overexpressed proteins were purified on a GSTrap FF 
column (GE Healthcare) in lysis buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM 
DTT at pH 7.4) and eluted with freshly prepared elution buffer (50 mM Tris, 150 mM 
NaCl, 1 mM DTT and 10 mM glutathione, pH 8.0). Following elution, glutathione was 
removed from PINK1 by two 2L dialysis changes against 50 mM Tris, 50 mM NaCl, 3 
mM DTT, pH 10, followed by a final 2L dialysis against 50 mM Tris, 50 mM NaCl, 3 
mM DTT, pH 7.5.  
 
For in-vitro phosphorylation, purified GST-PINK1 (10 µM) was incubated at 25 °C with 
either Ub (500 µM) or UBL (500 µM) and phosphorylation initiated by addition of MgCl2 
and ATP to a 10 mM final concentration. The reaction was monitored to completion 
using Phos-Tag SDS–PAGE as described bellow. Following the reaction, GST-PINK1 
was removed from the reaction using a GSTrap FF column, collecting the flow-through 
fractions containing pUb or the pUbl domain. A final purification step by gel filtration 
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was performed on a HiLoad Superdex 75 equilibrated in 25 mM HEPES, 100 mM NaCl, 
0.5 mM TCEP, pH 7.0, to remove residual GST-PINK1 and to remove excess ATP.  
 
Phos-tag acrylamide (Wako Pure Chemicals Ltd., Japan) was purchased and gels were 
prepared according to manufacturer’s instructions (28,29). 12 % polyacrylamide gels 
were prepared with 50 µM Phos-tag reagent and 0.7 mM ZnCl2 embedded in the gel. 
Protein samples for Phos-tag SDS-PAGE were always prepared in buffers without 
phosphate or EDTA, including the SDS gel-loading buffer. Empty lanes in gels were 
filled with equivalent buffer blank samples. Gels were run under constant current at 25 
mA per gel with the gel tank submerged in an ice bath until the dye front had left the gel. 
Phos-tag gels were always imaged with Coomassie blue stain.  
 
 
3.3  Results 
3.3.1  Synthesis of phosphorylated Ub and UBL by chemical modification 
Insertion of a phosphate group at the position of residue 65 in Ub and parkin’s UBL 
domain was first attempted by chemical modification of cysteine through a reactive 
dehydroalanine (DHA) intermediate. A cysteine substitution (S65C) was inserted at 
residue 65 in ubiquitin and in parkin’s UBL domain. While ubiquitin harbors no cysteine 
residue in its native sequence, parkin’s UBL contains one partially-accessible cysteine 
(C59) that could form undesired side products during cysteine modification. However, a 
C59S substitution in parkin UBL was largely insoluble, suggesting a more non-polar role 
for C59 in the context of the UBL structure. Therefore, a C59L/S65C double mutant was 
96
generated for modification of parkin UBL, obtaining overexpression and solubility of this 
double mutant comparable to the wild-type protein. 
 
Modification of cysteine 65 to dehydroalanine in Ub and parkin UBL was performed 
using α,α′-dibromo-adipyl(bis)amide (DBAA) (Figure 3.1 A), proceeding through an 
alkylation-elimination reaction mechanism. In the proposed reaction scheme, alkylation 
occurs rapidly at 37 °C, while longer incubation periods (up to 3 hours at 37 °C with 
shaking) promote cyclization and elimination of the DBAA adduct to form 
dehydroalanine (14). Reaction of parkin UBLC59L/S65C  with DBAA over 3 hours resulted 
in elimination to dehydroalanine, observed as a loss of 33 Da by electrospray ionization 
mass spectrometry (ESI-MS) (Figure 3.2 A-B). Roughly 60% conversion to UBL–DHA 
was achieved, estimated by peak intensities in the mass spectra. The presence of UBL–
DHA was also corroborated by successful addition of 2-mercaptoethanol to generate a 
thioether. The insertion of an electrophilic dehydroalanine group at position 65 in parkin 
UBL can therefore allow for subsequent modification with a variety of nucleophiles to 
generate a custom thioethers. Unexpectedly, the same reaction conditions of DBAA with 
UbS65C repeatedly produced less than 10% dehydroalanine product, remaining largely 
unmodified upon reaction with DBAA. To eliminate the possibility of cysteine oxidation, 
UbS65C was reacted with Ellman’s reagent (5,5'-dithiobis-2-nitrobenzoic acid) and 
underwent the expected color change to a bright yellow solution, confirming the presence 
of reduced cysteine. This dissimilarity in chemical reactivity suggested there is a 
difference in the structure or accessibility of residue 65 in Ub and parkin UBL. In an 
attempt to enhance the reactivity of cysteine 65 in UbS65C, the organic solvent 
dimethylformamide was added to the reaction with DBAA. This however, further 
97
ONH2
O
H2N Br Br
37 °C with shaking for 3 h  
+ 
SH 
Ubiquitin / UBL 
 S65C 
Ubiquitin / UBL 
dehydroalanaine 
Ubiquitin / UBL 
dehydroalanine 
A 
B 
37 °C with shaking for 4 h  
+ P S– 
O– 
O 
–O 3 Na+ 
SPO3 
Ubiquitin / UBL   
phosphocysteine65 
Figure 3.1. Reaction scheme to generate dehydroalanine and phosphocysteine 
modifications. 
(A) A cysteine substitution is inserted at the desired phosphorylation position. The 
reduced cysteine is modified with DBAA over 3 hours to generate dehydroalanine. The 
alkylated and cyclized reaction intermediates are shown. B) The dehydroalanine 
species is subjected to nucleophilic attack by sodium thiophosphate, generating a 
phosphocysteine residue. The phosphocysteine modification differs from phosphoserine 
by only one atom (O to S). 
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Figure 3.2. Chemical modification of UBL to generate UBL–phosphocysteine. 
Raw ESI-MS data collected during chemical modification of parkin UBL to insert a 
phosphate group at residue 65. The +8 charged ion species is shown in all cases with 
identical m/z range shown along the x-axis. The expected m/z for each intermediate is 
shown at the bottom, along with the corresponding molecular mass of the protein. (A) 
Starting material, purified UBL domain with C59L/S65C substitution. (B) After 
modification with DBAA, generating a dehydroalanine intermediate (loss of 33 Da). (C) 
After modifcation with sodium thiophosphate, generating a phosphocysteine residue 
(gain of 113 Da relative to DHA species). (D) Following cation exchange 
chromatography to separate UBL–SPO3 from unreacted products. 
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hindered elimination of DBAA, resulting in a +138 Da contaminant corresponding to Ub 
adducts with cyclized DBAA. 
 
To generate the phosphoserine mimic, UBL–DHA was reacted with a large excess of 
sodium thiophosphate (NaSPO3) over 4 hours to generate UBL phosphocysteine (UBL–
SPO3) (Figure 3.1 B). Ideal reactivity of thiophosphate occurred when the tribasic salt 
was added as a solid to UBL–DHA, consequently raising the pH of the reaction to ~10.5. 
Although most thiols would be partially nucleophilic around neutral pH, the –2 charge on 
the thiophosphate ion presumably raises the third pKa of the thiol and hinders its ability 
to function as a nucleophile. Thus the high pH of the reaction enhances deprotonation of 
the thiol to accelerate the reaction. Unfortunately, even under these optimal conditions, 
only ~50% conversion of UBL–DHA to UBL–SPO3 was obtained (Figure 3.2 B-C). 
Increasing the concentration of sodium thiophosphate to a 25,000-fold excess relative to 
UBL–DHA was unable to force the reaction to completion, similar to attempts in a 
previous study (17). Notably, cation exchange chromatography was able to separate 
unreacted products, leaving the desired UBL–SPO3, as detected by ESI-MS (Figure 3.2 
D). However, the significant loss of material over the reaction and subsequent purification 
precluded the use of this purified protein for structural studies. 
 
3.3.2  Refolding of a synthetic phosphorylated UBL peptide 
In an attempt to increase the quantity of phosphorylated parkin UBL for biophysical 
experiments, a lyophilized Ser65-phosphorylated UBL (pUBL) was synthesized and 
obtained from a commercial source. Unlike lyophilized ubiquitin, which is highly soluble, 
lyophilized pUBL was insoluble in aqueous buffers. Changing the ionic strength or pH of 
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aqueous buffers did little to enhance solubility of the pUBL peptide. We resorted to 
dissolving the pUBL peptide in 2 M guanidine hydrochloride, solubilizing an unfolded 
form of the protein. To refold the peptide, a refolding buffer containing 0.1 M arginine 
and glutamine was used, as arginine is an effective protein-stabilizing agent owing to its 
guanidinium side chain group (30,31). Diffusion-driven dialysis into the refolding buffer 
overnight was unable to refold pUBL, resulting in protein precipitation. A more 
successful result was obtained using a rapid dilution strategy, where the dissolved peptide 
in 2 M guanidine hydrochloride was slowly added drop-wise to a stirring solution of 
chilled refolding buffer. This resulted in a clear, dilute protein solution (4 µM pUBL) 
with only 75 mM guanidine hydrochloride. Overnight dialysis into the same refolding 
buffer removed the majority of residual guanidine hydrochloride without any protein 
precipitation, leaving a clear protein solution in 0.1 M arginine/glutamine refolding 
buffer. Further dialysis to remove arginine/glutamine, however, resulted in precipitation 
of pUBL. This suggested that arginine/glutamine was solubilizing a non-native structure 
of pUBL, which was only realized upon removal of arginine. This pUBL sample was 
subjected to SDS–PAGE analysis to assess the integrity of the protein. In contrast to other 
UBL variants, the synthetic pUBL peptide displayed heterogeneity by SDS–PAGE, 
observed as a smeared band with apparent degradation or contamination of the peptide 
with lower molecular weight species (Figure 3.3 A). Subsequent analysis of the peptide 
by ESI-MS confirmed a heterogenous sample of peptide masses, with multiple ion 
species observed in addition to the expected pUBL ion series (Figure 3.3 B). This 
heterogeneity likely results from complications of synthesis of such a long peptide by 
traditional stepwise peptide synthesis techniques. It is possible that a synthesis approach 
employing native chemical ligation might have been more successful, as the relatively 
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Figure 3.3. Refolding of a synthetic Ser65-phosphorylated UBL peptide. 
Custom synthesis of a Ser65-phosphorylated UBL peptide was performed by 
ChemPeptide Limited (Shanghai, China). (A) SDS-PAGE of UBL variants showing 
heterogeneity of the synthetic peptide. Native UBL, UBL S65E, and pUBL generated by 
orthogonal translation are shown for comparison. (B) Raw ESI-MS of synthetic peptide 
dissolved in 50/50% (v/v) H2O/acetonitrile. The observed parent ions expected for 
ionization of pUBL (molecular weight 8904 Da) are labelled. 
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short C-terminus of pUBL encompassing the phosphorylation site (residues 65-76) could 
presumably be synthesized separately with higher purity.   
 
3.3.3 Generation of phosphorylated Ub and UBL by orthogonal translation reveals 
codon skipping 
To generate Ser65-phosphorylated Ub and parkin UBL, an orthogonal translation system 
was used whereby phosphoserine is encoded into the DNA sequence of the protein by a 
TAG codon, normally reserved as a stop codon in E. coli. DNA sequences encoding Ub 
and parkin UBL, with a TAG codon at residue 65 (and terminating stop codons assigned 
as TAA), were cloned into a pUC-18 plasmid. The 1st generation pSer system in a pKD-
pSer1 plasmid (Addgene #52054) was co-transformed into E. coli ∆RF1 along with the 
pUC-18 plasmid. Overexpression of the two plasmids with IPTG in the presence of 
exogenous O-phospho-L-serine allowed for incorporation of phosphoserine at the UAG 
codon position. Protein products terminated at residue 65 were not observed, confirming a 
reassigned role for the UAG codon. Following affinity purification, Ub variants were 
analyzed by ESI–MS to determine the identity of overexpressed proteins.  
 
For ubiquitin, two major mass peaks were observed corresponding to two full-length 
protein products: one with the expected mass of pSer65 ubiquitin (pUb) and one with 
Gln65, an apparent mistranslation product (Figure 3.4 A). Notably, no product 
corresponding to native Ub (with Ser65) was observed, confirming serine incorporation 
was abolished and dephosphorylation of pUb does not occur under the conditions used for 
purification. The protein mixture was further purified using cation-exchange 
chromatography, which showed the two well-defined peaks, consistent with the two mass 
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Figure 3.4. Generation of genetically-encoded pUb variants by orthogonal 
translation. 
(A) Whole protein ESI-MS (deconvoluted) Ub protein expression products with Gln or 
pSer at position 65. (B) Cation-exchange chromatography shows separation of 
phosphorylated and non-phosphorylated Ub protein products. (C) Tandem MS/MS of 
trypsin-digested pUb confirms the protein identity and incorporation of phosphoserine at 
position 65. (D) Phos-tag SDS–PAGE showing ion-exchange fractions of orthogonally 
translated pUb variants (S65, S20 or S12). The gels show separation of mistranslated 
products (lanes 1-2) from pure phosphorylated protein (lanes 3-4). 
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peaks observed (Figure 3.4 B). The identity of pUb was confirmed by tandem ESI–
MS/MS (Figure 3.4 C) and by Phos-tag gels (28,29), which retard phosphorylated 
proteins so that a band-shift separates unphosphorylated Ub from pUb (Figure 3.4 D). 
The results confirm unambiguously the purification of pUb at a yield of ~11 µg/L from E. 
coli ∆RF1 cultures. This method to generate pUb was successfully extended to produce 
Ub phosphorylated at other putative phosphorylation sites, Thr12 and Ser20 (Figure 3.4 
D).  
 
To produce parkin UBL phosphorylated at Ser65, identical expression and purification 
steps were used as with ubiquitin variants. pUBL and Gln65-UBL were readily identified, 
however ESI–MS revealed a third and unexpected protein species. A protein mass 
corresponding to UBL entirely lacking the amino acid encoded at residue 65 (UBL ∆65) 
was observed as a third major species (Figure 3.5 A). This previously unknown 
interpretation of the UAG codon was verified by tandem ESI–MS/MS, identifying the 
trypsin digested peptide (VQNCDLDQQ64I66VHIVQPRPWR), and confirming deletion 
of the amino acid at position 65 and formation of a peptide bond between Gln64 and 
Ile66, apparently skipping the codon encoding residue 65 (Figure 3.5 C–E). Because we 
suspected this might have resulted from a contaminating plasmid lacking the TAG locus, 
the UBL expression plasmid was freshly transformed and 10 independent clones were re-
sequenced, showing no evidence for deletion in the DNA sequence. Two of these 
independent clones were re-expressed and purified with the pSer system in E. coli ∆RF1. 
The UBL ∆65 codon skipped product was robustly reproduced as observed by ESI–MS 
(Figure 3.6 A–C). Fascinatingly, other phosphoproteins produced using the pSer system 
did not show evidence for this codon skipping. The notable exception to this was UbpSer7, 
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Figure 3.5. Codon skipping as a byproduct of pUBL orthogonal translation.  
(A) Whole protein ESI-MS (deconvoluted) indicates UBL protein products protein 
products with Gln or pSer at position 65. Interestingly a protein mass corresponding 
exactly to the deletion of one Ser residue (relative to native UBL) is observed.             
(B) Cation-exchange chromatography shows separation of phosphorylated and 
mistranslated protein products. (C) Tandem MS/MS of purified phosphorylated UBL, 
confirming phosphoserine incorporation at residue 65. (D) Tandem MS/MS of purified 
mistranslated UBL, confirming glutamine incorporation at residue 65. (E) Tandem MS/
MS of purified mistranslated UBL, confirming the “skipping” of residue 65 during 
orthogonal translation. The resulting protein is native UBL, but lacks residue 65. 
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Figure 3.6. Reproducible codon skipping at position 65 in UBL by orthogonal 
translation. 
Full protein ESI-MS (deconvoluted) for all translated UBL products with TAG at position 
65. The codon skipped (∆65, lacking residue 65) protein appears reproducibly in 3 
independently-transformed and re-sequenced clones (A-C). 
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which showed evidence for the same codon-skipping phenomenon, albeit to a smaller 
extent than was observed with pUBL. This observation proves codon-skipping was not an 
anomaly of the UBL parent plasmid, and indicates that in release-factor 1 deficient E. 
coli, the UAG codons can be skipped or bypassed by the ribosome to yield proteins with a 
single deleted residue.  
 
3.3.4  Phosphorylation of Ub and UBL by insect orthologues of PINK1 
We were intrigued by recent reports that insect orthologues of PINK1 display constitutive 
kinase activity in-vitro (2,23). While human PINK1 is deficient for kinase activity, we 
wondered whether these insect forms could specifically phosphorylate serine 65 in human 
forms of ubiquitin or parkin’s UBL. The highest solubility of recombinant PINK1 was 
achieved with a GST–fusion of Pediculus humanus PINK1 lacking the N-terminal 
transmembrane domain (128–C). Expression of this construct in E. coli BL21(DE3) 
yielded on average 5 mg of PINK1 per litre of culture in LB media. Purified GST–PINK1 
was used to phosphorylate ubiquitin and parkin UBL the reaction monitored by Phos-tag 
SDS–PAGE (28,29). Remarkably, complete phosphorylation of ubiquitin and UBL at 
room temperature was observed on the order of minutes as observed by Phos-tag SDS–
PAGE, reflected by retarded migration of a band corresponding to the phosphorylated 
species  (Figure 3.7 A–B). Following removal of PINK1 and excess ATP, the integrity of 
these phosphorylated proteins were assessed by ESI–MS. The mass spectra clearly 
showed one main species corresponding to the mass of phosphorylated UBL (Figure 3.7 
C). Optimization of the reaction conditions revealed that phosphorylation by GST–
PINK1 proceeds to completion within minutes using ratios of PINK1:UBL as low as 
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Figure 3.7. Complete Ser65-phosphorylation of Ub and parkin UBL by Pediculus 
humanus PINK1. 
(A–B) Coomassie-stained Zn2+ Phos-Tag SDS-PAGE showing phosphorylation of (A) 
parkin UBL or (B) ubiquitin by Pediculus humanus PINK1 (GST tagged). The slower 
migrating band represents the phosphorylated protein species. (C) Mass spectrum of 
pUBL after phosphorylation and subsequent removal of GST-PINK1. Raw and 
deconvoluted spectra are shown. MWcalculated: 8,904 Da (8,824 Da + PO4).  
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1:50. The yields obtained of recombinantly expressed PINK1 are therefore sufficient for 
large-scale preparations of pUb or pUBL on the scale of tens of milligrams.  
 
To assess whether the generated Ser65-phosphorylated proteins could stimulate parkin, 
ubiquitination assays were conducted to monitor parkin’s ubiquitin ligase activity. 
Substitution of Ub with pUbkinase (phosphorylated by the kinase PINK1) in-vitro greatly 
enhanced autoubiquitination activity of parkin, observed by an increase in parkin species 
modified with progressively longer ubiquitin chains (Figure 3.8 A, lanes 1-3). Higher 
activity was observed with a 10:90 ratio of pUb:Ub rather than 100% pUb, further 
supporting an allosteric role for pUb as was proposed in chapter 2. The enhanced activity 
observed with a low pUb:Ub ratio was also consistent with reports from other research 
groups (32,33). However, in contrast to these reports, definitive incorporation of pUb into 
polyubiquitin chains was observed when pUb was the sole ubiquitin source, confirmed by 
differential SDS–PAGE migration using his-tagged Ub and tagless pUb (Figure 3.8 A, 
lanes 2-3), although incorporation of pUb occurred to a lesser extent over the timecourse 
of these experiments. In order to assess the integrity of the orthogonally-translated pUb 
(pUborthog) described in section 3.3.3, the same ubiquitination assay was conducted in the 
presence of 10% or 100% pUborthog generated in E. coli ∆RF1 (Figure 3.8 A, lanes 4-5). 
Essentially the same level of autoubiquitnation activity was observed whether pUbkinase or 
pUborthog were used, suggesting the pUb proteins generated by orthogonal translation are 
representative of ubiquitin phosphorylated by the kinase PINK1.  
 
Previous reports (6,32,33) and the data presented in Figure 3.8 A corroborate that pUb is 
an inefficient substrate for ubiquitination relative to native Ub. While it is possible that 
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Figure 3.8. Designer phosphorylated proteins can be used in biological assays. 
(A) Parkin auto-ubiquitination assays with unmodiﬁed Ub (His-Ub), PINK1 
phosphorylated Ub (pUbkinase) and orthogonally translated phosphorylated Ub (pUborthog) 
were visualized by western blot. All reactions contained Uba1 (E1), UbcH7 (E2), full-
length parkin (E3), ATP and different Ub variants. The % stoichiometry of each Ub 
variant is shown above each lane. (B) E2 (UbcH7)-loading assay with Ub and 
orthogonally translated pUb variants. The reaction at t=0 shows only free E2 and Ub 
reactants. Following a 5 minute reaction (after addition of ATP), the appearance of an 
upper band indicates formation of the E2~Ub or E2~pUb conjugate.  
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parkin’s catalytic activity is reduced when pUb is used as a substrate, it is also 
conceivable that pUb is a less competent substrate for E1 or E2 enzymes acting upstream 
of parkin. To explore this possibility, the ability of the E2 enzyme UbcH7 to engage in a 
Ub conjugate with phosphorylated Ub was tested. As observed by non-reducing SDS–
PAGE, pUb was less readily converted into an E2~Ub conjugate when compared to 
native Ub (Figure 3.8 B). In addition to pUbpSer65, we also tested the ability of another 
pUb variant generated by orthogonal translation, pUbpSer20, to form an E2~Ub conjugate. 
While both forms of phosphorylated Ub were hindered in their ability to form an E2~Ub 
conjugate, the effect was slightly more pronounced with pUbpSer65 (Figure 3.8 B). The 
results show that processing of phosphorylated ubiquitin is hindered at the E1 or E2 
enzyme stage, supporting observations that parkin ubiquitination is less efficient with 
phosphorylated ubiquitin. 
 
 
3.4  Discussion 
In this work, we set out to generate ubiquitin and UBL proteins homogenously 
phosphorylated at serine 65. Complete stoichiometry of the phosphorylated state is 
essential for biochemical studies, given the known effects of pUb stoichiometry on parkin 
activity (32-34). Further, the use of true phosphorylated proteins was sought, rather than 
the more accessible aspartate or glutamate phosphomimetics, as these mimetics are not 
proven to recapitulate pUb in vivo (34). Although these natural amino acids are negatively 
charged, the carboxylate side chains of aspartate and glutamate are poor 
phosphomimetics, harbouring a –1 charge rather than –2, and possessing planar geometry 
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compared to the tetrahedral phosphate group. These deficiencies of phosphomimetics was 
further evidenced in Table 2.2, where the parkin-binding properties of Ub/UBL 
phosphomimetics were significantly altered from the truly-phosphorylated counterparts. 
The generation of homogenous Ub and UBL variants possessing phosphoserine (or 
phosphocysteine) was demonstrated here by 3 independent methods. A summary of the 
investigated techniques is shown in Table 3.1.  
 
Chemical modification of cysteine through the dehydroalanine intermediate is a versatile 
method to introduce an assortment of protein modifications, including phosphate groups, 
onto proteins. We found that success of this method is heavily dependent on accessibility 
and chemical environment of the cysteine residue to be modified. For example UBLS65C 
was much more amenable to oxidative elimination than UbS65C. This may be due to 
weakened thermodynamic stability in UBL relative to Ub (35), that presumably increases 
the relative accessibility of partially buried amino acids, including residue 65. Further, Ub 
possesses a glutamic acid residue (E64) directly preceding residue 65, while UBL 
possesses a glutamine (Q64). This additional negative charge in Ub could further hamper 
modification at residue 65 by DBAA or the nucleophilic thiophosphate ion. Despite the 
relatively high stability of ubiquitin-like proteins, we found the harsh conditions required 
for reaction with DBAA and sodium thiophosphate result in substantial loss of soluble 
protein over the course of the modification, precluding its use in our structural studies.  
 
Orthogonal translation by recoding of E. coli UAG codons was successfully used to 
incorporate phosphoserine at residue 65 in both ubiquitin and parkin UBL. By this 
method, pure phosphoproteins were obtained on the order of ~10 µg per litre of LB media 
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Method Yield Potential contaminants 
Isotopic-labelling 
possible? Practicality 
Chemical 
modification 
of cysteine 
<40 % starting 
concentration, 
surface accessibility 
dependent 
DBAA adducts, 
Unmodified DHA  
Yes Technically 
challenging 
Synthetic 
peptide 
refolding 
Very protein-
dependent 
Peptide synthesis 
by-products, 
misfolded 
aggregates 
Not feasible Protein-
dependent 
Orthogonal 
translation of 
UAG codon 
~10 µg/L in LB 
media 
Mistranslated 
products 
Yes Facile, but 
laborious 
Catalytically
-active 
kinase 
>99 % starting 
concentration 
Added kinase Yes Facile 
Table 3.1. Comparison of methods to generate Serine 65-phosphorylated Ub and UBL 
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culture. While these quantities of protein preclude most structural techniques, further 
advances in this field continue to improve the yields of phosphoproteins closer to the 
realm required for X-ray crystallography and NMR spectroscopy (36,37). Importantly, 
this study reinforces that caution must be taken when employing phosphoproteins 
generated by this method, as mistranslation at the UAG locus contaminates the 
overexpressed proteins (20,21). Remarkably, in pUBLpSer65 and pUbpSer7 variants, 
phosphoserine insertion competed not only with near-cognate translation from glutamine 
but also with codon skipping. In both cases, protein products resulting from codon 
skipping include a peptide bond between the residues encoded immediately before and 
after the UAG codon. It is proposed that the ribosome underwent a +3 frameshift leading 
to a single in-frame amino acid deletion and a novel interpretation of the UAG codon. It 
is unclear why the incidence of this phenomenon varies between the different proteins 
tested in this study, although it is conceivable that mRNA sequence determinants 
surrounding the UAG codon confer a preference for codon skipping over near-cognate 
translation. Aside from an obvious comparison to ribosome frameshifting (38), the only 
other precedent for mRNA skipping is from recent work in mitochondria of the yeast 
Magnusiomyces capitatus. In this case, the ribosome bypasses ~100 nucleotide intragenic 
untranslated regions (UTR) in the mRNA and forms a peptide bond between the two 
residues encoded on either side of the UTR (39). Notably, pUb and pUBL could still be 
separated from the mistranslated products using cation exchange chromatography to yield 
pure phosphoprotein for in-vitro experiments, as shown by mass spectrometry and Phos-
tag gels. 
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Undoubtedly, this study shows the most efficient way to generate serine 65 
phosphorylated proteins is using a catalytically active form of insect PINK1, first 
identified by the Muqit laboratory (23). Pure phosphoproteins were obtained by this 
method on the order of tens of milligrams, sufficient quantities for structural studies. 
Importantly, the isolated expression of ubiquitin and UBL permit their isotopic labeling 
for techniques such as NMR spectroscopy. Further modifications could conceivably add 
affinity tags, paramagnetic ions, or fluorescent tags for a variety of biochemical 
applications. The main inconvenience of this method, the contamination of the protein 
sample by the added PINK1, is easily overcome by use of a GST–PINK1 fusion protein 
that can be reclaimed by affinity purification after the phosphorylation reaction. Despite 
initial worries of promiscuity from using a hyperactive kinase, we were pleasantly 
surprised by the remarkable specificity of Pediculus humanus PINK1 for serine 65. Mass 
spectrometry data for both ubiquitin and parkin UBL show only one phosphorylation site 
and little evidence for subsequent modifications, consistent with results in other studies 
(2,5,6,32). This is impressive since ubiquitin, in particular, harbours a phosphorylatable 
threonine 66 residue that is actually more solvent accessible than serine 65 but is 
apparently not phosphorylated by PINK1. Further, while the primary sequence of 
ubiquitin is essentially unchanged between Pediculus humanus and humans (99% 
identity), there is significant sequence divergence between Pediculus humanus and 
human parkin in the UBL domain (30% identity). Nonetheless, Pediculus humanus 
PINK1 can effectively phosphorylate human parkin UBL on a timescale similar to 
ubiquitin. This method for generating preparative amounts of phosphorylated ubiquitin 
and parkin will therefore be essential for further unraveling the roles of these 
phosphorylation signals in the cell.   
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Chapter 4 
  
Structure of phosphorylated parkin UBL domain and insights 
into PINK1-orchestrated activation†(1) 
 
4.1  Introduction 
Post-translational modifications are sophisticated biological “switches”, relaying 
molecular signals to govern cellular processes and respond to external stimuli. Multiple 
studies show parkin activity is stimulated through phosphorylation by the kinase PTEN-
induced kinase 1 (PINK1) in response to mitochondrial oxidative stress (2,3). This in turn 
facilitates parkin-mediated ubiquitination of several proteins at the outer mitochondrial 
membrane and signals the turnover of damaged mitochondria through the mitophagy 
pathway (4-6). Some mutations in parkin cause its dysfunction, leading to an 
accumulation of mitochondrial damage that appears to be especially detrimental in 
neurons (7).  
 
Parkin belongs to the RBR subfamily of E3 ubiquitin ligases (8) that function through a 
unique catalytic mechanism employing both a RING domain and a covalent thiolester 
intermediate (9). These enzymes are structurally autoinhibited in their native states by 
unique accessory domains (10-12), indicating that RBR ligases must be activated in order 
to carry out their full ubiquitination potential. Specifically, parkin contains an N-terminal 
ubiquitin-like (UBL) domain shown to inhibit Ub ligase activity (10). Three-dimensional 
 †  Data presented in this chapter has been published. It is reproduced here, with permission from:  
1. Aguirre, J.D., Dunkerley, K.M., Mercier, P.M., and Shaw, G.S. (2017) Structure of phosphorylated UBL
domain and insights into PINK1-orchestrated parkin activation. Proc Natl Acad Sci USA 114, 298-303 

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structures of parkin show the UBL domain associates with its C-terminal (RORBR) 
region through both ionic and hydrophobic interactions, blocking the proposed E2 
recognition site (see Chapter 2, (13,14)). 
 
PINK1 stimulates parkin activity through phosphorylation of both Ub and parkin’s UBL 
domain at an equivalent serine 65 position in sequence and structure (2,3,15-18). While 
each phosphorylation event can increase parkin activity independently, maximal activity 
is obtained when both parkin and Ub are phosphorylated (15,16). Phosphorylation of 
parkin at S65 decreases its affinity for RORBR while simultaneously increasing its 
affinity for phosphorylated ubiquitin (pUb) (see Chapter 2, (13,14,19,20)). Three-
dimensional structures show this results from an optimization of a pUb-binding site, 
remote from the UBL site (see Chapter 2). Further, binding of pUb allosterically induces 
a conformational change, activating parkin’s activity (see Chapter 2, (13,14,20,21)).  
 
Although the functional effect of PINK1 on parkin activity is well reported, the molecular 
interpretation of the phosphorylation signal, especially in conjugation with pUb, is less 
clear. In this work, we present the solution structure of PINK1-phosphorylated UBL 
(pUBL) from human parkin. A significant loss of thermodynamic stability results from 
changes to the UBL hydrophobic core, remodeling its secondary structure near the 
phosphorylation site. Changes to surface electrostatic potential from the phosphoserine 
group in pUBL disrupt its autoinhibitory association with the C-terminus of parkin. 
Further, it is shown that phosphorylation of both UBL and Ub are needed to form an 
extended structure where the E2-binding site is unprotected, allowing its recruitment 
during the ubiquitination cascade.  
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4.2  Materials and Methods 
4.2.1  Protein Expression and Purification  
Human parkin (1-465) and UBL domain (1-76) were overexpressed as His-SUMO fusion 
proteins in E. coli BL21(DE3). Disease-state mutations and the UBL-I44A mutation were 
introduced using a modified site-directed mutagenesis protocol (22). Cells were grown in 
LB or minimal media (supplemented with 500 µM ZnCl2 for full-length parkin) at 37 °C 
until an OD600 of 0.6 was reached at which point cells were cooled to 16 °C and induced 
with 0.5 mM IPTG for 16 hours. Cells were harvested and resuspended in lysis buffer (50 
mM Tris, 500 mM NaCl, 0.5 mM TCEP, 25 mM imidazole, pH 8.0). Cells were lysed 
using an EmulsiFlex-C5 homogenizer (Avestin), ultracentrifuged at 41,000 rpm (124,000 
x g) and proteins purified by Ni2+ affinity using a HisTrap FF column on an AKTA FPLC 
(GE Healthcare). Affinity captured proteins were eluted from the column with elution 
buffer (50 mM Tris, 200 mM NaCl, 0.5 mM TCEP, 500 mM imidazole, pH 8.0). 
Fractions containing the protein of interest were pooled, Ulp1 protease was added to 
cleave the His-SUMO tag (~1:50 ratio protease:protein) and dialyzed overnight at 4 °C 
against lysis buffer. After cleavage was complete, proteins were passed over the HisTrap 
FF column again in lysis buffer and the flow through was collected, containing proteins 
of interest. A final purification step by gel filtration was performed on a HiLoad 
Superdex75 pre-equilibrated in 25 mM HEPES, 100 mM NaCl, 0.5 mM TCEP pH 7.0. 
Proteins for phosphorylation time-course experiments were aliquoted, flash-frozen and 
stored at -80 °C until use. Proteins for structural experiments were always prepared fresh 
and used immediately after purification.  
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GST-tagged Pediculus humanus PINK1 (128-C) was expressed in E. coli BL21(DE3) 
cells in LB media. Cells were grown at 37 °C until an OD600 of 0.8 was reached, at which 
point overexpression was induced with 0.5 mM IPTG and the incubation temperature 
lowered to 16 °C for 18 hours. Overexpressed proteins were purified on a GSTrap FF 
column (GE Healthcare) in lysis buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM 
DTT at pH 7.4) and eluted with freshly prepared elution buffer (50 mM Tris, 150 mM 
NaCl, 1 mM DTT and 10 mM glutathione, pH 8.0). Following elution, glutathione was 
removed from PINK1 by two 2L dialysis changes against 50 mM Tris, 50 mM NaCl, 3 
mM DTT, pH 10, followed by a final 2L dialysis against 50 mM Tris, 50 mM NaCl, 3 
mM DTT, pH 7.5.  
 
4.2.2  Phosphorylation of Parkin and UBL domain 
For phosphorylation time-course experiments, purified GST-PINK1 was used to 
phosphorylate parkin and UBL mutants as follows. Proteins were diluted in 50 mM Tris, 
50 mM NaCl, 3 mM DTT, pH 7.5 to obtain a PINK1:parkin ratio of 1:2(1:20) for full-
length parkin(UBL domain) in a total volume of 200 µL. Phosphorylation reactions were 
initiated by addition of 20 mM MgCl2, 10 mM ATP, pH 7.5 and allowed to proceed at 25 
°C. The final concentration of parkin in reactions was 1 µM. At the specified time 
intervals, 10 µL of sample was quenched with 3x SDS-loading buffer (containing 100 
mM EDTA) and boiled at 95 °C for 5 minutes. Samples were then subjected to SDS–
PAGE (one 15-lane gel per time-course reaction).  
  
Unstained gels were cut to include the band corresponding to parkin or UBL. Proteins 
were then transferred onto a shared nitrocellulose membrane (0.2 µm pore size) using a 
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semi-dry iBlot2 apparatus (Invitrogen). The transfer voltage was as follows: 20 V for 1:00 
min, 23 V for 4:00 min, 25 V for 1:00 min. The membrane was then rinsed with water, 
blocked with 10X BSA blocker (Pierce) in TBS for 1 hour at room temperature. The 
membrane was rinsed with TBS + 10% aqueous Tween20 (TBST) and incubated with 
primary antibody (anti-pSer65 parkin, Ubiquigent Cat. No. 68-0056-100) overnight at 4 
°C. The next day, the membrane was rinsed with 3-4 washes of TBST, incubated with a 
fluorescent secondary antibody (anti-sheep Dylight 680nm, Pierce Cat No. SA5-10058) 
for 45 minutes and washed again 3 times with TBST. Membranes were scanned by 
Odyssey Imaging system (LiCor) and fluorescence intensity measured at 700 nm.  
 
Fluorescence intensity was plotted against time for each parkin variant, demonstrating the 
formation of phosphorylated parkin. The formation of pParkin can be described 
chemically as in eq (1), or kinetically through a second order rate law eq (2). Since the 
concentration of ATP is present at a 10,000-fold excess and largely unchanged over the 
reaction, the process was simplified as pseudo-first order eq (3) to yield the rate equation 
in terms of pParkin concentration eq (4).  
 
 Parkin    +    ATP                            pParkin    +    ADP          eq (1) 

– d Parkin
dt  =  k Parkin ATP                   eq (2) 

– d Parkin 
dt  =  k Parkin eq (3)

–d Parkin
   Parkin
t
0
= kt
t
0
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ln
Parkin t
 Parkin 0
= –kt 
[Parkin]t=[Parkin]0e–kt     
if  [Parkin] + [pParkin] = [T],      [T – pParkin]t = [T – pParkin]0e–kt  
and [pParkin]0 = 0,                        [T – pParkin]t = e–kt 
–[pParkin]t = T e
–kt – [T] 
[pParkin]t =e
–kt 
 
Non-linear regression was performed to determine k ± SE for each parkin variant. A two-
tailed T-test to assess for statistical variation from wild-type parkin was performed. All 
curve fitting and statistical tests were conducted in GraphPad Prism 6.  
 
For preparative-scale structural experiments, purified GST-PINK1 was used to 
phosphorylate parkin and UBL as follows. Proteins were dialysed into 50 mM Tris, 50 
mM NaCl and 1 mM DTT pH 7.5. A PINK1:parkin ratio of 1:2(1:30) was used to 
phosphorylate full-length parkin(UBL domain). Phosphorylation was initiated by addition 
of 20 mM MgCl2, 10 mM ATP, pH 7.5 and allowed to proceed at 25 °C. The reaction 
was monitored to completion using Phos-Tag SDS-PAGE and confirmed by mass 
spectrometry. Phosphorylated parkin species were further purified by a second GST 
affinity capture and gel filtration chromatography to remove GST-PINK1. 
 
 
 
eq (4) 
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4.2.3 Cicular Dichroism 
Thermal and chemical denaturation experiments were performed using a JASCO J-810 
CD spectropolarimeter equipped with a Peltier temperature control. Data points were 
collected as an average of 3 replicate scans. A 1 mM path length cuvette was used. For all 
experiments, purified protein samples were dialysed against 3 changes of 20 mM KH2PO4 
pH 7.0 at 4 °C to remove chloride ions. Protein concentrations were verified by 
measuring absorbance at 280 nm in 6 M Guanidine HCl. For thermal denaturation 
experiments, the temperature was increased from 5 °C to 85 °C at a rate of 10 °C per 
hour. For chemical denaturation experiments, proteins were aliquoted into solutions of 
freshly prepared urea at various concentrations and allowed to reach equilibrium 
overnight at 4 °C. CD spectra were collected the following day at 5 °C. All data were fit 
using GraphPad Prism to determine denaturation midpoint as previously described 
(23,24). Briefly, the free energy difference (∆GuH2O) between folded and unfolded forms 
of the protein and the slope of the unfolding transition (m) were determined by nonlinear 
regression for the dependence of the observed CD ellipticity (Yobs) as a function of urea 
concentration ([D]) according to eq (5) and (6) (25).  
 
Ku = e 
∆GuH2O + m[D]
–RT eq (5) 
 
Yobs=
Yf+YuKu
1+Ku
  eq (6) 
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The baselines prior to (Yf) and following (Yu) the unfolding transition were also fit to the 
linear relationships shown in eq (7) and (8) where mf and mu are the slopes of the pre- and 
post-unfolding transition and are the intercepts for the folded and unfolded states, 
respectively. 
Yf = Yf0+mf[D]eq 7 
Yu=Yu0+mu[Deq (8) 
 
4.2.4 NMR Spectroscopy 
All NMR data were collected on a Varian Inova 600 MHz NMR spectrometer equipped 
with a triple resonance cryogenic probe. All experiments were performed in NMR buffer 
(25 mM HEPES, 100 mM NaCl, 0.5 mM TCEP, pH 7.0, 10% (v/v) D2O) at 25 °C unless 
otherwise specified. 200 µM DSS was used as an internal reference and 300 µM 
imidazole was used as an internal pH indicator (26). Interaction experiments of (p)UBL 
and RORBR parkin were performed as previously described in Chapter 2.2.5. All data 
were processed using NMRPipe (27) and analyzed using NMRViewJ (28). 
 
pUBL Structure Determination  
Triple resonance experiments for assignment were collected with 13C/15N-labelled UBL 
samples at concentrations of 200-600 µM. Backbone and sidechain atom assignments 
were obtained from HNCA (29), HNCACB (30), CBCA(CO)NH (31), HNCO (29), 
C(CO)NH (30), HCCH-TOCSY (32,33) and (HB)CB(CGCD)HD (34) experiments. 15N-
NOESY and 13C-NOESY experiments were collected to define distance restraints. 
Histidine tautomers and protonation states were determined by Cδ chemical shifts and Nε 
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chemical shifts in 1H-13C HSQC and 1H-15N HMBC experiments (35,36). Structures were 
calculated in CYANA using manual and automatic NOE assignments and dihedral (φ, ψ) 
angle restraints from TALOS+ (37,38). TALOS+ restraints were not used for residues 56-
66, allowing this region of the structure to be driven solely by NOEs. The standard 
CYANA protocol was used with eight cycles of structure generation and refinement (100 
structures per round). The final 50 structures were water refined using a modified force 
field in XPLOR-NIH (39). The 25 structures with the lowest NOE energies were chosen 
as representative of the calculation. SSP scores were calculated using CA and CB 
chemical shifts (40). CSI scores were calculated using CA, HA and CO chemical shifts 
(41).  
 
Amide temperature coefficients 
UBL and pUBL temperature coefficients were determined by collecting 1H-15N HSQC 
spectra of 200 µM 15N-labelled UBL and pUBL from 6 °C to 40 °C in 5 °C increments. 
After each temperature change, samples were equilibrated for at least 30 minutes and the 
final temperature verified by the chemical shift of water referenced to DSS (42). For each 
residue, ∆δNH was plotted against ∆T and the slope of the line (temperature coefficient) 
determined by linear regression and visualized in GraphPad Prism 6. Plots of temperature 
coefficient vs chemical shift deviation were generated according to Andersen et al. (43).  
 
Hydrogen-deuterium exchange 
Hydrogen bonds were verified by hydrogen-deuterium exchange in 1H-15N HSQC 
spectra. A PD-10 desalting column (GE Healthcare) pre-equilibrated with NMR buffer in 
100% D2O was used according to manufacturer’s instructions. The earliest fractions 
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(containing D2O exchanged protein but not H2O buffer) were immediately loaded into 
NMR tubes and HSQC spectra re-collected identically (~20 minutes after exchange). 
 
pKa measurements  
1H-15N HSQC and 1H-13C HSQC experiments of 13C/15N-labelled UBL and pUBL at 200 
µM were collected over a range of pH 4.7-8.8. The chemical shift of imidazole was used 
to verify the final sample pH in the spectrometer (26). To calculate pKa of titrating 
residues, 1H chemical shifts of residues over the pH range were plotted and fit to a 
modified Henderson-Hasselbalch eq (9): 
 
δobs=
(10pH-pKa)δA+δHA
1+10pH-pKa
 
Where δ represents the chemical shift of the deprotonated (δA) or protonated (δHA) state. 
 
3JHNHA Coupling Constants 
3J backbone coupling constants for 13C/15N-labelled pUBL (500 µM) were determined by 
quantitative J-correlation (44). The HNHA experiment was collected in three dimensions 
(HN, N, HA) with a 1H-1H coupling period of 25 ms. Peak intensities were measured in 
NMRViewJ (27) and 3J coupling constants determined according to eq (10) (45). 
 
Iratio = −tan[π·J·0.025]tan[π·J·0.025]                               eq (10) 
Where Iratio is the ratio of intensities of the cross-peak and diagonal signals for a given 
proton resonance. 
 
 
eq (9) 
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Heteronuclear NOE 
1H-15N heteronuclear NOEs were measured using 15N-labelled UBL or pUBL (500 µµM) 
according to the method of (46). Proton saturation was achieved through a 3 s irradiation 
period following a 3 s recycling delay. The equivalent non-saturated experiment 
contained a 6 s recycling delay. Both saturated and non-saturated experiments were 
collected in duplicate in an interleaving manner. Peak intensities and heteronuclear NOEs 
were determined in NMRViewJ (27). 
 
T2 Relaxation Experiments 
T2 relaxation times of 15N-labelled full-length parkin and 15N-labelled UBL were 
determined by arraying the CPMG period and measuring the envelope of signal 
intensities at 8.75–9.25 ppm in the first increments of 1H-15N T2 spectra. Two-
dimensional 1H-15N HSQC spectra were then collected with a 30 ms T2 delay period (2 
× τ1/2 of full-length parkin) as a measure to distinguish short vs. long T2 species (47). The 
concentration of 15N-labelled parkin was 200 µM. The concentration of 15N-labelled 
pParkin was 150 µM with or without an excess of unlabeled pUb. 
 
4.2.5 Analytical Ultracentrifugation 
Sedimentation velocity experiments were performed on a Beckman XL-A analytical 
ultra- centrifuge equipped with an An60-Ti rotor. Double sector cells (1.2 cm) with quartz 
windows were filled with 380 µL sample and 400 µL reference buffer. All data were 
collected in 25 mM HEPES, 100 mM NaCl, 0.5 mM TCEP pH 7.0 at 20 °C with 60+ 
minutes for temperature equilibration. Experiments with isolated UBL were performed at 
55,000 rpm. Experiments with full-length parkin and pUb-bound parkin were performed 
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at 45,000 rpm. Cells were scanned at equal intervals (60 or 90 scans total) and absorbance 
measured at 280 nm. Data were processed by c(s) distribution analysis in SEDFIT v15.01 
(48), accounting for equilibration and rotor acceleration times. All data were fit to an 
RMSD <0.005 in SEDFIT. Partial specific volume (vbar) was 0.719 mL/g, viscosity (η) 
was 0.0103 Poise, and density (ρ) was 1.0043 g/mL. Sedimentation coefficients observed 
in buffer were corrected for 20 °C in water, and frictional coefficients (f/f0) were 
calculated from S20,w and known molecular weights of all species as follows:  
 
f  = 
M (1 – vbar· ρ)
NA· S20,w
eq 11 
 
f0        
3 · M · vbar
4 · π · NA
 
3
eq 12)
Where vbar is partial specific volume in mL/g, η is viscosity in units Poise, ρ is density in 
g/mL, M is molecular weight in g/mol, and NA is Avagadro’s number: 6.022 x 1023 mol-1. 
 
 
4.2.6 PINK1-activated parkin models 
Randomized models of the flexible linker region in parkin (residues 77-142) were 
generated using the Ensemble Optimization Method (v2.1) (49) using coordinates for 
pUb-bound parkin (5CAW) and pUBL as rigid bodies. 200 structural models were 
generated with native-like CA angles for disordered proteins. Shell models were 
generated for all 200 structures using residue-level primary models in HYDROPRO (50). 
The atomic elements radius (AER) was set at 4.8 Å for all simulations. Viscosity (η), and 
density (ρ) values were set to 0.01 and 0.99, respectively for 20 °C in water. Partial 
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specific volume was unchanged from SEDFIT analysis. Calculated radii of gyration and 
sedimentation coefficients were extracted for analysis. Visual representation of all 200 
structures was done in PyMOL. 
 
 
4.3  Results 
4.3.1 Molecular determinants of parkin phosphorylation and disease-state mutants 
As described in Chapter 3, a catalytically-active insect orthologue of PINK1, from 
Pediculus humanus (body louse), was employed to phosphorylate parkin at serine 65. 
Despite differences in primary sequence around the phosphorylation site between human 
parkin and P. humanus parkin (Figure 4.1 A), full phosphorylation was obtained of 
human parkin and ubiquitin using this insect form of PINK1. The most conserved regions 
in the UBL domain are in the β-sheet face containing the hydrophobic patch, a common 
recruitment site for ubiquitin-interacting motifs (UIMs) (51,52). Therefore, we wondered 
whether an I44A substitution, a conservative substitution commonly employed to disrupt 
UIM binding (53,54), could still be phosphorylated by PINK1. I44 is distant in structure 
(>12 Å) and primary sequence from S65, and should not sterically impede the 
phosphoryl-transfer reaction catalyzed by PINK1. However, I44A-UBL was severely 
impaired in its ability to be phosphorylated, as observed by Phos-tag SDS–PAGE. While 
native UBL was 50% phosphorylated within approximately 2 minutes in-vitro, nearly no 
phosphorylated I44A-UBL was observed after the same time (Figure 4.1 B). This 
provides evidence that the hydrophobic patch of UBL is involved in the recruitment of 
PINK1 or the phosphoryl-transfer reaction.  
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Figure 4.1. Detection of parkin Serine 65 phosphorylation by PINK1. 
(A) Structure-based sequence alignment of parkin’s UBL domain from Homo sapiens 
(human), Rattus norvegicus (rat), Drosophila melanogaster (fly) and Pediculus humanus 
(louse). The sequence of human ubiquitin is shown at bottom. Areas of high sequence 
conservation are highlighted in green and the S65 phosphorylation site is highlighted in 
blue. A linear domain map showing UBL secondary structure elements is shown above 
for reference. (B) PINK1-phosphorylation time-course of UBL and I44A-UBL monitored 
by Phos-Tag SDS–PAGE. The retarded band represents the phosphorylated species. 
(C) Detection of phosphorylated parkin using a pSer65-specific antibody. Purified parkin 
and Ser65-phosphorylated parkin (pParkin) of known concentrations were probed by 
Western Blot, detected by a fluorescent secondary antibody at 700 nm. (D) PINK1-
phosphorylation time-course of full-length parkin and UBL under identical conditions 
monitored by a pSer65-specific antibody. Fluorescence was measured and plotted 
against time to determine relative rate constants (k) of phosphorylation. 
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 Similar attempts were made to characterize phosphorylation of full-length forms of parkin 
by Phos-Tag SDS–PAGE. However, poor resolution and a “laddering” of gel bands 
corresponding to parkin precluded a conclusive analysis of phosphorylation rates in the 
context of the full-length protein. This is likely a by-product of the zinc-binding nature of 
parkin, which could competitively chelate variable numbers of Zn2+ ions from the Phos-
Tag gel matrix. Therefore, a pSer65-parkin phospho-specific antibody was instead used to 
characterize in-vitro phosphorylation of parkin by fluorescence. The specificity of the 
antibody for the phosphorylated form of parkin was verified using purified native parkin 
and Ser65-phosphorylated parkin (Figure 4.1 C). Negligible background fluorescence 
was observed for non-phosphorylated parkin at concentrations below 1 µM, therefore 1 
µM protein was used in subsequent phosphorylation reactions. Time-course reactions of 
parkin showed the isolated UBL domain was phosphorylated approximately 16x faster 
than the full-length protein under identical conditions (Figure 4.1 D). This result is 
consistent with the hypothesis of the hydrophobic patch recruiting PINK1, which is 
occupied by autoinhibitory associations in full-length parkin and consequently slows the 
rate of phosphorylation relative to the isolated UBL. 
 
To further examine the molecular determinants of parkin phosphorylation, especially in 
the context of disease-causing mutations, relative rates of phosphorylation were 
determined for parkin and disease-state parkin mutants. Five PD-causing parkin mutants 
were chosen; G12R, R33Q, R42P, P37L and T55I, sampling the structure of the UBL 
domain without affecting the antibody epitope (residues 60-72) (Figure 4.2 A). Time-
course phosphorylation experiments were performed with both full-length parkin (1:2 
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Figure 4.2. Disease-state mutations impair S65 phosphorylation by PINK1. 
(A) Structure of parkin UBL domain (PDB: 2ZEQ), showing the positions of disease-
state mutants examined in this study. The S65 phosphorylation site is also shown in red.  
(B) Purified parkin and UBL mutants. 10X concentrated loading controls used for time 
course experiments. (C) Representative phosphorylation time-course experiments 
showing Ser65-phosphorylation of purified wild-type and disease state mutants of 
parkin. The R42P mutant could not be purified in the context of the isolated UBL.        
(D) Relative rates of parkin phosphorylation determined from time-course experiments 
as in B. The presented rates are a global fit of 3 independent experiments ± SE 
(represented by error bars). * and ** represent statistically significant deviation (P ≤ 0.05 
and P ≤ 0.01, respectively) from wild-type as determined by a two-tailed T-test.  
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ratio PINK1:parkin) and the isolated UBL (1:20 ratio PINK1:UBL) variants (Figure 4.2 
B–C). Whether full-length parkin or isolated UBL were used, the G12R and R33Q 
mutants were significantly impaired in PINK1-phosphorylation relative to the wild-type 
protein (Figure 4.2 D). Conversely, the P37L and T55I mutants were phosphorylated at a 
rate comparable to their wild-type counterparts. In all replicates, however, the slowest 
mutant to be phosphorylated was R42P in the context of full-length parkin. This mutation 
is known to unfold the UBL domain in-vitro and consequently could not be purified in the 
context of the isolated UBL (23). Unexpectedly, none of the tested disease-state parkin 
variants were impaired in phosphorylation to the extent of the I44A substitution studied 
earlier. The data show that certain disease-state mutations in parkin’s UBL domain are 
compromised in their ability to be phosphorylated at serine 65. 
 
4.3.2  Phosphorylation of the UBL decreases its thermodynamic stability 
Compared to UBL, phosphorylated UBL (pUBL) was more difficult to handle, with 
decreased solubility and a greater propensity to precipitate. It was hypothesized that 
phosphorylation negatively impacted the stability of the UBL fold. Circular dichroism 
(CD) spectra for native UBL and pUBL showed both proteins had a similar spectral 
signature with minima observed near 205 nm and 222 nm (Figure 4.3 A), characteristic 
of a β-grasp ubiquitin fold. However, thermally-treated pUBL showed minimal change in 
ellipticity near 218 nm, in contrast with UBL which underwent a large and obvious 
unfolding transition. The lack of change to this region of the CD spectrum of pUBL 
suggested heating promoted β-aggregation rather than thermal unfolding. 
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Figure 4.3. S65 phosphorylation destabilizes the UBL domain of parkin. 
(A) Circular dichroism (CD) spectra showing thermal denaturation of UBL and pUBL. 
Spectra were collected from 5 °C (blue curves) to 75 °C (red curves) in 10 °C 
increments. At right, a temperature-course experiment is shown monitoring change in 
CD ellipticity in UBL and pUBL at 205 nm. (B) Urea denaturation of UBL and pUBL 
monitored by CD spectropolarimetry from 0 M urea (blue curves) to 6.5 M urea (red 
curves) in 0.5 M increments. At right, the unfolding profile of UBL and pUBL as a 
function of urea is shown by CD ellipticity at 222 nm. Observed denaturation midpoint ± 
SE is indicated beside each curve. (C) Bis-ANS fluorescence in the presence of UBL 
and pUBL. An increased fluorescence for pUBL indicates a greater exposed 
hydrophobic surface than for UBL. 
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To eliminate interferences from aggregated species in the experiment, the stability of 
pUBL was tested against chemical denaturation by urea. In this experiment, urea 
solubilizes an unfolded, random coil form of the protein rather than forming aggregates. 
Chemical denaturation confirmed pUBL was significantly less stable than UBL, 
undergoing a much earlier unfolding transition in urea (50% unfolded at 3.3 M vs 4.4 M 
urea, respectively) (Figure 4.3 B). Thermodynamically, this indicates pUBL is 
approximately 4.3 kJ/mol less stable than its unphosphorylated form and would be 
approximately 2% unfolded in its native state. Since pUBL was less stable and more 
susceptible to aggregation than UBL, the fluorescent probe, 4,4’-bis-1-
anilinonaphthalene-8-sulfonate (bis-ANS) was used to probe for changes in 
hydrophobicity upon phosphorylation. Interestingly, bis-ANS showed markedly greater 
fluorescence in the presence of pUBL compared to UBL (Figure 4.3 C), suggesting the 
hydrophobic surface of pUBL is altered. Taken together, the results show that 
phosphorylation of UBL is associated with structural changes that perturb its folding 
pathway and thermodynamic stability by modifying the hydrophobicity of pUBL. 
 
4.3.3  Solution NMR structure of phosphorylated Parkin UBL 
To identify the structural effects of phosphorylation and establish how this modifies the 
UBL association with parkin, the solution structure of pUBL was determined using NMR 
spectroscopy (Figure 4.4 A, Table 4.1). The 25 lowest-energy structures of pUBL form a 
canonical β-grasp ubiquitin-like fold: a four-strand β-sheet (β1, M1-R6; β2, F13-V17; β3, 
L41-I44; β4, V67-Q71) and two α-helices (α1, I23-Q34; α2, V56-C59). However, 
obvious changes occur near the S65 site of phosphorylation, where ligation of the 
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Figure 4.4. Solution structure of Ser65-phosphorylated parkin UBL. 
(A) pUBL structure (closest to average) represented as a cartoon with secondary 
structure as described in the text. (B) Expanded view of pUBL structure around pSer65. 
(C) UBL structure (extracted from PDB 5C1Z) is shown for comparison. (D) Expanded 
view of pUBL structure showing hydrophobic residues affected by phosphorylation. (E) 
Chemical shift perturbations in methyl resonances upon Ser65 phosphorylation. 
Resonance assignments for methyl groups in pUBL are indicated (red spectrum), 
reporting changes to the hydrophobic core upon phosphorylation. (F) Chemical shifts 
observed during the pH titration of UBL (black curves) and pUBL (red curves). 1H 
chemical shifts were measured at each pH and fit by nonlinear regression to determine 
pKa ± SE (indicated beside the curve).  
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a Talos-derived phi/psi angles 
b As reported by Xplor-NIH, using all residues 
c No distance violation < 0.1Å 
d As reported by Procheck, using all residues 
e RMSD to averaged coordinates using residues 1-71 
 
Completeness of resonance assignments 
       Backbone (N.CA) (147/149) – 98.7% 
       Sidechain (C,H) (663/679) – 96.4% 
       HN    (71/73) – 97.3% 
       HA      (79/79) – 100.0%   
       HB  (122/122) – 100.0% 
NMR distance restraints and dihedral angles 
       Total distance restraints 1014 
       Intra-residue restraints 299 
       Inter-residue restraints 
             Sequential (|i – j| = 1)  258 
             Medium-range (1<|i – j| < 5)  152 
             Long-range (|i – j| ≥ 5)  305 
             Intermolecular 0 
       Hydrogen bonds 52 
       Dihedral angle restraints (phi, psi)a 38 
Violationsb 
    Distance constraints, Åc 0 
    Dihedral angle constraints, º 0.267 ± 0.154 
    Max. dihedral angle violation, º    1.82 
    Max. distance constraint violation, Åc  0 
Deviations from idealized geometry  
    Bond lengths, Å 0.006 ± 0.000 
    Bond angles, º 0.582 ± 0.014 
    Impropers, º 0.740 ± 0.067 
Ramachandran Statisticsd  
   Most favored 85.1 % 
   Additionally favored  14.2 % 
   Generously favored   0.2 % 
   Disallowed   0.6 % 
RMSD to Mean Structure (Å)e  
       Heavy      1.104 ± 0.123 
       Backbone   0.658 ± 0.110 
Table 4.1. Structural statistics for 25 lowest energy structures of pUBL 
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phosphate group rotates the protein backbone and exposes the sidechain of phosphoserine 
65 (pSer65) to a solvent accessible position. This conformational change eliminates a 
hydrogen bond between the S65 hydroxyl and backbone amide of Q62. The 
reorganization is translated to the upstream residues, L61-I66 (Figure 4.4 B–C), forming 
a new α-helix-like structural element (α2-L, L61-Q64) that appears as a one-turn helix in 
water refined structures. Secondary structure propensity scores (40) of pUBL Cα/Cβ 
chemical shifts are in agreement with calculated structures, as were 3JHNHA coupling 
constants (44) and chemical shift indices (55), including the observed helical propensity 
in α2-L (Figure 4.5). As a result of these structural changes in pUBL, sidechain atoms of 
D62, Q63 and Q64 are oriented away from the backbone into solvent, while the aliphatic 
sidechain of L61 is buried into the protein core. 1H-15N HSQC data also report the change 
in backbone structure upon phosphorylation, with large chemical shift changes observed 
for residues near pSer65 (Figure 4.6), consistent with observations in a previous study 
(20). Backbone amides of residues D60 through I66 all undergo chemical shifts larger 
than 0.5 ppm. Significant chemical shift changes were also propagated to more distant 
residues comprising the β-sheet face and hydrophobic patch of pUBL including residues 
R6, I44, H68 and V70.  
 
To investigate changes in hydrogen bonding in the pUBL fold, hydrogen-deuterium 
exchange experiments were collected by NMR. After 20 minutes in D2O solvent, only 
~15% of pUBL amide resonances were detected in 1H-15N HSQC spectra (Figure 4.7). 
Conversely, ~26% of amides in unphosphorylated UBL were observable after the same 
time. For instance, amide protons of V67 and I69 were protected from solvent exchange 
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Figure 4.5. Secondary structure propensity in pUBL. 
Secondary structure map from the solved pUBL structure is displayed above for 
reference. (A) Secondary structure propensity (SSP) for pUBL. Positive values are 
indicative of α-helical propensity and negative values indicate a propensity to β 
structure. SSP was determined from CA and CB chemical shift assignments, using the 
software “SSP”. pSer65 was omitted from analysis. (B) Residue plot of 3JHNHA coupling 
constants obtained from quantitative 3J correlation experiments. Secondary structure 
thresholds are indicated by dashed lines. (C) Chemical shift index analysis using HA, 
CA, and CO chemical shifts. A red symbol indicates an α-helical chemical shift 
propensity. A blue symbol indicates β-strand propensity. 
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Figure 4.6. Amide chemical shift perturbations in UBL upon phosphorylation. 
(A) 1H-15N HSQC spectra showing backbone amide resonances in parkin UBL (UBL, 
black spectrum) and following phosphorylation (pUBL, red spectrum). Resonance 
assignments are labeled in red for pUBL. Where large chemical shift changes occur, an 
arrow is indicated to show the chemical shift from UBL upon phosphorylation.              
(B) Weighted chemical shift perturbations upon phosphorylation. CSP was calculated as 
CSP = [∆δHN2 + 0.2∆δN2]0.5 
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Figure 4.7. Backbone amide protection in UBL and pUBL. 
1H-15N HSQC spectra of parkin UBL and pUBL in 10% D2O (top panels) and following 
exchange into 100% D2O (bottom panels). NMR spectra in D2O were collected 
approximately 20 minutes following first contact with 100% D2O (total 9.5 minutes 
experiment acquisition time). Resonances that are detectable after exchange into 100% 
D2O are indicated.  
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in UBL but showed faster exchange in pUBL and were not observable after 20 minutes. 
The loss of signal is indicative of overall weaker structural bonding in the pUBL 
structure, and supports an overall decrease in protein stability. Since deuterium exchange 
for most amides was faster than could be detected by NMR, amide temperature 
coefficients were also determined to obtain a comprehensive analysis of hydrogen 
bonding throughout the entire protein backbone in UBL and pUBL. Backbone amide 
protons that exchange rapidly with water exhibit a strong linear change with temperature, 
whereas protons involved in hydrogen bonds are more protected from this effect (43,56). 
Therefore the slope of a plot of 1H chemical shift vs temperature represents the 
temperature coefficient (∆δNH/∆T), where a less-negative slope is indicative of hydrogen 
bonding or rigidity of the amide (57). Comparison of measured temperature coefficients 
in pUBL vs UBL agrees remarkably with the initial amide chemical shift analysis. In 
particular, amide temperature coefficients (∆δNH/∆T) for pUBL showed large decreases 
near the S65 phosphorylation site, including Q63 and Q64 in the α2-L structural element 
(Figure 4.8), indicative of amide hydrogen bonding. In contrast, the amide of pSer65 
showed increased temperature dependency, reflecting the loss of structural hydrogen 
bonds with F4 in β1, consequently shortening the terminal β4 strand. These findings were 
also corroborated by 1H-15N heteronuclear NOE measurements that showed 
phosphorylation increases flexibility in the backbone loop of D62-Q64 and releases 
pSer65 and I66 from the β4 strand of the β-sheet (Figure 4.9). While S65 and I66 showed 
heteronuclear NOE values near the average for structured regions of the UBL, the 
intensity of these NOEs were markedly reduced in pUBL, indicative of a loss of structure 
in this region.  
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Figure 4.8. Amide temperature coefficients in UBL and pUBL. 
(A) Residue plots demonstrating the effect of temperature on chemical shift in UBL 
(black) and pUBL (red) backbone amides (note: several residues are near-perfectly 
overlapped). Amide proton chemical shifts were plotted against temperature and fitted 
by linear regression. The x-axis of each plot spans 279–313 K and the y-axis spans 0.5 
ppm (1H). Residues with slope (∆δNH/∆T, the temperature coefficient) less negative than 
−4.5 ppb/K are indicated by an asterisk in each plot. (B) Plot of temperature coefficient 
vs. chemical shift deviation for amide protons in pUBL. A cutoff line identified in 
Andersen et al., ∆δNH/∆T = −2.11−(CSD×2.41), to include hydrogen-bonding amides is 
indicated by a dashed line. Residues that fall on or below the cutoff are listed. 
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Figure 4.9. Backbone flexibility increases around the phosphorylation site in pUBL.  
1H-15N Heteronuclear NOE measurements for UBL (black squares) and pUBL (red circles) 
backbone amides. The values plotted are an average of two independent experiments at 
600 MHz, indicated by error bars. The average NOE for data within 1 SD of the mean is 
indicated by a dashed line for each species. The S65/pSer65 data point is indicated for 
reference. 
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A hydrophobic core comprising residues M1, V3, V5, I23, F45, A46, L50, V56, V67 and 
centered around L61 exists in pUBL as supported by extensive backbone and sidechain 
NOEs between these aliphatic residues. This network also exists in unphosphorylated 
UBL, where the S65 hydroxyl group is partially buried, forming a structural hydrogen 
bond across this core to the backbone amide of D62. The movement of pSer65 into the 
bulk solvent uncovers a portion of this hydrophobic core in pUBL (Figure 4.4 D). While 
backbone 1H-15N HSQC data do not report this change, 1H-13C HSQC spectra 
demonstrate extensive changes in methyl resonance positions of M1, V3, I23, A46, L50 
and L61 upon phosphorylation (Figure 4.4 E), despite being distant in space from the 
phosphate group in our structure. In addition, the structure shows pSer65 resides adjacent 
to I66 that results in large chemical shift changes to its sidechain methyl atoms. These 
changes to the hydrophobic core reaffirm the bis-ANS experiments that show modified 
hydrophobicity in pUBL upon phosphorylation. 
 
4.3.4 Phosphoserine 65 modifies the ionization network in pUBL  
In pUBL, the pSer65 phosphate is directed towards R6 and H68 in most of the calculated 
structures (avg distance: 4.8 Å), owing to multiple NOEs observed between I66, R6 and 
H68 (Figure 4.4 B). Therefore, it was hypothesized that a transient ionic interaction may 
exist between the negative phosphate group on pSer65 and basic sidechains of R6 or H68. 
Consistent with this idea, chemical shifts obtained from 1H-15N HMBC and 1H-13C HSQC 
spectra confirmed the Nε2-protonated tautomer of H68, with Nε2 oriented towards 
pSer65 in all calculated structures [(35,36)]. To further investigate this, pH titrations were 
performed to measure the pKa of histidines in UBL and pUBL by tracking the sidechain 
imidazole Hε chemical shift in 1H-13C HSQC spectra. Owing to the central position of R6 
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in β1 (Figure 4.4 B), pKa’s for both H11 and H68 in UBL (6.01 and 5.50, respectively) 
were suppressed from values expected for an average histidine (~6.6) (58). However, 
while phosphorylation had no effect on the pKa of H11, the pKa of H68 increased by a 
half unit from 5.50 to 5.97 in pUBL (Figure 4.4 F). Therefore, this change in pKa can be 
attributed to the proximity of the negatively charged pSer65 sidechain, which could 
engage the ionized form of H68.  
 
It was noted that in addition to H68, sidechain methyl groups of L61 in pUBL (but not 
UBL) titrated with pH, suggesting their chemical environment is also affected by 
ionization. Fitting of the L61 titration data results in a pKa of 6.41 (Figure 4.4 D). Since 
this value is distinct from the histidine pKa and L61 is distant from H68 in our pUBL 
structures, it was suspected this might be reporting ionization of the pSer65 phosphate 
from the −1 to −2 charge state. This was confirmed by measuring the titration of the 
pSer65 amide proton, calculating a similar pKa of 6.47, consistent with observations for 
phosphoproteins (59,60). This indicates the ionization network in pUBL is altered upon 
S65 phosphorylation, and provide evidence that pSer65 partially neutralizes the H68 
positive charge.  
 
4.3.5 Phosphorylation alters the autoinhibitory association in parkin 
Given that parkin autoinhibition is maintained through intramolecular interactions with 
the β-sheet face and I44 patch of UBL, we sought to examine how phosphorylation might 
directly perturb this binding interface. The decreased affinity of pUBL for RORBR was 
reported in Chapter 2 (see Figure 2.13), and other studies have also reported a loss of 
UBL–RORBR interaction upon phosphorylation (14,20). The results presented in Chapter 
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2 in particular showed ~10-fold weaker binding of pUBL vs UBL measured by 
isothermal titration calorimetry in trans (13). To investigate the structural basis of the 
weakened affinity, the surface electrostatic potential of the UBL–RORBR binding 
interface was calculated (61). On its parkin-interacting surface, UBL has an overall 
positive surface that interacts with an overall negative surface on RORBR (Figure 4.10 
A). Upon phosphorylation, the predominantly −2 charge of the O-phosphate group 
changes the surface to a more negative state by partially neutralizing charges on the β-
sheet face of pUBL (Figure 4.10 A). The additional negative potential on the pUBL 
surface is unfavorably brought into close proximity to the negative binding pocket on 
RORBR. A model of pUBL-bound parkin was generated maintaining the I44-centered 
binding interface observed in crystal structures (13,14) (Figure 4.10 B–C). In this model, 
I44 and V70 maintain contact with L266, as their aliphatic sidechains show minimal 
change in structure and chemical environment upon phosphorylation (Figure 4.4 E). 
However, pSer65 is brought into close proximity of the RING1 domain, specifically the 
carboxylate group of D274, resulting in electrostatic repulsion and disruption of the polar 
interactions of D274 with H68 and R6 in UBL (Figure 4.10 C). These changes to 
electrostatic interactions in the binding pocket provide a rationale for the poorer 
autoinhibition observed in phosphorylated parkin.  
 
To further examine how phosphorylation of the UBL domain modulates its interaction 
with parkin, the pUBL-RORBR interaction was probed by TROSY NMR spectroscopy 
from the perspective of RORBR. Consistent with the calorimetric data, NMR experiments 
showed pUBL is still able to bind parkin in trans, despite the weakened affinity. Many of 
the perturbed residues in RING1 and BRcat are affected in a similar fashion for binding 
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Figure 4.10. Changes to surface electrostatic potential upon phosphorylation of 
UBL disrupt autoinhibitory interactions with RORBR. 
(A) Surface potential is indicated by color in red (negative), white (neutral), and blue 
(positive), as calculated by PDB2PQR and APBS. Surface potential was calculated 
separately for RORBR, UBL (left and middle), and pUBL (right). At left, UBL-bound 
parkin is shown for reference. In middle and right panels, UBL and pUBL, respectively, 
are shown dissociated from RORBR to reveal potential on the interacting surface.       
(B) Structure of parkin RORBR (PDB: 5C1Z, residues 142–465) with pUBL aligned in 
the UBL binding region. Unresolved tether residues (A383–A390) were modelled in 
UCSF Chimera. (C) Expanded view of B, showing proposed pUBL-binding interface. 
Residue numberings are coloured according to their respective domains. pSer65 is 
brought into close proximity of D274 (<5 Å), a possible source of charge repulsion.  
152
of pUBL and UBL, indicating the RING1/BRcat interface is still used for pUBL 
recruitment (Figure 4.11). Further, no chemical shift changes were observed in the 
RINGO or Rcat domains upon binding of pUBL, indicating the arrangement of these 
domains is not modified nor does pUBL interact specifically with either domain. The 
most significant changes in chemical shift upon phosphorylation occur in the tether region 
(residues F381-T415) connecting the BRcat and Rcat domains (Figure 4.11). Much of 
this region is flexible based on heteronuclear NOE experiments (see Figure 2.7) and is 
unresolved in crystal structures (13,62). Chemical shift perturbations also showed that a 
portion of this tether (residues F381-G385) lies near the UBL domain in the autoinhibited 
state. However, phosphorylation of the UBL leads to more pronounced changes in the 
magnitude and direction of chemical shifts for several residues in the tether (G385-E395) 
when pUBL is titrated into RORBR parkin (Figure 4.11). Notably, no chemical shift 
changes were observed to residues beyond R396, a region that includes W403, and is 
proposed to suppress ubiquitin ligase activity by blocking the E2 binding site (62,63). 
These differences when pUBL is bound, especially in residues G385-E395, suggest these 
are specifically reporting the phosphate moiety and indicate that pSer65 is likely near this 
portion of the tether.  
 
4.3.6 pUb activation leads to an extended parkin structure  
Most biophysical experiments to evaluate the impact of S65 phosphorylation have been 
conducted in trans, using pUBL and RORBR constructs of parkin. To examine how 
phosphorylation might alter the structure of full-length parkin in cis and to identify how 
pUb activation further modulates this, analytical ultracentrifugation was used to probe the 
hydrodynamic shape of parkin in solution. We purified native parkin, fully S65-
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Figure 4.11. Interaction of UBL and pUBL with RORBR parkin. 
(A) Selected 600 MHz 1H-15N TROSY HSQC spectra of 2H/15N-labelled parkin RORBR 
highlighting differences in UBL (purple, top panels) and pUBL (red, bottom panels) 
interactions with the tether domain. UBL and pUBL interactions were ~96% and ~92% 
saturated, respectively, according to affinities in Table 2.2. (B–C) Full chemical shift 
perturbation (CSP) plots for RORBR domain interactions with UBL (purple) and pUBL 
(red). Grey bars indicate resonances that broaden or shift beyond assignment in the 
bound form. CSP was calculated as CSP = [∆δHN2 + 0.2∆δN2]0.5 
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phosphorylated parkin (pParkin) and homogenous pParkin/pUb complexes by size 
exclusion chromatography (13,19). Both parkin and pParkin displayed similar 
sedimentation profiles and rates (S20,w = 3.86 S and 3.88 S, respectively), indicating both 
forms of parkin are monomeric and retain the same compact shape under the conditions 
tested, where the UBL (pUBL) domain is associated with the RORBR domains (Figure 
4.12 A, black and red). To complement these studies, hydrodynamic properties of 
autoinhibited parkin were calculated using available three-dimensional structures 
(13,20,50). Results from this computational approach (3.86 S, RG = 27 Å) match nearly 
perfectly with the experimental data for parkin and pParkin. In contrast, pParkin/pUb was 
reproducibly found to sediment faster by ultracentrifugation, at 4.02 S (Figure 4.12 A, 
blue). Whereas an increase in sedimentation coefficient is expected due to the addition of 
pUb (~9 kDa), the modest increase in the sedimentation rate must be offset by a change in 
hydrodynamic shape, reflected in the frictional coefficient (f/f0). Indeed, f/f0 increased 
from 1.30 to 1.37 with the addition of pUb, indicating pParkin/pUb adopts a more 
extended conformation in solution. Hydrodynamic calculations using the autoinhibited 
structure (13) with pUb bound to the observed pUb-binding site (20) yielded a 
sedimentation coefficient of 4.56 S, much larger than observed experimentally (4.02 S). 
Together, the data show pParkin/pUb does not maintain a compact structure.  
 
In order to determine the position of pUBL in the pParkin/pUb complex, 200 models 
were generated where pUBL is randomly displaced from RORBR by its disordered 65-
residue linker (residues G77-I142) (49). Visual inspection shows that pUBL samples the 
available conformational space surrounding RORBR in different models (Figure 4.12 B). 
As expected, the generated structures occupied a Gaussian distribution of sedimentation 
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Figure 4.12. Hydrodynamic shape analysis of PINK1-activated parkin. 
(A) Sedimentation velocity experiments show little change in hydrodynamic shape upon 
UBL phosphorylation. A more extended conformation is observed only in the presence of 
pUb (higher f/f0). Example surface representations for the given hydrodynamic shapes 
are shown. (B) Ten representative pParkin/pUb models with a “displaced” pUBL domain. 
200 models were generated, allowing pUBL linker to sample random conformations 
relative to the RORBR/pUb complex (shown dark/light grey). Modelled structures are 
shown according to their sedimentation coefficients as in C. (C) Distribution of 
sedimentation coefficients of activated pParkin/pUb models and autoinhibited pParkin/
pUb. Histogram x-axis shows calculated S20,w values grouped by ± 0.05 S. 
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coefficients centered on an average of 3.89 S (Figure 4.12 C).  The most extended model 
had a sedimentation coefficient of 3.36 S, reflecting pUBL displaced by a near-linear 
linker (RG = 54 Å). In contrast, the most compact model observed was autoinhibited 
pParkin/pUb (4.56 S, RG = 27 Å). Taking all calculated structures into account, the 
observed sedimentation coefficient (4.02 S) for pParkin/pUb is most consistent with an 
average structure whereby pUBL is displaced from RORBR with RG ≈ 32 Å, occupying a 
range of positions dictated by the configuration of the disordered linker.  
 
To support a model that both phosphorylation of parkin and engagement by pUb are 
needed to release the pUBL domain, a series of T2-filtered 1H-15N HSQC experiments 
were collected for parkin, pParkin, and pParkin/pUb. Because backbone 15N atoms in 
parkin have a short bulk T2 (20 ms) consistent with its 52-kDa size, a short T2 relaxation 
period was used to effectively suppress most signals arising from the structured domains 
of parkin. As expected, the resulting 1H-15N HSQC spectrum of parkin showed only a 
series of sharp signals arising from the flexible linker (residues K76–R140), the tether 
region (E382–T414), and multiple loops in the protein (Figure 4.13 A). Remarkably, the 
addition of pUb to pParkin resulted in the complete appearance of amide resonances 
assigned to pUBL (Figure 4.13 C) due to a much longer T2 of these atoms after 
displacement from RORBR. Notably, in pParkin (without pUb engagement) resonances 
corresponding to pUBL showed only marginal increases in intensities (Figure 4.13 B), 
consistent with pParkin maintaining a compact shape, albeit sampling a displaced 
structure more often due to the weakened affinity of pUBL for RORBR. This is 
exemplified by the progressive increase in intensity of resonances such as A31, which is 
not directly involved in the autoinhibitory interaction, but reports the overall T2 of the 
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Figure 4.13. pUb displaces pUBL in full-length, phosphorylated parkin.  
1H-15N CPMG, T2-filtered HSQC spectra (scaled identically) of (A) 15N-labelled full-length 
parkin, (B) 15N-labelled pParkin, and (C) 15N-labelled pParkin after addition of excess, 
unlabelled pUb. Spectra were collected with a 30-ms spin-echo period to attenuate 
signals from the fastest-relaxing component. The much slower decay of free UBL signal 
compared to parkin can therefore serve as a reporter for release of autoinhibition. In the 
autoinhibited state, only signals from flexible loops are visible (A). After PINK1 
phosphorylation (B) and to a greater extent after pUb binding (C), pUBL is released from 
RORBR and relaxes as a smaller molecular mass entity, enabling its detection beyond 
the applied spin-echo period. (D) Superposition of 1H traces through the resonance for 
Ala 31, showing the progressive release of the UBL with each phosphorylation event. 
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UBL domain with each phosphorylation event (Figure 4.13 D). These results support the 
sedimentation velocity experiments that show the full extrusion of the UBL domain 
occurs only upon PINK1 phosphorylation and recruitment of pUb. 
 
 
4.4  Discussion 
Phosphorylation of both parkin and ubiquitin at serine 65 are, at present, the most 
convincing activators of parkin’s ubiquitin ligase activity. However, a recent crystal 
structure of pUb showed the ubiquitin structure is largely unchanged upon 
phosphorylation (18). The UBL domain of parkin shares high sequence and structural 
similarity with ubiquitin, but is significantly less thermodynamically stable (23). 
Consequently, phosphorylated parkin has evaded crystallographic analysis. In this study, 
the structure of pUBL was solved in solution, revealing significant changes to the 
secondary structure and hydrophobicity of the protein upon phosphorylation. 
Phosphorylation of S65 results in a further loss of UBL thermodynamic stability, likely a 
result of structural rearrangements in the hydrophobic core that largely maintains the fold 
of ubiquitin-like proteins (64,65). Importantly, the pUBL structure stands in stark contrast 
to the pUb structure where the phosphate group is accommodated in the loop preceding 
S65 and maintains a hydrogen bond with the backbone amide of Q62 (18). Conversely, in 
pUBL this hydrogen bond is abolished and the phosphoserine group rotates the backbone 
forming a new structural element, α2-L, and instead engages in an ionic interaction with 
H68. The orientation of pSer65 in pUBL is therefore opposite to that observed in pUb and 
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provides an explanation for the key differences in physical and functional properties 
between pUb and pUBL. 
 
In all calculated structures, the sidechain of pSer65 in pUBL faces towards Nε2 of H68, 
engaging in an ionic interaction that was supported by a decrease in the pKa of H68 upon 
phosphorylation. This association was also evidenced by the neutralization of surface 
electrostatic potential across the β-sheet face of UBL upon phosphorylation. Since this 
region of UBL forms the autoinhibitory interface with RORBR in parkin, this provides a 
rationale for the weakened affinity between pUBL and RORBR that has been observed in 
trans (13,14,20). It is conceivable this occurs by pSer65 disrupting the critical H68–D274 
ionic interaction at the autoinhibitory interface. It is also noteworthy that this disruption 
does not fully abolish pUBL binding to RORBR, but rather shifts the equilibrium of the 
pUBL–RORBR association. Therefore, it is conceivable that UBL phosphorylation serves 
a dual purpose: it optimizes the pUb-binding site and primes the upstream region of the 
tether for remodeling to accommodate the incoming E2~Ub conjugate, as supported by 
previous affinity measurements (14). 
 
Unquestionably, the analytical ultracentrifugation data and T2 relaxation experiments 
show the full displacement of the UBL domain occurs only upon both phosphorylation of 
parkin and recruitment of phosphoubiquitin. Significant changes to both the frictional 
ratio (which reports the shape of a molecule) and T2 relaxation time of UBL (which 
reports molecular tumbling and indirectly, molecular size) occurred only upon 
engagement by pUb, providing strong evidence that pUb indispensible to parkin 
activation. Notably, the hydrodynamic properties determined here experimentally for 
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autoinhibited and activated parkin were in excellent agreement with previous molecular 
dynamics simulations (66). The allosteric pUBL/pUb relationship highlights the 
importance of both PINK1 phosphorylation signals in remodeling parkin to an extended 
structure where the E2~Ub binding site is presumed to be more accessible.    
 
Interestingly, certain Parkinson’s disease mutations in the UBL domain were found to 
impede S65 phosphorylation by PINK1. In particular, the G12R, R33Q and R42P variants 
were phosphorylated significantly more slowly than the wild-type protein. This suggests 
these mutants may be impaired in E3 ligase activity and consequently in activating 
mitophagy, a possible cause of their deleterious effects. In contrast, two mutations, P37L 
and T55I, did not affect the ability of the UBL to be phosphorylated by PINK1. This was 
unexpected given T55I was the closest tested mutation to the S65 phosphorylation site in 
both sequence and structure. Rather, the efficiency of phosphorylation seemed to be more 
closely correlated with the stability of the UBL fold. The R33Q and R42P substitutions 
have markedly decreased thermodynamic stabilities relative to the wild-type protein, with 
the R42P substitution resulting in complete unfolding of the UBL domain (23,24). 
Likewise, we observed the I44A substitution could not be efficiently phosphorylated by 
PINK1. These results suggest the hydrophobic patch and overall fold of the UBL may 
govern PINK1 recruitment, rather than a consensus sequence around S65, which is not 
immediately obvious. 
 
Beyond activation of parkin’s E3 ligase potential, it will also be interesting to see how 
UBL phosphorylation affects its function with other UBL-interacting motifs, including 
the S5a proteasomal subunit and deubiquitinating enzymes, including ataxin-3 (67,68). 
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The pUBL structure solved here and model of phosphorylation-induced UBL release will 
be vital to further understanding the full cellular significance of parkin function and 
increase our knowledge of regulation in the ubiquitin-proteasome system. 
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Chapter 5 
Probing the catalytic mechanism of parkin ubiquitination 
 
5.1  Introduction 
Parkin belongs to the family of E3 ubiquitin ligases known as RING1–BRcat–Rcat (RBR) 
ubiquitin ligases (1-3). This family of E3 ligases catalyze ubiquitination using a unique 
hybrid mechanism, employing both an E2-recruiting RING domain and a covalent 
catalytic intermediate with ubiquitin (4). This covalent intermediate is absolutely 
dependent on a conserved catalytic cysteine in the C-terminal Rcat domain (4-6). 
Experiments showed this intermediate is readily hydrolyzed by 2-mercaptoethanol, 
suggesting the cysteine linkage is a thiolester bond with the C-terminus of ubiquitin (4-6). 
The Rcat~Ub thiolester intermediate prepares the Ub moiety for transfer to a substrate 
protein lysine, presumably the ultimate target of the ubiquitination cascade.  
 
Recent structures of RBR proteins including parkin, HHARI and HOIP have revealed a 
conserved fold for the catalytic Rcat domain (7-13). The structures show Rcat domains 
adopt a unique bilobal fold governed by two structural Zn2+ ions that are coordinated in a 
linear fashion (see Figure 5.1 A, C). The proposed catalytic cysteine is surface exposed 
and lies adjacent to zinc site II and the C-terminus of the Rcat domain. Interestingly, these 
structures are completely distinct from canonical zinc-binding RING domains commonly 
found in ubiquitin ligases. Instead, the Rcat fold closely resembles BRcat (Benign Rcat) 
domains found upstream in sequence of Rcat domains in all RBR E3 ligases. (14). An 
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important distinction is that BRcat domains show no intrinsic catalytic activity due to lack 
of the catalytic cysteine that is conserved in Rcat domains (4,14). 
 
The precise chemical mechanism of ubiquitin transfer is unknown for RBR ubiquitin 
ligases, although it is possible that these enzymes function in a similar manner to HECT-
type ubiquitin ligases and deubiquitinating (DUB) enzymes that catalyze ubiquitination 
and deubiquitination, respectively, through thiolester intermediates. The active site 
structures of many cysteine-dependent DUBs are well studied and function similar to 
papain-like cysteine proteinase enzymes (15-18). In these enzymes, a conserved histidine 
residue is polarized by a nearby acidic residue, consequently raising the pKa of the 
histidine. This histidine serves to deprotonate a catalytic cysteine that acts as a 
nucleophile on the protein substrate, forming a thiolester intermediate with the active site 
cysteine. This cascade repeats with a water molecule acting as the nucleophile to 
hydrolyze the protein substrate. It is conceivable this process proceeds analogously in 
RBR ubiquitin ligases, with a nucleophilic substrate lysine substituting for water in the 
second half of the reaction, forming an isopeptide bond between ubiquitin and substrate.  
 
The catalytic triads of these enzymes are well suited to analysis by Nuclear Magnetic 
Resonance (NMR) spectroscopy, owing to the high sensitivity of a nucleus’ chemical 
shift to atomic structure, ionization, and hydrogen bonding (19). The chemical shifts of 
histidine nuclei in particular are remarkably sensitive to ionization, allowing 
identification of protonation, tautomeric state and pKa determination (20-22). Similarly, 
deprotonation of the thiol group in cysteine can be studied by NMR spectroscopy, 
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specifically by analysis of β proton and carbon chemical shifts, although these 
phenomena are notoriously less sensitive than for histidine (23).  
 
This study investigates the catalytic mechanism employed by the Rcat domain in parkin, 
using NMR spectroscopy to elucidate ionization properties in the Rcat active site. The 
presence of a conserved, functional catalytic triad was established that likely exists across 
the entire family of RBR ligases. Quantitation of sidechain pKa’s for the active site 
residues in Rcat was conducted, revealing that a central histidine acts as a base catalyst 
throughout the catalytic mechanism. Further, the application of irreversible electrophilic 
ubiquitin probes was comprehensively studied to develop a method to generate stable 
Rcat~Ub conjugates, that mimic the covalent intermediate formed during catalysis. 
Together, the work provides new insight into the chemical mechanism of parkin 
ubiquitination and the thiolate-imidazolium ion pair that enhances the reactivity of a 
catalytic cysteine in Rcat-containing ubiquitin ligases.  
 
 
5.2  Materials and Methods 
5.2.1    Cloning, Protein Expression and Purification  
Drosophila melanogaster parkin Rcat (residues 410-482) was overexpressed as a His-
SUMO fusion protein in E. coli BL21(DE3). Single point mutants were generated using a 
modified site-directed mutagenesis protocol (24). Cells were grown in LB or minimal 
media (supplemented with 500 µM ZnCl2) at 37 °C until an OD600 of 0.6 was reached at 
which point cells were cooled to 16 °C and induced with 1 mM IPTG for 16 hours. Cells 
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were harvested and resuspended in lysis buffer (50 mM Tris, 200 mM NaCl, 0.5 mM 
TCEP, 25 mM imidazole, pH 8.0). Cells were lysed using an EmulsiFlex-C5 
homogenizer (Avestin), ultracentrifuged at 41,000 rpm (124,000 x g) and proteins 
purified by Ni2+ affinity using a HisTrap FF column on an AKTA FPLC (GE Healthcare). 
Affinity captured proteins were eluted from the column with elution buffer (50 mM Tris, 
200 mM NaCl, 0.5 mM TCEP, 500 mM imidazole, pH 8.0). Fractions containing the 
eluted protein of interest were pooled, Ulp1 protease was added to cleave the His-SUMO 
tag (~1:50 ratio protease:protein) and dialyzed overnight at 4 °C against lysis buffer. 
After cleavage was complete, proteins were passed over the HisTrap FF column again in 
lysis buffer and the flow through was collected, containing proteins of interest. A final 
purification step by gel filtration was performed on a HiLoad Superdex75 pre-
equilibrated in 25 mM HEPES, 100 mM NaCl, 0.5 mM TCEP pH 7.0. If Rcat protein was 
being used to generate Rcat~Ub conjugate, Ulp1 digestion was omitted and SUMO–Rcat 
was instead purified by gel filtration chromatography performed at pH 8.3 without any 
reducing agent present. 
 
The ubiquitin plasmid used to generate the Rcat~Ub conjugate was obtained as a kind gift 
from Brian Mark (University of Manitoba) in a pTXB1 vector (as a Ub/intein/CBD fusion 
protein). The plasmid was transformed into BL21(DE3) cells, and a single colony picked 
to inoculate starter cultures in LB media that were grown to saturation overnight. The 
next day, one litre cultures were inoculated and grown at 37 °C until an OD600 of 0.6 then 
dropped to 25 °C and induced 15 minutes later with 1 mM IPTG. Cells were harvested 4 
hours after induction and resuspended on ice in lysis buffer (50 mM HEPES, 100 mM 
NaOAc pH 6.5). Cells were lysed and immediately centrifuged at 41,000 rpm (124,000 x 
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g) for at least 1 hour. Clean chitin beads (3 x 15 mL slurries) were extensively pre-
equilibrated with lysis buffer to remove ethanol or azide storage solution. Cleared cell 
lysates were added to chitin beads and allowed batch bind for 1 hour. Beads were applied 
to a gravity column, allowed to settle, and unbound lysate slowly passed over the beads. 
Chitin beads were then washed well with lysis buffer (3 manual washes with ~20 mL 
buffer). Beads were quickly rinsed with 10 mL cleavage buffer (lysis buffer + 100 mM 
MESNA), then another 10 mL fresh cleavage buffer was added and the column incubated 
at room temperature (or optimally, 37 °C) for 24-48 hours. Following cleavage, the 
column was opened and cleaved Ub~MESNA proteins were collected. Another 5 batches 
of 5 mL lysis buffer was added to push through remaining Ub~MESNA proteins, until all 
Ub~MESNA was eluted, as judged by SDS-PAGE. Ub~MESNA was immediately 
concentrated down to 2 mL (at 4 °C) and applied to a HiLoad Superdex75 column in 50 
mM NaOAc, 100 mM NaCl, pH 5.0 (the column must be absolutely free of reducing 
agents and at a mildly acidic pH to stop Ub~MESNA hydrolysis). Fractions containing 
Ub~MESNA were pooled and used immediately or flash frozen in liquid nitrogen and 
stored at -80 °C.  
 
5.2.2 Synthesis of electrophilic Ub probes 
UbBr was synthesized as described in (25). Briefly, 0.9 g of bromopropylamine 
hydrobromide was dissolved in 10 mL of 400 µM Ub~MESNA in 50 mM NaOAc, 100 
mM NaCl, pH 5.0. The solution was basified with 1.5 mL of 2 M NaOH and rapidly 
mixed to avoid prolonged protein exposure to NaOH. The final pH of the solution was 
9.8-10.3 and was agitated/rocked for 15 minutes at room temperature. After this time, the 
reaction was quenched with 1.5 mL of 2 M HCl to restore the pH to near 5.0. This 
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solution was then dialyzed in a 10 K MWCO dialysis bag against 50 mM NaOAc, 300 
mM NaCl, pH 5.0 for 8-12 hours, followed by a final dialysis for 4 hours against 25 mM 
HEPES, 100 mM NaCl, pH 8.3. UbBr probes were spin-concentrated and used 
immediately at this stage for conjugation to Rcat. 
 
UbVS was synthesized as described in (25). Briefly, 50 mg glycine vinyl sulfone was 
dissolved in 600 µL of 2 mM Ub~MESNA in 50 mM NaOAc, 100 mM NaCl pH 5.0. N-
hydroxysuccinimide was dissolved separately in buffer to make a 2 M stock, which was 
brought to pH 6.5 with NaOH. 90 µL of this 2 M stock of N-hydroxysuccinimide was 
added to the protein solution. To initiate the reaction, 50 µL of 2 M NaOH was added to 
the solution to increase the pH of the reaction to 7.6. The solution was incubated at 37 °C 
for 90 minutes with light shaking, and then quenched with 50 µL of 2 M HCl. The protein 
was subjected to gel filtration to remove excess salts and reagents and then used 
immediately. 
 
5.2.3 Generation of Rcat~Ub conjugate 
The optimized conditions to generate Rcat~Ub conjugate were as follows. SUMO-Rcat 
was purified as described to homogeneity by Ni2+ affinity and size exclusion 
chromatography leaving the SUMO fusion protein intact. SUMO-Rcat and UbBr were 
exchanged into 25 mM HEPES, 100 mM NaCl, pH 8.3. The two proteins were mixed 
together to obtain a final solution (~10 mL volume) of 100 µM SUMO-Rcat and 800 µM-
1000 µM UbBr. The reaction progress was monitored by SDS-PAGE and allowed to 
proceed overnight. The reaction was quenched by applying the solution to a Ni2+ column, 
where unreacted Ub products were extensively washed away from SUMO-Rcat. Affinity 
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captured proteins were eluted stepwise with 5, 10 and 50% gradients of Ni2+ elution 
buffer, 50 mM Tris, 200 mM NaCl, 0.5 mM TCEP, 500 mM imidazole, pH 8.0. The 
eluted proteins were pooled, Ulp1 protease was added (1:50 ratio protease:proteins) and 
the solution dialyzed overnight against 50 mM Tris, 200 mM NaCl, 0.5 mM TCEP, pH 
8.0. The following day, proteins were reapplied to the Ni2+ affinity column and the 
affinity purification repeated, collecting flow through fractions that contained 
predominantly Rcat~Ub conjugate with some unreacted Rcat species. This solution was 
spin concentrated, and applied to a Superdex75 Increase (24mL) column in 300 µL 
injection batches running at 0.5 mL/min in 25 mM HEPES, 100 mM NaCl, 0.5 mM 
TCEP, pH 7.0. Fractions containing Rcat~Ub as judged by SDS-PAGE were pooled and 
concentrated again for NMR experiments.  
 
5.2.4   NMR Spectroscopy 
All NMR data were collected on a Varian Inova 600 MHz NMR spectrometer equipped 
with a triple resonance cryogenic probe. All experiments were performed in NMR buffer 
(25 mM HEPES, 100 mM NaCl, 0.5 mM TCEP, pH 7.0, 10% (v/v) D2O) at 25 °C unless 
otherwise specified. 200 µM DSS was used as an internal reference and 300 µM 
imidazole was used as an internal pH indicator (26). All data were processed using 
NMRPipe (27) and analyzed using NMRViewJ (28). 
 
Histidine tautomers and protonation states were determined by Cδ chemical shifts in 1H-
13C HSQC experiments (21). For pH titrations, 1H-15N HSQC and 1H-13C HSQC 
experiments of 13C/15N-labelled Rcat (free or Ub-conjugated) at 200-500 µM were 
collected over a range of pH 5.9-10.5. To adjust the pH, approximately 1 mL of protein in 
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NMR buffer was rapidly mixed with 0.2-1.0 µL increments of 1 M HCl or NaOH and 
monitored by a micro pH meter until the desired pH was reached. The chemical shift of 
imidazole was also used to verify the final pH in the spectrometer (26). To calculate pKa 
of titrating residues, 1H chemical shifts of residues over the pH range were plotted and fit 
to a modified Henderson-Hasselbalch equation 1: 
 
δobs=
(10pH–pKa)δA+δHA
1+10pH–pKa
 
Where δ represents the chemical shift of the deprotonated (δA) or protonated (δHA) state. 
 
5.2.5   Mass Spectrometry 
Whole protein ESI-MS was performed on a QTof Ultima mass spectrometer (Waters) 
equipped with a Z-spray source and run in positive ion mode with an Agilent 1100 HPLC 
used for flow injection. The survey range was set as m/z 600-1800, the source 
temperature was 80 °C and cone voltage was 50 V. Raw data were deconvoluted by 
MaxEnt algorithm.  
 
Tandem ESI-MS/MS for Rcat~Ub conjugate was performed on a Thermo Orbitrap Elite 
mass spectrometer equipped with a nanoflex spray ESI source and run in positive ion 
mode. The instrument was run in FT/IT/CID Top15 mode. Trypsin digested peptides 
were introduced into the spectrometer from a C18 HPLC column in H2O/acetonitrile. The 
survey range was set as 350-1800 with +1 charged ions rejected from the collision cell. 
 
 
eq (1) 
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5.3  Results 
5.3.1 Evidence for a catalytic triad in parkin’s Rcat domain 
Recent three-dimensional structures of parkin show the active site geometry in the Rcat 
domain is well conserved across organisms from humans to Drosophila melanogaster (8-
11). Additionally, NMR structures of the isolated Rcat domain show little difference 
when compared to structures in the context of RORBR, suggesting the presence of other 
domains in parkin do not modify the overall fold of Rcat (9). Due to solubility issues with 
human Rcat, this study describes the Rcat domain from Drosophila melanogaster, 
employing a construct spanning amino acids 410-482, according to the fly residue 
numbering.  
 
To confirm the catalytic nature of the Rcat domain, the reactivity of Rcat was tested 
towards the irreversible ubiquitin probe, ubiquitin vinylsulfone (UbVS), an electrophilic 
probe that conjugates non-reversibly onto the catalytic cysteines of ubiquitin ligating and 
deubiquitinating enzymes (29,30). Formation of a non-reducible Rcat~Ub conjugate was 
dependent on the presence of the catalytic cysteine, C449 (Figure 5.1 B). Examination of 
Rcat sequences from parkin and other related RBR ubiquitin ligases revealed several 
conserved features in the active site around this catalytic cysteine (Figure 5.1 C). Firstly, 
the catalytic cysteine is contained within a GGCxH motif, where two tandem glycines 
(G447, G448 in fly parkin) form a tight turn preceding the catalytic cysteine, and a 
histidine residue follows at the +2 position (H451 in fly parkin). The imidazole sidechain 
of the histidine is therefore oriented in a similar direction as the catalytic cysteine relative 
to the protein backbone. Secondly, an acidic or polar residue is found further in sequence 
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H451 
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E462 
M476 
F481 
W471 
M452 
G447 
V453 
G448 
W463 
W465 
RINGO 
RING1 BRcat 
Rcat 
A
Figure 5.1. A catalytic triad mediates ubiquitin transfer in parkin’s Rcat domain.  
(A) Structure of parkin RORBR (PDB: 4I1H). A dashed cyan line represents missing 
electron density in the crystal structure. Grey spheres represent the 8 Zn2+ ions in the 
protein. The Rcat domain is colored in black with the proposed catalytic triad shown in 
yellow. An expanded view of the Rcat domain around the catalytic site is shown beneath. 
(B) Conjugation of an irreversible ubiquitin probe, ubiquitin vinyl sulfone (UbVS) onto the 
Rcat is dependent on C449.  The reaction was performed at pH 7.5 where thiols, but not 
hydroxyls, are nucleophilic towards UbVS. (C) Structure-based sequence alignment of 
Rcat domains from Drosophila melanogaster (Dm) parkin, human (Hs) parkin, and four 
other human RBR ubiquitin ligases. Active site residues (as described in the text) are 
highlighted in blue. Zinc coordinating residues are highlighted in yellow. 
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Hs Dorfin     DIKPCPRCAAYIIKMNDGSCNHMTCAV--CGCEFCWLCMKEISDL--HYLSPSG--CTFWG 
Hs HOIP       NGIDCPKCKFSY-ALARGGCMHFHCTQ--CRHQFCSGCYNAFYAKNKCPEPN----CRVKK 
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but adjacent to the histidine sidechain in three-dimensional space (E462 in fly parkin). 
Finally, an aromatic residue follows distant in sequence but again adjacent in space to the 
histidine (W471 in fly parkin). 
 
The structure and geometry of active sites in RBR ligases therefore resemble catalytic 
triads found among a broad range of ligase and hydrolase enzymes. In these enzymes, a 
central histidine residue serves as a general base to deprotonate a nucleophilic cysteine or 
serine residue, which becomes covalently bonded to the substrate of interest through a 
thiolester or ester linkage, respectively. To test whether catalytic residues in parkin harbor 
this characteristic of canonical catalytic triads, we examined the parkin Rcat domain by 
NMR spectroscopy. Parkin Rcat contains two histidine residues: the proposed catalytic 
histidine (H451) and a second histidine (H479) involved in coordination of a structural 
Zn2+ ion. While the resonances corresponding to aromatic protons of H479 appear in the 
expected regions of a 1H-13C HSQC spectrum, the δ2 proton of H451 does not have the 
expected chemical shift for a histidine aromatic proton. (HB)CB(CGCD)HD correlation 
experiments instead assigned the H451 δ2 proton at ~5.7 ppm (Figure 5.2 A), 
approximately 1.5 ppm (1H) upfield of the average chemical shift (avg 7.19 ppm, 
BioMagResBank: www.bmrb.wisc.edu/ref_info/statful). This chemical shift indicates 
extensive shielding occurs on the H451 δ2 proton, a result of significant nearby electron 
density. Based on the parkin Rcat structure, a glutamate residue (E462) resides adjacent 
to the histidine sidechain. Therefore, we hypothesized this glutamate polarizes the 
histidine residue adjacent to the catalytic cysteine. While substitution of the catalytic 
cysteine did not affect the chemical shift of the H451 δ2 proton, substitution of E462 to 
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Figure 5.2. Polarization of H451 is dependent on E462.  
(A) Aromatic 1H-13C HSQC spectrum of parkin Rcat domain superimposed with selected 
active site mutants, C449F (blue) and E462A (red). Substitution of E462 reverts the 
chemical shift of H451 δ2 to that of an average histidine resonance (shift shown by red 
arrow). A dashed box represents the expanded region shown in B. (B) Upfield region of 
the aromatic 1H-13C HSQC spectrum of parkin Rcat (wild-type). The pH-dependant 
titration of the resonance corresponding to H451 δ2 is shown from low pH (light 
contours) to high pH (dark contours). Histidine atom nomenclature is shown. 
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alanine reverts the chemical shift of the δ2 proton to ~7.2 ppm, as expected for an average 
histidine (Figure 5.2 A). The assignment of histidine protons in Rcat E462A was verified 
using constant-time (CT) 1H-13C one-bond correlation experiments, where 13C nuclei 
coupled to 0 or 2 carbon nuclei are in opposite phase to 13C nuclei coupled to 1 carbon 
nucleus, identifying the δ2 protons in histidine.  
 
In addition to 1H chemical shifts, 13C chemical shifts also provide valuable information 
about tautomeric states of histidine. Specifically, the 13C chemical shift of the δ2 histidine 
carbon can distinguish between Nδ1 and Nε2-protonated tautomers (21). Analysis of 13C 
chemical shifts in Rcat show H451 adopts an Nε2-protonated tautomer when in the 
uncharged state, owing to a δ2 chemical shift well below the threshold of ~122 ppm 
(Figure 5.2 A). Conversely, the zinc-coordinating histidine, H479, shows a δ2 chemical 
shift of 126 ppm, suggesting this histidine is Nδ1-protonated, consistent with its zinc-
coordinating role in the Rcat structure. Taken together, the data show H451 is polarized 
through an association with E462. 
 
5.3.2    pKa determination for residues in the parkin catalytic triad 
In canonical catalytic triads, the active site histidine is elevated in pKa, conferring its role 
as a general base (18). To determine whether the pKa of H451 is elevated in this manner, 
we measured the sidechain pKa by NMR spectroscopy in a pH titration. The chemical 
shifts of δ2 and ε1 histidine protons are highly sensitive to protonation state of the 
aromatic ring, reporting the average distribution of charged and neutral states in solution 
(20,31). Therefore, measurement of these chemical shifts over a range of pHs covering 
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the ionization event allows the precise determination of a histidine pKa. 1H-13C HSQC 
spectra covering the aromatic proton region were collected for Rcat from pH 6–9. The 
upfield δ2 proton of H451 showed a pH dependent shift of 0.34 ppm (1H) during the 
titration, confirming ionization of H451 occurs over the measured pH range (Figure 5.2 
B). An even larger titration shift of ~1.0 ppm (1H) is observed for the ε1 proton of H451, 
reporting the same ionization event (Figure 5.3 A). The increased sensitivity of the ε2 
proton to ionization provides the more accurate measurement of pKa (31), therefore we 
performed non-linear regression to fit the ε2 proton chemical shift to a Henderson-
Hasselbalch curve, solving for a single pKa of 7.40 ± 0.01 (Figure 5.3 A). Importantly, 
the lack of change to resonances of F461 or the other histidine H479, which coordinates a 
structural Zn2+ ion and is thus “locked” in the neutral state, confirm the protein fold was 
maintained over the titration. Consequently, spectra at conditions below pH 6 were not 
possible due to protein unfolding and precipitation, likely resulting from protonation of 
zinc coordinating histidine and cysteine ligands.  
 
The observed pKa of 7.40 for H451 is significantly higher than an average histidine 
residue in proteins, frequently cited between 6.0-6.6 (31-33). To test whether this pKa is 
influenced by neighbouring residues in the active site, the pKa of H451 in the context of 
C449F and E462A active site mutants was also measured. C449F was used to due to this 
being a pathogenic ARJP mutation by elimination of the catalytic cysteine, while E462A 
was chosen as a simple alanine mutant to eliminate the charged nature of glutamate. 
While substitution of the catalytic cysteine did not change the pKa of H451, substitution 
of the adjacent glutamate, E462, reverted the pKa of H451 to a value of 6.71 ± 0.07 
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Figure 5.3. pKa determination of parkin’s catalytic histidine.  
(A) Aromatic 1H-13C HSQC spectrum of parkin Rcat showing the pH-dependent titration 
of H451 from low pH (light contours) to high pH (dark contours). Titrations were repeated 
with C449F and E462A substitutions and observed chemical shift plotted as a function of 
pH (graph at right). Plots were fit by non-linear regression to a modified Henderson-
Hasselbalch equation to determine pKa ± SE. (B–C) Selected regions of 1H-15N HSQC 
spectra during pH titrations show several resonances specifically respond to ionization of 
H451. Chemical shift vs pH plots for the indicated residues are shown at right. 
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(Figure 5.3 A). The results show that E462 chemically shields the aromatic protons of 
H451 and subsequently increases its pKa, supporting its proposed role as a base catalyst.  
 
While most resonances in Rcat are unaffected over the course of the pH titrations, several 
other atoms in the active site do experience chemical shift changes upon ionization of the 
active site histidine. For example, a tryptophan sidechain itself is not ionizable, however 
the W471 indole proton resonance titrates simultaneously with H451 as observed in 1H-
15N HSQC spectrum (Figure 5.3 B). The titration curve is shifted in the E462A mutant, 
suggesting this tryptophan sidechain is responding specifically to ionization of H451. In 
another Rcat mutant lacking the catalytic histidine (H451F) the resonance for the W471 
indole amine proton was unaffected by pH and undergoes no measurable titration, 
confirming its dependence on H451. In addition, another tryptophan in the active site, 
W463, also shows similar chemical shift changes in both its backbone amide and, to a 
lesser extent, sidechain amine protons during the pH titrations (Figure 5.3 B–C). The 
position of this tryptophan in the Rcat structure explains this effect, with the backbone 
nitrogen of W463 only 4.7 Å from the histidine aromatic ring, and the indole nitrogen 
separated by a larger distance of 7.9 Å. The data show that ionization of the catalytic 
histidine in Rcat results in chemical changes that propagate to other residues composing 
the active site.  
 
Next, the pKa of the catalytic cysteine itself was investigated. Cysteine sulfhydryl groups 
are deprotonated, on average, near a pH of 8.6 (34). This ionization event can be observed 
in chemical shift changes in aliphatic beta atoms of the cysteine sidechain by NMR 
spectroscopy, although the magnitude of these chemical shift changes are markedly 
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smaller than those observed for histidine residues (23). Indeed, observation of an 
inflection point for the C449 beta group over the pH titration was complicated by the 
clear influence of multiple chemical events. As observed in 1H-13C HSQC spectra, an 
initial upfield shift occurs in the two C449 beta proton chemical shifts, followed by a 
larger downfield change in 13C chemical shift (Figure 5.4 A). The initial 1H shift could be 
fit to an inflection at 7.20 ± 0.05, before the 1H shift reverses downfield again. 
Conversely, the 13C chemical shift could not be fit to a pKa, as the rate of this chemical 
shift change continues to increase as a function of pH well beyond the pH range that 
could be studied (>10.5). Importantly, over the data points used for curve fitting, the 
chemical shifts of other Rcat cysteine residues that coordinate Zn2+ were unchanged, 
again confirming the integrity of the protein fold during the experiment (Figure 5.4 A). 
The measured pKa is similar to that calculated for H451, although outside of the margin 
of error. It is worth mentioning that both pKa’s were determined from spectra collected 
back to back on identical samples. Therefore, the difference in fitted pKa cannot be due to 
differences in sample conditions or error in pH measurement. The data suggest the 
formation of a thiolate–immidazolium ion pair between C449 and H451 interconverting 
in solution near neutral pH. 
 
Since the initial nucleophilic attack by the catalytic cysteine relies on its deprotonation, 
the pH dependence of this nucleophilic attack was studied using UbVS. The reactivity of 
Rcat towards UbVS was conducted from pH 5.8 to 9.0 and monitored by reducing SDS–
PAGE. Conjugation of UbVS occurred in a pH-dependent manner, following a sigmoidal 
shape consistent with the pH titrations conducted by NMR. Fitting of the data results in 
an inflection at pH 7.10 ± 0.07, within error of that observed for the C449 beta proton 
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Figure 5.4. pKa determination of parkin’s catalytic cysteine.  
(A) Aliphatic 1H-13C HSQC spectrum of parkin Rcat showing the pH-dependent titration 
of C449 Cβ from low pH (light contours) to high pH (dark contours). Zinc-coordinating 
residue, C459, is shown as a reference. Observed chemical shifts were plotted as a 
function of pH (graph at right). Data were fit by non-linear regression to a modified 
Henderson-Hasselbalch equation to determine pKa ± SE. The fit pKa excludes data 
points where the chemical shift reverts and begins to increase again. (B) pH-dependent 
reactivity of Rcat for ubiquitin vinyl sulfone probe. Proteins were mixed at various pHs 
and allowed to react for 1 hour. The resulting complex migrates at ~16 kDa by reducing 
SDS-PAGE. At right, band intensity at ~16 kDa was measured using an Odyssey Imager 
(Licor), plotted against pH and fit to a modified Henderson-Hasselbalch equation to 
determine an “apparent” pKa ± SE. 
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(Figure 5.4 B). The experiment shows the catalytic cysteine in Rcat is enhanced in 
chemical reactivity relative to an average cysteine residue.  
 
5.3.3  Generation of a non-hydrolyzable Rcat~Ub conjugate 
After determination of the ionization properties in the free Rcat active site, it was desired 
to obtain similar parameters for the enzyme in the catalytic intermediate. This state is 
represented by a thiolester-bound Rcat~Ub complex, where the catalytic cysteine of Rcat 
is covalently linked to the carboxy C-terminus of ubiquitin. Due to the extremely transient 
nature of this intermediate, a more stable structural mimic must be employed for solution 
studies. The irreversible Ub probe, UbVS, satisfies this requirement by generating an 
thioether-bound Ub intermediate, which is non-hydrolyzable. The quantities of UbVS 
required for a preparative scale synthesis necessitated that UbVS be synthesized in-house. 
This is accomplished using a self-cleaving intein expression method to generate a C-
terminally-reactive Ub moiety (Figure 5.5) (35). A “warhead” with a thiol-reactive group 
is then ligated to Ub to create an irreversible Ub probe. Glycine vinylsulfone, glycine 
vinylmethylester and glycine vinylcyanide are commonly used warheads, whereby the 
vinyl group reacts with an active site cysteine by a Michael addition (25,29). Various 
alkyl halides are also employed due to their thiol-reactive nature, with bromopropylamine 
and chloroethylamine being the best characterized (25).  
 
To synthesize UbVS, a purified Ub~MESNA adduct was reacted with glycine 
vinylsulfone in the presence of N-hydroxysuccinimide to catalyze formation of an 
activated ester, as described (25). After 1.5 hours, the reaction was quenched and 
products assessed by LC-ESI-MS. Negligible signal corresponding to the Ub~MESNA 
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reactant was observed, however multiple Ub-derivative products were detected. The 
dominant product was the desired product, UbVS (MW: 8623 Da), however multiple 
other Ub derivatives were also detected (Figure 5.6 A). Base-hydrolyzed Ub, harbouring 
a native C-terminal carboxylic acid, was observed (MW: 8507 Da). Moreover, adducts of 
+135 Da from the desired product were readily observed in the mass spectra, consistent 
with addition of more than one glycine vinylsulfone molecule onto the parent ubiquitin 
protein. The structures of these products are polymers whereby the primary amine of one 
glycine vinylsulfone group reacts with the vinyl group of another (Figure 5.6 A). 
Unfortunately, each of these adducts are still reactive Ub probes, as the terminal 
vinylsulfone group contains a reactive alkene. Subsequent attempts to conjugate Rcat and 
UbVS products therefore resulted in a mixture of Rcat~Ub products with varying 
separating linker lengths (Figure 5.6 B). The NMR spectra of these conjugates are highly 
complicated by the differing chemical environments around each of these linkers, 
precluding their characterization by NMR. Unfortunately, attempts to minimize 
polymerization by optimizing reaction conditions were unsuccessful. Subsequent 
investigation showed the glycine vinylsulfone reagent and UbVS showed similar 
polymerization patterns as tested by ESI-MS. This shows glycine vinylsulfone 
spontaneously undergoes a polymerization reaction in solution, generating a 
heterogeneous mixture of adducts.  
 
To circumvent the issue of polymerization, synthesis of another electrophilic probe, 
ubiquitin bromopropylamine (UbBr) was attempted. This alkyl halide probe reacts with a 
catalytic cysteine through an SN2 substitution mechanism, generating a thioether (see 
Figure 5.5). To synthesize UbBr, Ub~MESNA was rapidly mixed with bromoproylamine 
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Figure 5.6. Electrophilic vinyl sulfone generates heterogeneous Ub probes. 
(A) Deconvoluted ESI-MS spectrum of ubiquitin species following conjugation with 
glycine vinyl sulfone. The desired product is observed at 8623 Da (UbVS), however Ub 
species with multiple vinyl sulfone groups are significant contaminants (observed as 
+135 Da species). The proposed chemical structures of the addcuts are shown, where 
“Ub” represents residues 1-75 in ubiquitin. (B) Deconvoluted ESI-MS spectrum of 
Rcat~Ub species generated with UbVS probes. Each species shows evidence of 
polymerization with multiple vinyl sulfone groups, manifesting as +135 adducts, labelled 
on the spectrum. 
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hydrobromide at high pH, allowed to react for 15 minutes with shaking and then 
quenched with acid. Products were assessed by LC-MS, revealing 3 main Ub species 
(Figure 5.7 A). UbBr was the dominant product, with the expected molecular weight 
(MW: 8626 Da). Base-hydrolyzed Ub from the MESNA conjugate was again observed, 
although to a lesser extent as before, likely due to a shorter reaction time. Finally, base-
hydrolyzed UbBr was also observed (MW: 8564 Da), consistent with hydrolysis of the 
halide group by water to form a primary alcohol. Unlike with UbVS, the contaminant 
products from synthesis of UbBr are unreactive towards cysteine and therefore pose no 
problem in subsequent reactions. Conjugation of Rcat and UbBr subsequently generated 
an Rcat~Ub conjugate, as monitored by SDS-PAGE (Figure 5.7 B). Following 
conjugation, an additional affinity chromatography step was performed to remove 
unreacted Ub products, followed by gel filtration as a final sample clean-up and to 
remove any unreacted Rcat (Figure 5.7 C).  
 
The final Rcat~Ub conjugate appeared pure by SDS-PAGE (Figure 5.7 C) and was next 
assessed by mass spectrometry. ESI-MS of the protein complex confirmed one main 
species of the expected molecular weight of one Rcat and one Ub molecule (Figure 5.8 
A). To confirm that Rcat and Ub were linked through the catalytic cysteine, a trypsin 
digest of the complex was performed and tryptic peptides analyzed by tandem MS/MS. 
Both the expected +2 and +3 charged peptides were readily observed for a 13C/15N-
labelled Rcat peptide harbouring the catalytic cysteine (peptide MW: 1440.71), 
containing an additional 115.15 Da for the propyl linker and C-terminal glycine of 
ubiquitin. MS/MS fragmentation of these two peptides confirmed the catalytic cysteine 
was specifically modified, with all y and b fragment ions assigned between the two 
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Figure 5.7. Electrophilic alkyl halides generate “homogenous” Ub probes. 
(A) Deconvoluted ESI-MS spectrum of ubiquitin species following reaction with 3-
bromopropylamine. The desired Ub probe is observed at 8626 Da. Base-hydrolyzed by-
products are observed but are unreactive towards thiols. The proposed chemical 
structures of observed species are shown, where “Ub” represents residues 1-75 in 
ubiquitin. (B) Reaction of Ub* with Rcat shows formation of an Rcat~Ub conjugate. 
Following the reaction, the protein was re-purified by Ni2+ affinity, cleaved with Ulp1 and 
another Ni2+ affinity step performed before concentration for size-exclusion 
chromatography. (C) Size-exclusion chromatography for final sample cleanup and 
removal of unreacted Rcat species. An SDS-PAGE gel is shown beneath the 
chromatogram, showing the contents of the fractions. ** denotes Rcat~Ub complex that 
was further characterized by mass spectrometry and NMR (lanes 14-17 were pooled). 
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Figure 5.8. Generation of a stable, ether-linked Rcat~Ub conjugate. 
(A) Deconvoluted ESI-MS spectrum of Rcat~Ub conjugate generated using an alkyl 
halide Ub probe. The Ub species is at natural isotope abundance and Rcat is 13C/15N-
labelled, leading to a broad deconvoluted peak. Theoretical mass assuming complete 
13C/15N incorporation is 17262 Da. (B) Theoretical y/b ion table for a 13C/15N-labelled 
Rcat tryptic peptide harboring the catalytic cysteine and ether modification. Masses 
correspond to those expected using the employed isotopic labelling scheme. (C) MS/MS 
spectrum showing fragmentation of +3 ion of theoretical peptide (m/z = 480.88). 
Observed y/b ions by manual fragment assignment are indicated. (D) MS/MS spectrum 
as in C showing fragmentation of +2 ion of theoretical peptide (m/z = 720.83).  
D 
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spectra (Figure 5.8 B–D). The other cysteine residue contained within the Rcat peptide 
was modified with iodoacetamide during reduction and alkylation steps, confirming the 
UbBr probe does not modify other cysteine residues in Rcat that are zinc-coordinated.  
 
5.3.4 Characterization of the Ub-bound catalytic intermediate  
After confirming the integrity of the Rcat~Ub conjugate by mass spectrometry, the 
protein conjugate was characterized by NMR spectroscopy. In conjugates generated for 
NMR studies, the Rcat moiety was 13C/15N isotopically-labelled while the ubiquitin 
moiety was at natural isotopic abundance. Optimized reaction conditions produced an 
NMR sample containing approximately 400 µM Rcat~Ub. 1H-15N HSQC spectra of this 
Rcat~Ub conjugate revealed many resonances had been perturbed from their chemical 
shifts in the spectrum of free Rcat (Figure 5.9 A). All amide resonances for residues 
composing the active site loop, including G447, G448, C449, M450 and H451 were 
shifted from their position in free Rcat, consistent with a change in chemical environment 
from conjugation to Ub. Other amide resonances in the active site also showed significant 
perturbations, including E462, W463 and W471, which were all shown to be responsive 
to histidine ionization in the earlier pH titration experiments. Beyond chemical shift 
changes in the active site, we also observed several unexpected chemical shift changes in 
the N and C terminal regions of the Rcat domain in the context of the Rcat~Ub 
intermediate. These included E418, A424, N426 in the N-terminal region preceding Rcat, 
which are unstructured and unassociated with the active site in all previous NMR and X-
ray crystal structures (8-11,36). Additionally, resonances at the C-terminus of parkin 
showed significant chemical shift changes upon Ub conjugation, despite not being 
directly in the active site. These C-terminal residues included amides of A478, H479 and 
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Figure 5.9. Chemical shift perturbations in parkin Rcat~Ub intermediate. 
(A) 1H-15N HSQC spectrum of Rcat~Ub intermediate (black spectrum) superimposed 
with free Rcat (red spectrum). The spectra were collected under identical conditions. 
Amide resonances that show noticeable perturbations in the Ub-bound state are 
labelled on the spectrum. (B) Surface representation of parkin Rcat structure (PDB: 
2LWR). Residues labelled in A are coloured blue on the surface. The catalytic cysteine, 
conjugated to the C-terminus of ubiquitin, is shown in red. 
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the terminal residue G482. Mapping of the perturbed amide resonances onto the structure 
of free Rcat reveals a broad interacting surface localized to one face of the molecule, 
where Ub presumably sits in the catalytic intermediate (Figure 5.9 B). However, the 
changes in chemical environment remote from the catalytic cysteine suggest there may be 
a minor conformational change in Rcat that occurs transiently upon conjugation of Ub. 
Such a change would not be unexpected given structural rearrangements that would occur 
to accommodate a ubiquitin molecule. Nonetheless, the majority of amide resonances are 
unchanged in chemical environment between Rcat and Rcat~Ub, including most zinc-
coordinating residues, confirming the overall protein fold is maintained in this catalytic 
intermediate. To assign the amide resonances of Rcat in the Ub-bound state, three-
dimensional experiments were collected in the context of Rcat~Ub. Unfortunately, signal 
intensities in these experiments were extremely weak for most atoms in the structured 
region of Rcat, especially surrounding the catalytic cysteine. This prevented a conclusive 
re-assignment of these peaks in the context of the Rcat~Ub intermediate.  
 
Sufficient signal in two-dimensional spectra, however, allowed for analysis of the 
catalytic histidine ionization through 1H-13C HSQC spectra as was described for the 
isolated Rcat. A constant-time experiment was first collected to verify the assignment of 
aromatic H451 atoms in the context of the Rcat~Ub conjugate. A resonance at ~5.9 ppm 
was observed in phase corresponding to one 13C nucleus coupling, most likely the H451 
δ2 proton (Figure 5.10 A). Thus, the shielding of this nucleus that was described earlier 
in free Rcat persists in the Rcat~Ub conjugate. This would suggest that in the Rcat~Ub 
intermediate, E462 remains in close contact to the δ2 proton of H451, consistent with a 
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Figure 5.10. pKa determination of catalytic histidine in a Ub-bound intermediate.  
(A) Aromatic 1H-13C HSQC spectrum of Rcat~Ub intermediate. The spectrum was 
collected as a constant-time experiment, where 13C nuclei coupled to zero or two carbon 
atoms (black) appear in opposite phase to those coupled to one carbon atom (red). 
Atom assignments for histidine residues are labelled. (B) Selected region of the 1H-13C 
HSQC spectrum showing the pH-dependent titration of H451 from low pH (light 
contours) to high pH (dark contours). (C) Observed chemical shifts from pH titrations 
were plotted as a function of pH and fit by non-linear regression to determine pKa ± SE. 
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base-catalyst role for H451 in the second (Ub-discharging) reaction. To assess this in a 
quantitative manner, a pH titration was performed with Rcat~Ub and monitored through 
aromatic 1H-13C HSQC spectra. As was observed in free Rcat, a pH dependent shift was 
readily observed for the ε1 proton resonance of H451 (Figure 5.10 B). The corresponding 
resonance for H479 was largely unaffected by this change in pH, consistent with a zinc 
coordinating role for H479 in Rcat~Ub. Fitting of the titration data for H451 revealed a 
single inflection corresponding to a pKa of 7.02 ± 0.03 for this histidine in the context of 
Rcat~Ub. While this pKa value remains increased relative to an average histidine, it is not 
increased to the extent observed in the free Rcat state (pKa: 7.40). However, the influence 
of E462 on H451 persists, as this pKa is still higher than observed in the context of the 
E462A mutant. This suggests this glutamate may have less of an effect on H451 in the 
context of the Rcat~Ub intermediate, likely dictated by the Ub adduct. The results show 
the Ub-bound intermediate of parkin arranges the active site in a manner that prepares the 
catalytic histidine to act as a base catalyst for ubiquitin discharge to a substrate lysine.  
 
 
5.4  Discussion 
The release of multiple RBR ubiquitin ligase structures in recent years uncovered a new 
mechanism of ubiquitin transfer employing Rcat domains. Solution and crystal structures 
showed a conserved catalytic cysteine is positioned in a manner remarkably similar to 
catalytic triads in other cysteine protease enzymes (7-13). Here, chemical properties of 
the parkin active site were studied by NMR spectroscopy, which is uniquely suited to 
investigating these catalytic mechanisms (19). A histidine (H451) central to the active site 
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structure is polarized by an association with E462, raising its pKa for its role as a base 
catalyst. Interestingly, the orientation of this histidine in RBRs is distinct from other 
catalytic triads in enzymes such as subtilisin and alpha-lytic protease, where an Nδ1-
protonated histidine is hydrogen bonded to an adjacent acidic residue (19,37). Instead we 
show Rcat domains adopt an Nε2-protonated histidine in close contact to a negative 
carboxylate anion, leading to a highly shielded δ2 proton that may exist across all 
members of the RBR family. This histidine orientation is shared by some DUB enzymes, 
including UCHL1, that use a cysteine protease mechanism to perform the reverse reaction 
of ubiquitin ligases (38). Interestingly, DUB enzymes also harbor a highly-conserved 
glutamine residue in the active, proposed to stabilize the tetrahedral transition state (39). 
An equivalently positioned electropositive sidechain is missing in Rcat structures. 
However, the conserved “GG” motif preceding the catalytic cysteine is highly 
reminiscent of chymotrypsin-like hydrolase enzymes, where the catalytic cysteine is often 
preceded by GG or GS in a tight turn. In these proteases, backbone amides of these small 
amino acids provide an electropositive contribution to form an “oxyanion hole” that 
stabilizes formation of the tetrahedral transition state (40-42). Finally, the structures of 
Rcat domains show a conserved tryptophan sidechain positioned parallel to the histidine 
imidazole ring, separated by only 3.5 Å. This distance is within the ideal contact distance 
for π-stacking (43), suggesting the arrangement of these aromatic residues may be 
important over the catalytic cycle. Although the precise chemical role of this tryptophan 
is unknown, this rationalizes why an aromatic residue at this position is found across the 
family of RBR ubiquitin ligases. 
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It has been hypothesized that rearrangements of the Rcat active site occur during 
catalysis, as the distance between the histidine and cysteine sidechains (~5 Å in all Rcat 
structures) is too large in the resting state to favor a thiol–immidazolium ion pair (8,9). To 
investigate a potential active site reorganization, a structure of the covalent Rcat~Ub 
catalytic intermediate is highly desirable. The investigation of electrophilic ubiquitin 
probes for this purpose revealed several insights into the use of these probes for structural 
studies. Importantly, the vinyl-containing probes were prone to polymerization, and thus 
the synthesis of fresh probes and their chemical precursors is essential. Vinyl-containing 
probes, including UbVS, are commonly used in biochemical assays, where a gel mobility 
shift serves as a reporter of ubiquitin ligase or deubiquitinase activity. Although not 
resolvable by gel, it is possible (and highly probable) that these modified products are 
heterogeneous in nature and therefore care should be taken when interpreting these 
results. This explains why, despite the multitude of crystal structures of protein 
complexes with electrophilic ubiquitin probes, none have successfully employed UbVS, 
instead preferring the alkyl halide probes (17,44-47). A notable exception to this is a 
crystal structure of a ubiquitin C-terminal hydrolase (UCH) in complex with ubiquitin 
vinylmethylester (38). It is worth mentioning that the precursor for generation of the alkyl 
halide UbBr probe, 3-bromopropylamine, is readily available and significantly less 
expensive compared to precursors like glycine vinylsulfone used to synthesize UbVS.  
 
The integrity of the covalent Rcat~Ub intermediate generated in this study was validated 
extensively by both mass spectrometry and NMR spectroscopy. Extensive amide 
chemical shifts in Rcat upon Ub conjugation support the idea of a structural 
rearrangement, and could support previous hypotheses of a Ub-associating region in the 
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unstructured N-terminus of Rcat (48,49). Importantly, the reaction scheme employed here 
to generate the Rcat~Ub conjugate allows for segmented isotopic labeling of either Rcat 
or Ub moieties, enabling its future use in a multitude of NMR studies. The obstacle of 
low signal intensity observed in the triple-resonance experiments could be a combined 
consequence of sample concentration, conformational exchange, or the size of the 
molecule (over 17 kDa). Nonetheless, this is promising for ultimately obtaining a three-
dimensional structure of this intermediate in solution, which would be the first RBR 
E3~Ub catalytic intermediate. In summary, this study represents the first description of 
active site ionization equilibria in parkin and will be important for unraveling the full 
catalytic mechanism of RBR ubiquitin ligases. Further, these data will be valuable for 
designing therapeutics that directly perturb the catalytic machinery. 
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Chapter 6 
Summary and Perspectives 
 
6.1 Autoinhibition in parkin 
Autoinhibition of parkin activity by its UBL domain is a fascinating evolutionary result to 
suppress substrate binding in a ubiquitin ligase enzyme. Parkin’s UBL domain shares 
high sequence and structural similarity with its own substrate, Ub, however the UBL is 
significantly less thermodynamically stable (1,2). It was shown in Chapter 2 the UBL 
associates with the C-terminal RBR region of parkin with micromolar affinity in trans, 
maintaining a compact tertiary structure (see Figure 2.2, Figure 2.13, Table 2.2). 
Surprisingly, the affinity of Ub for the same C-terminal parkin fragment was found to be 
an order of magnitude weaker, despite both proteins primarily employing their highly 
conserved I44-patch to bind to parkin. Apparently, UBL binding is preferred over Ub, 
possibly owing to a secondary interface near the β1-β2 connecting loop–the most 
divergent region in sequence and structure between UBL and Ub (see Figure 1.6). It 
would be interesting to see if a Ub-UBL chimera, harbouring the primary sequence of Ub 
but substituting the β1-β2 connecting loop from UBL, interacts with parkin more 
favourably than native Ub to support this hypothesis. The fact that parkin autoinhibition 
occurs naturally in cis is also a major factor discriminating UBL binding from Ub, as the 
local concentration of UBL is drastically increased by its physical tethering to the C-
terminus of parkin. In this regard, it would also be interesting to test whether another 
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parkin chimera, with the whole N-terminal UBL substituted for Ub, is even suppressed in 
ubiquitin ligase activity compared to ∆UBL parkin.  
 
There is evidence that during the ubiquitination cascade, an E2~Ub conjugate is recruited 
to parkin and the Ub moiety partly occupies the UBL binding site (3). This would suggest 
that, at some stage, Ub binding becomes preferred over UBL binding. It is possible this 
preference is governed by the E2 enzyme in the context of an E2~Ub conjugate, as it has 
been shown that E2~Ub conjugates can bind cooperatively to their respective E3 ligase 
partners (4). Although the E2 enzyme UbcH7 binds with comparable affinity as the UBL 
domain to parkin (5), it is possible that in the context of an E2~Ub conjugate this affinity 
is enhanced such that E2~Ub can outcompete the autoinhibitory UBL association.  
 
In addition to UBL-mediated autoinhibition, there may be other endogenous factors that 
regulate parkin’s ubiquitin ligase activity. The available crystal structures of parkin show 
the proposed E2 binding site, the RING1 domain, is obstructed not only by the UBL 
domain but also by a so-called “tether” spanning residues 377-415 (6-9). In particular, a 
region of this tether from residues 395-404 is rigidly associated with RING1 (see Figure 
2.7–2.8). Interestingly, neither UBL nor its phosphorylated form (pUBL) change the 
chemical environment of backbone atoms in this region (see Figure 4.11). Without 
further changes, this tether would block a canonical E2~Ub interaction (10). It is worth 
noting, however, that parkin actually lacks several conserved features of RINGs that 
normally engage an E2~Ub conjugate. This could suggest that parkin utlizies a non-
canonical E2-binding mechanism, perhaps actually utilizing this tether to recruit E2 
enzymes, rather than obstructing them. Using the amide chemical shift assignments for 
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this region, it should be possible to test whether these residues gain flexibility or lose 
flexibility upon E2 binding, representing a displacement or contribution from E2 binding, 
respectively. Elucidating this mechanism of E2-binding will be the next step in 
understanding the full catalytic cycle of parkin.  
 
The multiple crystal structures of autoinhibited (UBL-bound) parkin and ∆UBL parkin 
represented a breakthrough in our understanding of parkin’s tertiary structure. The most 
remarkable feature of these structures was the sheer lack of difference between the UBL-
bound and ∆UBL structures of parkin. Specifically, the orientation and accessibility of the 
catalytic cysteine was essentially identical across all structures. Indeed, the NMR 
chemical shift perturbation experiments of RORBR ± UBL confirmed the chemical 
environment of the catalytic site is not altered by UBL dissociation (see Figure 2.9). 
However, the NMR data allowed us to discern more subtle changes not apparent by 
simple superposition of the RORBR ± UBL crystal structures. Specifically, in addition to 
the UBL-binding interface on RING1, binding of the UBL propagates a structural change 
from the BRcat through helix H3 to the RINGO/RING1 interface. This revealed a hinge 
at the RINGO/RING1 interface that is responsive to UBL binding, causing a subtle 
closing/opening of parkin with UBL association/dissociation, respectively (see Figure 
2.12). This conformational change is allosteric by definition, as binding of UBL induces a 
structural change at a secondary site. This allosteric switch could potentially be targeted 
by therapeutics to perturb the balance of these conformational states that govern parkin 
autoinhibition.  
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It should not have been surprising then, that nature already exploits this allostery through 
an endogenous effector molecule that favours the “open” state to displace the UBL. What 
was shocking is that this allosteric effector is in fact parkin’s substrate, ubiquitin! The 
discovery that ubiquitin phosphorylated at serine 65 (pUb) by PINK1 binds to this 
allosteric site rationalized the genetic links originally identified between PINK1 and 
parkin (11-13). Additionally, parkin itself is phosphorylated at the same serine 65 site in 
its UBL domain to further activate its ubiquitin ligase activity (14,15). Suddenly, the 
focus of this thesis became unraveling how these two phosphorylation events cooperate to 
modify the autoinhibited structure of parkin to an activated state.  
 
 
 
6.2 Cooperation of pParkin and pUb to induce mitophagy 
Remarkably, phosphorylation of parkin’s UBL decreases its affinity for RORBR 
(weakening the inhibitory association), while phosphorylation of Ub confers the opposite 
effect, drastically increasing its affinity for RORBR (see Figure 2.13, Table 2.2). The 
question of how phosphorylation of serine 65 in Ub and parkin’s UBL activate parkin was 
initially seemingly contradictory: How could a phosphate group at the identical position 
in two homologous molecules (Ub and UBL) confer opposite biochemical effects, yet 
cooperate to stimulate parkin activity? Somehow, these phosphorylation events weakened 
the inhibitory properties of UBL, yet enhanced binding of parkin’s substrate, Ub. The 
finding that pUb is primarily an allosteric activator, binding at a site distinct from the 
UBL, began to unravel this mystery (see Figure 2.14). The next major advancements 
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came from elucidating the structures of these two phosphorylated molecules. While the 
structure of pUb is basically unchanged upon phosphorylation, pUBL undergoes a larger 
structural change to accommodate the phosphate moiety (Figure 6.1). The significant 
structural differences in pUBL show why it cannot compete for the pUb binding site, yet 
can independently increase parkin activity, if only partially. The latter arises by the 
phosphate group in pUBL interfering with the autoinhibitory association with RING1 and 
the tether domain (see Figure 4.10–4.11). However, an important finding from this work 
is that engagement of parkin by pUb is absolutely necessary to form an extended parkin 
structure where pUBL is displaced, uncovering the E2~Ub binding site (see Figure 4.12–
4.13). 
 
 
Figure 6.1. Comparison of phosphorylated Ub and parkin UBL.  
Superposition of pUBL structure (red, PDB: 5TR5) and pUb structure (gray, PDB:
4WZP). An expanded view around the phosphorylation site is shown to demonstrate the
significant conformational changes observed in UBL vs. Ub upon phosphorylation.
pSer65 in ubiquitin maintains a hydrogen to the backbone amide of Q62, whereas
pSer65 in UBL is oriented into solvent and facing H68. 
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While the specific order of phosphorylation events in cells remains controversial, parkin 
has evolved such that each phosphorylation signal induces a positive effect on its activity 
while the receptors for each signal are physically distinct. This cooperativity is evidenced 
in two possible scenarios below: 
 
If parkin were initially phosphorylated (Figure 6.2 A), the autoinhibitory interaction is 
weakened and this modestly increases its ubiquitin ligase activity, beginning to 
ubiquitinate substrate proteins on the mitochondrial membrane. These ubiquitin chains 
are subsequently phosphorylated by PINK1, retaining parkin at the mitochondrial 
membrane and maximizing its ubiquination activity by the full extrusion of the UBL 
domain. Polyubiquitin chains accumulate on the mitochondria and become 
phosphorylated by PINK1, and the pathway feeds forward. An unanswered question 
about this scenario is how PINK1 is able to phosphorylate the UBL in autoinhibited 
parkin if both I44 and S65 in parkin, which are needed for the phosphorylation event, are 
occluded in the autoinhibitory association. 
 
If Ub were initially phosphorylated (Figure 6.2 B), this pUb signal recruits parkin and 
stimulates its activity by displacing the UBL domain. This allows parkin to begin 
synthesizing polyubiquitin chains on the mitochondria. Further, the displaced nature of 
the UBL domain facilitates its phosphorylation by PINK1, maintaining parkin in its 
activated state. The polyubiquitin chains synthesized by parkin are subsequently 
phosphorylated by PINK1, and the pathway feeds forward. A lingering question of this 
model is how the initial ubiquitin is added to a substrate if parkin is still autoinhibited. It 
is possible that the latent activity of autoinhibited parkin may be sufficient to catalyze this 
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Figure 6.2. Mechanisms of induction of a feed-forward PINK1/parkin pathway. 
Two potential scenarios for PINK1/parkin cooperativity. See text for a detailed description 
of each scenario. Blue diamonds on the OMM represent various putative parkin 
substrates described previously in Chapter 1. Yellow pac-man shape represents putative 
autophagy/mitophagy receptors. (A) Parkin is initially phosphorylated by PINK1. (B) Ub 
is initially phosphorylated by PINK1. 
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initial ubiquitination event, or perhaps this occurs by another unidentified E3. This would 
not be surprising, as multiple E2/E3 pairs have been previously shown to cooperate in 
catalyzing polyubiquitin chains (16,17). In these examples, one E2/E3 pair serves to 
initiate the cascade via a monoubiquitination event, while a second E2/E3 pair 
subsequently elongates the polyubiquitin chain. It is conceivable that such a mechanism 
could also occur with parkin, providing an initial ubiquitin substrate before any 
phosphorylation event. 
 
Conveniently, either of the aforementioned scenarios converge by a rapid accumulation of 
ubiquitin chains coated over the OMM, which are subject to further phosphorylation of 
PINK1. Therefore, the proposed mechanisms of activation are consistent with a feed-
forward amplification model to rapidly induce parkin activity at any stage in the 
mitophagy cascade (18). Recent work has identified that polyubiquitin chains and, more 
specifically, phosphorylated polyubiquitin chains, are the signal that recruits autophagy 
machinery to initiate mitophagy (19-21). Two autophagy receptors in particular, NDP52 
and OPTN, were shown to be specifically recruited to polyubiquitin chains (and 
phosphorylated polyubiquitin chains) on the OMM (20,21). Interestingly, another kinase, 
Tank-binding kinase 1 (TBK1), was shown to facilitate this binding to polyubiquitin by 
phosphorylating these autophagy receptors (22). It will be interesting to further uncover 
potential crosstalk between these autophagy receptors and PINK1/parkin. For example, if 
parkin maintains a strong affinity for pUb throughout mitophagy, is parkin engulfed into 
lysosomes with damaged mitochondria? Presumably a recycling mechanism for parkin 
would be beneficial for other mitochondria that may be under similar stressors. 
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6.3 Mechanistic insights into RBR ubiquitin ligases 
Although parkin was largely the focus of this thesis due to its direct implication with PD, 
it is likely that many of the findings here extend to other members of the RBR ubiquitin 
ligase family. All other members of this family contain the RBR domains in the same 
sequential order, suggesting they share at least some common catalytic features. Despite 
this presumption, recent structures of other RBR members HHARI and HOIP show 
completely different spatial orientations of the RBR domains. In parkin and HOIP 
structures, the RING1 domain is found central to the RBR module (7,23). Conversely, in 
HHARI, the BRcat domain is more central with Rcat and RING1 domains on opposite 
sides of BRcat and not in contact with each other (24). It is important to note that these 
observations have been largely made in the context of the autoinhibited enzymes, and it is 
likely that upon engagement by an E2~Ub conjugate and during Ub transfer these RBR 
enzymes undergo large conformational changes to occupy similar active catalytic 
orientations. The structures released to date therefore exemplify the extraordinarily 
diverse mechanisms by which RBR ubiquitin ligases have evolved to be structurally 
autoinhibited in their native states.  
 
Additional insight into mechanisms of RBR ubiquitin transfer will certainly come by 
understanding how E2~Ub conjugates engage this family of ubiquitin ligases. Recent 
discoveries in HOIP and HHARI have shown that RING1 of these RBRs stabilize “open” 
conformations of E2~Ub conjugates (23,25), in contrast to canonical RING domains that 
stabilize predominantly “closed” E2~Ub conformations (26). Consistent with this idea, 
the so-called “linchpin” residue conserved throughout canonical RING domains, a 
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conserved basic residue (Arg/Lys) that donates a hydrogen bond to promote the closed 
conformation, is absent in all RBR ubiquitin ligases (25,26). Further, RING1 domains in 
RBR ligases contain an insertion of varying length in the L2 loop that is known to govern 
E2~Ub binding (10,27). This is further evidence that RING1 domains of RBR ubiquitin 
ligases utilize a novel method of E2~Ub recruitment. 
 
It is now known that Rcat structures in RBR ubiquitin ligases are well-conserved, 
suggesting the chemistry of ubiquitin transfer is shared across RBR members. The active 
site chemistry in parkin was examined in this thesis to determine the roles of several 
conserved residues in increasing the reactivity of the catalytic cysteine. It was shown here 
that a conserved glutamate residue in parkin polarizes a histidine to enable deprotonation 
of the catalytic cysteine, analogous to papain-like catalytic triads (see Figure 5.1–5.2). It 
was further proposed that a “GG” motif preceding the catalytic cysteine might play a role 
in stabilizing the tetrahedral transition state during the Ub transfer reaction. This has 
direct pathological implications, as many of these residues, including G429, G430, C431 
and E444 in human parkin (G447, G448, C449, E462 in Drosophila parkin) are targeted 
by missense mutations that cause ARJP. Interestingly, the pathogenic mutations G429E 
and G430D are both substitutions that insert negative charges in the loop preceding the 
catalytic cysteine, and would disfavour formation of the tetrahedral transition state by 
acting as oxyanion destabilizers. The E444Q substitution would presumably be impaired 
in raising the pKa of the adjacent histidine (although notably, one RBR member–HOIP–
actually contains a glutamine residue at this position). Finally, the lack of an active site 
nucleophile altogether is a clear rationale for the deleterious effects of the C431F 
substitution. Future studies on the catalytic Rcat~Ub intermediate using the protocol 
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developed in this thesis will certainly provide additional insight into the second half of 
this mechanism, the discharge of Ub from Rcat onto substrate. It remains to be discovered 
whether Rcat domains are able to recruit substrates independently or whether other 
regions in parkin act as substrate scaffolds for this final Ub transfer reaction.  
 
 
 
6.4  Significance of the work 
It is truly remarkable how much knowledge of parkin and other RBR ubiquitin ligases has 
come about throughout the duration of this thesis. It is worth re-mentioning that at the 
commencement of this project, no structures of intact RBR domains were available and 
the first report of autoinhibition in parkin had only recently surfaced. Unraveling the 
details of this autoinhibitory mechanism in solution therefore represents a significant 
advancement of our understanding of parkin regulation, especially with regards to its role 
in activating mitophagy. This work showed that conformations of autoinhibited parkin 
captured in multiple crystal structures are indeed representative of the structure in 
solution. Importantly, this work revealed many details not discernable from these static 
structures. For example, many flexible tethers and loops in parkin are unresolved in 
crystal structures, and this thesis shows at least some of these flexible regions are 
involved in transient interactions with the UBL to maintain autoinhibition. Additionally, 
changes in NMR chemical shifts propagated through the parkin backbone helped identify 
a structural hinge that regulates autoinhibition in an allosteric manner. The NMR 
assignments for parkin determined here allowed identification of the pUb binding site on 
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parkin, generating a model of pUb-bound parkin. These NMR assignments will also be 
extremely valuable in the future to identify binding sites of potential substrates proteins, 
as well as small molecules that may activate or inhibit parkin activity with therapeutic 
applications.  
 
The structure of the phosphorylated UBL domain solved here also provides a significant 
advancement in our understanding of how PINK1 relieves parkin autoinhibition. The 
phosphorylated form of the UBL has not been amenable to crystallization and we showed 
this likely results from a substantial destabilizing effect of the pSer65 group on the pUBL 
structure. However, the results in this dissertation add to a growing consensus that it is 
primarily the pUb signal that is responsible for the conformational change that relieves 
UBL-mediated autoinhibition (3,28-30). In this sense, it is curious the lack of significance 
that phosphorylation of the UBL may actually play in this displacement. If UBL 
phosphorylation is dispensable, it is possible that its phosphorylation is actually just a 
byproduct of Ub phosphorylation–the true signal for mitophagy machinery–and occurs 
simply due to homology between UBL and Ub. Perhaps the sequence and structure of 
pUBL has evolved over time to assist in amplifying this signal, rather than directly 
mimicking pUb. In the future, it will be interesting to see how PINK1 actually recognizes 
these two substrates and if PINK1 can distinguish between Ub and UBL. The findings 
here would suggest that PINK1 might recognize the overall Ub/UBL fold rather than a 
consensus sequence around the phosphorylation site, which is not immediately obvious. 
This could explain why positional scanning efforts to determine the optimal PINK1 
substrate yielded a peptide sequence with no similarity to Ub or UBL (31) and why 
peptides encompassing Ser65 cannot be phosphorylated by PINK1 (15). These studies 
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will also shed further insight into the molecular basis of disease-state mutations, not only 
in parkin’s UBL, but also in PINK1 that are mutated in ARJP. 
 
The intricate orchestration of phosphorylation and ubiquitination signals by PINK1 and 
parkin are a remarkable example of crosstalk between multiple post-translational 
modifications to regulate cellular processes. The new roles of ubiquitin as both an 
activator of an E3 ligase and a receptor for mitophagy machinery are remarkable 
examples of the non-degradative roles attainable by ubiquitination. Although commonly 
referred to as the Ubiquitin-Proteasome system, it is clear today the signaling role of 
ubiquitin in cells extends far beyond the proteolytic role for which it was originally 
described.  
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